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Several studies investigating the molecular characteristics of Staphylococcus aureus have been 
conducted worldwide, however, in South Africa, most of these have focused on Methicillin-
resistant S. aureus (MRSA). This study investigated the phenotypic and genotypic 
characteristics of isolates of S. aureus collected from the blood and nasal cavity of patients 
admitted to Tygerberg Hospital, South Africa. Investigations included determining the 
association between blood and nasal isolates, describing the molecular epidemiology of the 
population, determining the prevalence of various virulence factor genes among the different 
clones and descibing the accessory gene regulator (agr) functionality of S. aureus clones.  
Pulsed-field gel electrophoresis (PFGE), performed on 208 blood and nasal isolates from 162 
patients with S. aureus bacteraemia, showed that 93 (57.4%) of the patients were colonised 
with the same strain type (p =0.061). MRSA was significantly associated with endogenous 
bacteraemia (same strain obtained from the blood and the nose) (p = 0.042).  
Molecular typing of the 208 blood and nasal isolates (43.3% MRSA) revealed that the 
majority of strains were ST239-t37-agr I (25.5%) which harboured different SCCmec types 
including SCCmec type III and a potentially novel type presumed to consist of  ccrC/Class A 
mec. ST612-MRSA-IV was the second most predominant clone (10.2%).  Other MRSA clones 
included ST5-t045 with a potentially novel variant of SCCmec type I consisting of ccrA1B1 
and a ccrC/Class B mec; and ST461-MRSA-IV, reported for the first time in South Africa. All 
18 (8.7%) pvl-positive isolates were MSSA except one isolate (ST612-MRSA-IV). The 
identification of novel MRSA clones (ST641-MRSA-IV), MSSA STs (ST2122, ST2126), and 
the potentially novel SCCmec type and type I variant suggest the local emergence of new 
clones.  
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Twenty-one isolates (representing nine clonal complexes (CCs)) previously characterised by 
Multi-locus Sequence Typing (MLST) were analysed for the prevalence of 38 virulence factor 
genes. There was an association between different enterotoxin gene cluster (egc) gene 
combinations and CC5, CC22, CC30, and CC45. Both CC15 and CC97 were negative for 
Superantigen (SAg) genes. The intracellular adhesion locus A (icaA) gene was common 
(90.4%) and detected in all CCs (except CC30) and the enterotoxin I (sei) gene was 
significantly more widespread in MRSA isolates (77.8% in MRSA; 25.0% MSSA; p = 0.03).  
Accessory gene regulator dysfunction was significantly higher amongst MRSA than MSSA 
isolates and was more commonly associated with ST36-MRSA-II, ST239-MRSA-III and 
ST239-MRSA- ccrC/Class A mec. Shifting of agr in the same host was not common. Key 
findings in this study relate to the likely emergence of populations at Tygerberg Hospital, as 
evidenced by novel STs and potentially novel SCCmec types. 
 The identification of a circulating clone within the burns unit both illustrates the potential for 
organisms to spread within the hospital, as well as reinforcing the value of molecular typing 
for infection control purposes. The association of different agr types, agr functionality, and 
virulence factors with typing data has shown results consistent with other studies, as well as 
some unusual results. However, the clinical relevance of these associations is not yet well 
understood, and should form the basis of further research. 
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OPSOMMING 
Verskeie studies wat die molekulêre eienskappe van Staphylococcus aureus ondersoek, is al 
wêreldwyd uitgevoer, maar in Suid-Afrika het die meeste gefokus op Methicillinweerstandige 
S. aureus (MRSA). Hierdie studie ondersoek die fenotipiese en genotipiese eienskappe van 
bloed en nasale S. aureus isolate van pasiënte wat by Tygerberg-hospitaal opgeneem is. 
Ondersoeke sluit in die bepaling van die verwantskap tussen bloed en nasale isolate, die 
beskrywing van die molekulêre epidemiologie van die bevolking, die bepaling van die 
teenwoordigheid van verskeie virulensiefaktorgene tussen die verskillende klone; en die 
beskrywing van die “accessory gene regulator” (agr) funksie van S. aureus klone.  
 
“Pulsed-Field Gel Electrophoresis” (PFGE), wat op 208 bloed en nasale isolate (afkomstig van 
162 pasiënte met S. aureus bacteriemie) uitgevoer is, toon dat 93 (57.4%) van die pasiënte 
gekoloniseer is met dieselfde stam tipe (p = 0.061). MRSA vertoon ‘n betekenisvolle 
verwantskap met endogeniese bakteremie (dieselfde stam teenwoordig in bloed en nasale 
isolate) (p = 0.042).  
 
Molekulêre tipering van die 208 bloed en nasale isolate (43.3% MRSA) het getoon dat die 
meerderheid van die stamme deel van ST239-T37-agr I (25.5%) is en uit SCCmec tipe III en 
'n potensiële nuwe tipe (ccrC/KlasA mec) bestaan. ST612-MRSA-IV was die tweede mees 
oorheersende kloon (10.2%). Ander MRSA klone het ST5-t045 ingesluit, wat 'n potensiële 
nuwe variant van SCCmec tipe I (bestaande uit ccrA1B1 en 'n ccrC / Klas B mec); en ST461-
MRSA-IV wat vir die eerste keer in Suid-Afrika gevind is. Al 18 (8.7%) PVL-positiewe 
isolate was MSSA behalwe een isolaat (ST612-MRSA-IV). Die identifisering van nuwe 
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MRSA klone (ST641-MRSA-IV), MSSA STs (ST2122, ST2126), en die potensiële nuwe 
SCCmec tipes reflekteer die plaaslike ontstaan van hierdie nuwe klone.  
 
Een-en-twintig isolate wat voorheen beskryf is deur “Multi-locus Sequence Typing” (MLST) 
is bestudeer vir die teenwoordigheid van 38 virulensiefaktor gene. 'n Assosiasie tussen 
verskillende “enterotoxin gene cluster” (EGC) geen kombinasies en CC5, CC22, CC30 en 
CC45 is gevind. Beide CC15 en CC97 was negatief vir die “Superantigen” (SAg) gene. Die 
“intracellular adhesion locus A” (icaA) geen was algemeen (90.4%) en in al die CCe 
waargeneem (behalwe CC30). Die “enterotoxin I” (sei) geen was aansienlik meer teenwoordig 
in MRSA isolate (77.8% in MRSA; 25,0 % MSSA; p = 0.03).  
 
“Accessory gene regulator” disfunksie was aansienlik hoër in die MRSA groep (in 
vergelyking met die MSSA groep) en was geassosieer met ST36-MRSA-II, ST239-MRSA-III 
en ST239-MRSA-ccrC/Klas A mec. Die verskuiwing van agr funksionaliteit tussen isolate 
afkomstig van die bloed of neus was skaars. 
 
Hoof bevindinge in hierdie studie hou verband met die moontlike ontstaan van bevolkings 
(nuwe STs en potensiële nuwe SCCmec tipes) by Tygerberghospitaal. Die identifisering van 'n 
sirkuleerende kloon in die brandwonde-eenheid illustreer die potensiaal van organismes om te 
versprei in die hospitaal, asook die waarde van molekulêre tipering vir infeksiebeheer 
doeleindes. Die verband tussen die verskillende agr tipes, agr funksionalitiet en die 
virulensiefaktore met tiperingsdata toon soortgelyke resultate as die literatuur, asook ‘n paar 
buitengewone resultate. Die kliniese belang van hierdie assosiasies moet in die toekoms verder 
ondersoek word. 
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CHAPTER 1 GENERAL INTRODUCTION 
1.1 Background 
Staphylococcus aureus, a potent Gram-positive pathogen, was discovered in 1880. S. aureus 
is the primary cause of a wide range of diseases from skin and wound infections to life-
threatening conditions including necrotising pneumonia and bactaeremia (1). The mortality 
rate of S. aureus infections was high (≈ 80%) prior to the discovery of penicillin in 1940. 
Later in 1942, the first S. aureus isolates resistant to penicillin were identified and the 
resistance rate steadily increased to 80% in 1960. The resistance mechanism is found on a  
plasmid encoding a penicillinase enzyme (2). S. aureus infections have become more 
prevalent over the past seven years and it is the second most common species (14.9%) 
isolated from specimens collected from outpatient clinics in the United States (3).  
In 1961 Jevons et al., isolated the first methicillin-resistant S. aureus (MRSA) and said “It is 
well known that patients with infected skin can be a dangerous source of infection in 
hospitals, and the finding of just such a patient infected with a celbenin (methicillin) -
resistant strain in this instance adds an additional warning” (4). When S. aureus acquires 
resistance to methicillin it becomes resistant to all β-lactam antibiotics, including the 
penicillinase-resistant penicillins: the cephalosporins and the carbapenems (5, 6). Since 1961, 
MRSA has emerged as a major concern and has led to different clinical infections in the 
community and hospitals (7-9). The rate of community associated MRSA (CA-MRSA) 
(MRSA identified from blood culture within 48 hours in hospitalised patients who do not 
have extensive contact with health care) and health-care associated MRSA (HA-MRSA) 
(MRSA identified from blood culture either after 48 hours of admission or from patients with 
extensive health care contact) (10), bacteraemia has increased over the past decades leading 
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to lengthy hospital stays and elevated treatment costs (11). MRSA clones are well adapted to 
survive in intensive antibiotic usage environments and this has led to the evolution of strains 
with a decreased susceptibility to vancomycin, including intermediate vancomycin resistant 
(VISA) or hetero-resistant vancomycin (hVISA) S. aureus (12, 13) 
 
1.2 S. aureus Bacteraemia 
S. aureus is considered a common cause of bacteremia and may lead to increased mortality 
and longer hospital stay (14-16). It is the third most common cause of nosocomial bacteremia 
in intensive care units in the USA (17, 18). Furthermore, it has been estimated that >400,000 
hospitalisations per year are related to S. aureus infection, leading to approximately 11,000 
deaths annually (19). 
The emergence of highly resistant strains with reduced susceptibility to vancomycin increases 
the treatment cost and adds a burden to the health care units (20). Blood stream infection 
sources are classified as either primary, when the source is unknown; or secondary, when the 
source is skin or soft tissue infection sites (including intravascular device-associated 
infections) (21). 
S. aureus was the second most common organism isolated from nosocomial bacteremia 
during the time period 1995 to 1998 in the United States of which 29% were MRSA (22) and 
similar findings were reported in 2004 (23). In Tygerberg Hospital, South Africa, S. aureus 
bacteremia is a major concern and the prevalence of MRSA amongst blood culture isolates 
steadily increased from 25% to 30.1% over a period of 14 years (1985 to 2009) (24, 25). 
There are many factors that predispose to MRSA BSIs including extended periods of 
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antibiotic use, prolonged hospital admissions, the presence of intravenous devices and the 
host’s immune status (11, 26). S. aureus infection can lead to significant complications. 
Fowler et al., found that 43% (n=310) of patients who had SAB developed complications of 
which 282 had HA-MRSA and developed these complications within 72 hours of 
hospitalisation. Complications included endocarditis (39%), septic arthritis (24%), deep tissue 
abscesses (18%), osteomyelitis (10%), meningitis (5%), epidural abscesses (8%), septic 
thrombophlebitis (8%), psoas abscess (6%); and other complications (7%). Furthermore, they 
found that patients could have more than one complication at the same time (27).  
Different findings have been reported in studies examining the association of MRSA with 
complications and outcome. MRSA BSIs are associated with a higher morbidity and 
mortality rate  than methicillin-sensitive S. aureus (MSSA) associated BSIs (28). In the 
United Kingdom, the mortality rate for MRSA BSI was significantly higher than for MSSA 
BSI (11.8% vs 5.1%, respectively) (29). Similar results have been reported in South Africa, 
where the mortality rate after 14 days of infection was 33.3% (35/105) for MRSA BSI 
compared to 20.1% (69/344) for MSSA BSI (30). In contrast however, at Duke University 
Medical centre the outcome and associated complications of MRSA and MSSA bacteraemia 
were similar (31). 
 
1.3 Staphylococcus aureus Nasal Carriage 
S. aureus colonises the skin and nose of humans and animals. The more common colonisation 
sites on skin include the axilla and perineum (32). The nose is the most common carriage site 
of S. aureus (33).  S. aureus has also been found to colonise the throat and intestines with a 
significant association with nasal carriage. Identification of the same isolates obtained from 
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the nasal cavity and other body sites suggests that nasal carriage may spread from the nose 
into other body sites (34, 35). While colonisation rarely leads to infection, it is still 
considered the main source and highest risk factor for nosocomial and community-acquired 
infections (36, 37). Approximately 6.6% of carriers are colonised with more than one strain 
and because of the genetic diversity of these strains it is hypothesised that the nose is an ideal 
site for horizontal genetic transfer between colonising strains (38). 
To colonise the nose S. aureus needs to: reach the nose, adhere to nasal tissues or specific 
receptors, evade the immune system; and multiply (39). S. aureus nasal colonisation is 
therefore a result of host pathogen interactions (1). The hands are an important source of S. 
aureus nasal colonisation especially in those who indulge in rhinotillexis (nose picking) (40). 
Airborne transmission also plays an important role in S. aureus nares colonisation and 
respiratory infections (41). Hospitalisation also been found to predispose to nasal colonisation 
(42). Children who acquire MRSA nasal colonisation due to nosocomial transmission are at 
higher risk of developing a subsequent S. aureus infection than those colonised before 
hospital admission (43). This may be explained by another study finding where they reported 
that persistent carriers show strong immune responses toward specific virulence factors 
expressed by their colonising strains (44). Mothers are a common vector in the colonisation 
of their infants’ nares and the level of colonisation was found to steadily decrease from 8 
weeks to 6 months of age as children were weaned from the breast (45) Furthermore, family 
members tend to be colonised with genotypically identical strains (46).  
The lack of cell wall teichoic acid significantly reduces the ability of S. aureus to attach to 
nasal epithelial cells (47). However, S. aureus can adhere to desquamated nasal epithelial 
cells by relying on clumping factor B (ClfB), serine-aspartic acid repeat proteins SdrC and 
SdrD; and iron regulated surface determinant protein A (IsdA) (48). Cytokeratin 10 is a 
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squamous cell surface component and ClfB ligand (49) and S. aureus surface protein G 
(SasG) assists in nasal colonisation by enhancing adherence to the epithelial cells (48). 
Microbial surface components recognising adhesive matrix molecules (MSCRAMMs) 
mediate S. aureus adherence to fibronectin, fibrinogen, and collagen related polysaccharides 
(50). These will be discussed in more detail later (chapter 4). 
To successfully colonise the nose; S. aureus needs to be able to evade the host immune 
response in the nasal cavity. The thick peptidoglycan layer of the cell wall of S. aureus 
prevents cell wall destruction by lysozyme (one of the nasal mucosal fluid components) (51). 
Staphylokinase, produced by S. aureus, can overcome cytolysis by decreasing the negative 
charge of the bacterial cell wall, thereby rendering it less attractive to the cationic 
antimicrobial peptides (52). The staphylococcal surface protein A binds to the fragment 
crystallisable (Fc) region of immunoglobulin G (IgG) and IgA antibodies, thereby 
inactivating them (53). Neutrophil chemotaxis is another innate immune response against S. 
aureus nasal colonisation, however, the extracellular adherence protein (Eap) can reduce 
neutrophil endothelial attachment leading to less neutrophil recruitment and therefore 
diapedesis inhibition (54). Nasal fluid collected from carriers suppresses growth of 
exogenous S. aureus and provides permissible growth conditions for the isolates from carriers 
(55). 
Historically, S. aureus nasal carriage among healthy people was classified into: persistent 
carriers (20%), intermittent carriers (30%) and noncarriers (50%) (39, 56, 57). A recent study 
found that persistent nasal carriers have a higher bacterial load of S. aureus and a greater risk 
of developing infection than intermittent and non-nasal carriers, while the risk difference 
between the last two groups was non-significant. For this reason the authors suggested a 
reclassification of nasal carriers to only two groups: persistent and other carriers. 
Stellenbosch University  https://scholar.sun.ac.za
 6 
Furthermore, they found that persistent and intermittent carriers represent 24% and 47% of 
healthy individuals, respectively. The authors also demonstrated a specific predisposition of a 
carrier for their original colonising strain by inoculating a mixture of strains into the nose of 
the persistent and intermittent carriers after de-colonising the subjects with mupirocin. Fifty-
eight and 17% of the persistent and intermittent carriers respectively became re-colonised 
with their own resident strain, suggesting that each strain is well adapted to its specific host 
and highlights the strong interaction between carriers and their colonising strains (58). 
Similar results were obtained when a mixture of S. aureus (including the resident strain) was 
inoculated into persistent and noncarriers. Seven of 11 persistent carriers re-colonised with 
their original strains and prevented the colonisation with other strains. This reflects a specific 
acclimatisation between the host and resident strain, as each strain re-colonised its original 
niche (59). Re-colonisation with the original strain could be due to both environment and host 
factors (60). Nasal colonisation may also be influenced by the interaction between the S. 
aureus strain and the normal flora resident in the nasal cavity (61) as it has been found that 
certain nasal microbiota, including S. epidermidis, prevent S. aureus colonisation(62). 
Certain diseases may enhance MRSA nasal colonisation and increase the risk of infection. 
Human immunodeficiency virus (HIV) patients are more likely to be colonised with MRSA 
as is evidenced by a previous study which showed that 17% of HIV-I positive outpatients 
were colonised with MRSA, in contrast to 6% of HIV-I uninfected individuals (63). Also, 
what was interesting in this study was that overall S. aureus colonisation was higher in HIV 
infected compared to HIV uninfected individuals. S. aureus nasal carriage is also 
significantly higher in type 2 diabetic patients who are on insulin or antibiotic treatment, 
compared to those who use oral anti-diabetes drugs or non-diabetic individuals (64). Diabetic 
patients are more likely to suffer from diabetic foot ulcer MRSA infection, and nasal 
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colonisation is hypothesised to be the source of infection (65). MRSA nasal carriage has also 
been found to be significantly associated with subsequent infections in dialysis patients and 
may be the main source of MRSA transmission in dialysis staff and their family members 
(66). Individuals suffering from perennial allergic rhinitis are also more prone to S. aureus 
nasal carriage which may aggravate their symptoms even further (67). 
Age is also associated with nasal colonisation, with a large study in the USA, ranging from 
healthy individuals aged 1 to 70  (pooled in increments of 5 years), showing the highest S. 
aureus carrier rate (~45%) amongst 6-11 year olds while MRSA nasal colonisation was 
associated with people ≥60 years old (68). This study did not comment on MRSA nasal 
colonisation in children, however, another study reporting on a similar time period in the 
USA found that MRSA nasal colonisation in healthy children aged from 2 weeks to 21 years 
significantly increased over a 3 year period (0.8% in 2001 to 9.2% in 2004) (69). Korean 
researchers have reported similar S. aureus nasal carriage rates (32%) amongst children who 
visited an outpatient paediatric department in the Samsung Medical Centre tertiary-care 
Hospital; however, their MRSA rate was much higher than that reported in the USA (18.9%) 
(70).  
A study investigating the effect of MRSA/MSSA nasal carriage on developing nosocomial 
SAB found that the rate of bacteraemia among MRSA carriers was 38% and 9.5% among 
MSSA carriers (26). Prolonged antibiotic treatment has also been shown to lead to a shift in 
MSSA nasal and skin carriage to MRSA nasal colonisation (71). MRSA nasal carriage in 
long-term care facility patients is a significant risk factor to develop subsequent clinical 
infection, more so than with patients colonised with MSSA (72). A systematic review of 
studies comparing invasive clinical infection caused by MRSA or MSSA nasal isolates 
showed that patients colonised with MRSA were four times more likely to develop 
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endogenous infection (73).  
More than 80% of S. aureus strains isolated from blood are genetically identical to strains 
carried in the patient’s anterior nares. (74-76). This (and similar findings) provides good 
evidence that the colonised nose could be the source of infection in patients with bacteraemia 
(i.e. endogenous infection). In the Netherlands, Wertheim et al., found that patients colonised 
with S. aureus had a three-fold increased risk of S. aureus bacteremia compared to 
noncarriers. However, bacteraemia in noncarriers was associated with a higher morbidity and 
mortality rate (76). This could be due to the immune system of the carriers adapting to the 
colonising strains. In support of this hypothesis the carriers induced high level of antibodies 
against the super antigens produced by their own strains (77). Others have reported that 
antibodies against toxic shock syndrome toxin-1 (TSST-1), enterotoxin A (SEA), clumping 
factor A (ClfA) and clumping factor B (ClfB) are at higher levels in persistent carriers than in 
noncarriers (78). However, this is not the case for other exogenous virulence factors where 
experimental colonisation with the low virulence strain 8325-4 does not elicit more antibody 
production (44). In another study conducted in the Netherlands, infection caused by 
exogenous MSSA strains was found to be more virulent than by the endogenous strains (76). 
  
1.4 S. aureus Genotyping 
Molecular epidemiological studies are required to identify the bacterial population structure 
and to follow the evolutionary history of newly emerging pathogenic strains. These studies 
also allow us to determine the impact of new antibacterial agents and vaccinations on the 
bacterial population structure (79). Molecular characterisation of S. aureus strains, new 
emerging clones and molecular changes in identified clones are required to plan a successful 
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prevention and control strategy for S. aureus outbreaks in different communities and 
environments (80). Genotyping the different strain types allow a better understanding of the 
movement of S. aureus lineages among different populations. Additionally, conserved genes 
within specific strain types may be used to determine strain relatedness and their putative 
ancestors (81, 82). Currently the most commonly used techniques for strain typing and 
relatedness identification include: Pulsed-Field Gel Electrophoresis (PFGE), Staphylococcal 
Protein A (spa) typing, Multi Locus Sequence Typing (MLST) and Staphylococcal cassette 
chromosome mec (SCCmec) typing for MRSA (83-85). Whole genome sequencing (86, 87) 
and microarray analysis have been used for S. aureus strain typing (88), however, their 
technical requirements and cost have limited their use. 
 
1.4.1 PFGE 
This DNA macro-restriction based technique has been reported as the most reliable method to 
identify outbreak-strain relatedness and is considered the gold standard to investigate 
outbreaks and to conduct epidemiological studies (80, 85, 89, 90). The discriminatory power 
of PFGE is the highest compared to other typing techniques, therefore it is often the first 
method used, followed by other typing methods (SCCmec and MLST) for representative 
isolates from each PFGE cluster (91).  
Pulsed-field gel electrophoresis  is labour intensive, with results taking 3 to 5 days to 
generate; and costly, requiring expensive consumables and equipment (92, 93). Furthermore, 
inter-laboratory comparisons are difficult to perform. Inter-gel variation can also occur due to 
numerous factors including differences in bacterial genome concentration, agarose 
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concentration variations, current voltages, gel running temperatures and buffer strengths (94).  
Many attempts to standardise PFGE protocols and nomenclature have shown limited success 
due to the numerous factors influencing the results analysis (90, 95, 96). 
In the USA, consensus has been reached to identify eight particular S. aureus PFGE types 
(designated as USA100 to USA800) (97). Some of these pulsotypes (USA 300 and USA 400) 
have been recognised by the Centre for Disease control and prevention (CDC) as being 
associated with community-associated MRSA (98). 
 
1.4.2 Spa Typing 
Staphylococcal Protein A is one of the S. aureus cell wall components which binds 
covalently to the peptidoglycan layer (99). Protein A contains two different domains 
including the NH2-terminal region which binds to the Fc region of mammalian 
immunoglobulin thereby inhibiting phagocytosis by polymorphonuclear leucocytes; and the 
C-terminal fragment that anchors protein A to the cell wall (figure 1) (100, 101). The Protein 
A gene (spa) includes two regions, the immunoglobulin G-binding (IgG) region and C-
terminus (X) that consists of the polymorphic short sequence repeat region (SSRs) (also 
known as the repetitive X region (Xr)) and the cell wall attachment region (Xc). The 
polymorphic X region is flanked by well-defined conserved regions and generally includes a 
variable number of tandem repeats (VNTRs), which are usually 24 bp in length, although 
repeats of 21 to 27 bp repeat units have also been recorded (93, 100, 102). The genetic 
variability of the SSR region has been attributed to point mutations and/or the deletion or 
duplication of the consecutive repeats units (103). 
Stellenbosch University  https://scholar.sun.ac.za
 11 
 
Figure 1 : Schematic structure of protein A gene 
Adapted from Hallin et al (104). (a) Different components of the spa gene: S, signal sequence; A-E IgG binding protein; C-
terminus region (Xr is the polymorphic short sequence repeat region and Xc is the cell wall attachment region). Arrows 
indicate the flanked conserved region. (b) Variable structure of the Xr region with both Kreiswirth and Ridom nomenclature. 
(c) Nucleotide length and sequence of one repeat. 
 
The number of repeats in the polymorphic region was used in 1994 to discriminate between 
epidemic and non-epidemic MRSA (105). Sequencing of the spa polymorphic region was 
found to be a valid technique for S. aureus typing and can be used to identify strain types. 
Compared to other typing techniques, spa typing is rapid, easy to perform and interpret; and 
results and data may be shared between different laboratories (106). The discriminatory 
power of spa typing is suitable for epidemiological studies, but improved discrimination is 
obtained when performed in combination with PFGE, MLST and SCCmec typing methods 
(107). spa typing is less discriminatory than PFGE, but more discriminatory than MLST 
(108). spa typing can be used to study MRSA hospital outbreaks and the evolution of MRSA 
strains (109). In long term outbreaks, epidemiological studies which used a combination of 
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spa typing and PFGE have shown better results than using spa or PFGE alone in determining 
strain relatedness and in identifying the genetic background of the resolved clusters (107, 
110). 
Two common spa type nomenclature classification methods exist, including that proposed by 
Kreiswirth et al., where each repeat identified is represented alphanumerically (106). The 
second nomenclature classification method assigns repeats to numerical codes (111). Ridom 
StaphType software (Ridom GmbH, Würzburg, Germany) is widely used for spa sequence 
analysis in European countries. The software modules determine the nucleotide sequence, 
identify repeats and their sequence; and thereby assign the spa type. Furthermore, the 
software can also perform spa type clonal cluster analysis by using the Based Upon Repeat 
Tandem Patterns function (BURP). To avoid missing or including extra repeats the software 
can detect both leading and ending repeats of each spa type.  
Identified spa types can be submitted to the online central spa server 
(http://www.spaserver.ridom.de) and novel spa types and repeats will receive the appropriate 
nomenclature and be added to the central database (111).   
 
1.4.3 Multi Locus Sequence Typing (MLST) 
Multi locus sequence typing is a commonly used technique to identify strain characteristics, 
the evolutionary history and bacterial population structure. Resultant data can be compared to 
the online MLST database (http://mlst.net) to identify the strain relatedness and population 
structure (79, 112). 
In S. aureus, MLST is based on the analysis of the sequence variation of internal fragments 
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(402 to 516bp) of seven housekeeping genes (carbamate kinase (arc), shikimate 
dehydrogenase (aroE), glycerol kinase (glpF), guanylate kinase (gmk), phosphate 
acetyltransferase (pta), triosephosphate isomerase (tpi) and acetyl coenzyme A 
acetyltransferase (yqiL)). Results are presented as an allelic profile (sequence type, ST) 
consisting of seven variable loci. MLST therefore provides enough discriminatory power to 
estimate the relatedness between different strains, excluding the random allelic profile 
similarity which may occur between unrelated strains (113-115). Strains with the same ST or 
those that have a single locus difference (single locus variants (SLVs)) in the allelic profile 
are closely related and subsequently grouped into one MLST clonal complex (MLST-CC). A 
clonal complex refers to a group of isolates having high ST similarity (5 or more of the seven 
loci) and thus likely evolved from a common ancestor.  (113, 116).  
Multi locus sequence typing has been shown to be a useful technique with good 
discriminatory power capable of assigning both MRSA and MSSA strains into known and 
novel ST (115). In the event that strains with different ST are assigned into one MLST-CC, 
the founder (putative ancestor) is identified as the ST which consists of the largest number of 
single locus variants as compared to other related STs. A sub-group of the founder is defined 
as when the founder’s progeny (SLVs) become a prevalent ST from which their own SLVs 
and double locus variants (DLVs) evolve (79, 115). 
Multi locus sequence typing  is a useful tool to investigate the long term epidemiology and S. 
aureus population structure as well as the evolutionary history of different MRSA and MSSA 
clones (115, 117). However, MLST analysis requires the sequencing of seven housekeeping 
genes which increases the technique costs. In addition the methodology is labour intensive 
and time consuming (80). 
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1.4.4 Staphylococcal Cassette Chromosome mec (SCCmec) Typing 
Staphylococcal cassette chromosome mec  is a mobile genetic element which encodes for β-
lactam antimicrobial resistance (80, 118). This mobile element also contributes to genetic 
transfer between staphylococcal species and provides essential support to S. aureus to 
withstand a hostile environment (119, 120). Well adapted epidemic MSSA clones can acquire 
the SCCmec element by horizontal gene transfer, thereby successfully evolving into MRSA 
clones. These clones are the ancestors of reduced vancomycin susceptibility (hVISA and 
VISA) clones (121).  
Staphylococcal cassette chromosome mec element sizes can range from 21 to 67 kb 
depending on the SCCmec type. This transposable element integrates into the open reading 
frame (orfx) close to the origin of replication (122). Integration occurs into a specific 15 bp 
nucleotide sequence in the bacterial genome known as the bacterial chromosomal attachment 
site (attBCC) located downstream of the orfx. As a consequence of SCCmec element 
integration, the attBCC unique sequence will flank the SCCmec element at both the right 
(attR) and left (attL) chromosomal SCCmec junctions (123). The attBCC integration hotspot 
allows for easy acquisition and loss of SCCmec elements to and from bacterial chromosomes 
(124, 125). 
Two conserved variable loci are located in each SCCmec element: (1) mecA and its 
regulatory genes (mecI and mecR1) which confer antimicrobial resistance by encoding for an 
altered penicillin-binding protein (PBP2a) and (2) the chromosome recombinase complex 
(ccr) that encodes for the recombinase enzyme which confers SCCmec element mobility 
(122, 126, 127). A third SCCmec component is the variable J regions (Junkyard regions also 
known as the Joining regions) which contain a variety of integrated plasmids (such as pT181, 
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pU110, and p1258), transposons (Tn554) which confer resistance to non-β-lactam antibiotics 
or heavy metals (128);  and insertion sequences (IS431, IS1272 and IS256) (129). 
In S. aureus, many mecA class variants in the different SCCmec types have been identified: 
class A where the two genes (mecI and mecR1) are present in their entirety (considered the 
wild type) and classes B, C1, C2, and E where varying portions/combinations of one or both 
of these genes are deleted. The ccr gene complex in S. aureus also consists of different 
allotypes depending on nucleotide sequence variations: ccr1 (ccrA1B1), 2 (ccrA2B2), 3 
(ccrA3B3), 4 (ccrA4B4), 5 (ccrC), 7 (ccrA1B6) and 8 (ccrA1B3) 
[(130)http://www.SCCmec.org/Pages/SCC_TypesEN.html]. SCCmec contains three J 
regions; J1 located in the area between the right junction (attR) and the ccr complex, J2 
which occupies the area from the ccr genes to the mec complex and the third J region 
expanding from the mec complex to the left junction (attL) as shown in figure 2 (131, 132). 
The SCCmec element therefore consists of the following structure: J3-mec-J2-ccr-J1 (80). 
Sequence differences in the J regions lead to the classification of SCCmec type variants 
(133). 
Currently, eleven SCCmec types have been identified according to the mecA class and ccr 
allotype combination in the mobile genetic element (126, 134) ( 
Table 1) (http://www.SCCmec.org/Pages/SCC_TypesEN.html). 
The International Working Group on the Classification of Staphylococcal Cassette 
Chromosome Element (IWG-SCC) in December 2009 established certain rules and 
guidelines for SCCmec element nomenclature unification and identification worldwide (125). 
They proposed to keep the first Roman numeral nomenclature followed by the ccr gene 
complex allotype and mec gene complex class in parenthesis (Table 1). Many variants have 
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been identified for different SCCmec types based on the J region nucleotide differences. 
Furthermore, some SCCmec elements carry more than one ccr allotype. These are also 
classified by the IWG-SCC as a type variant of the original SCCmec type (125). 
 
Table 1 : ccr allotypes and mecA class components of the eleven identified SCCmec 









I 1 (A1B1) B 1B 
II 2 (A2B2) A 2A 
III 3 (A3B3) A 3A 
IV 2 (A2B2) B 2B 
V 5 (C1) C2 5C2 
VI 4 (A4B4) B 4B 
VII 5 (C1) C1 5C1 
VIII 4 (A4B4) A 4A 
IX 1 (A1B1) C2 1C2 
X 7 (A1B6) C1 7C1 
XI 8 (A1B3) E 8E 
 
SCCmec type I (34.3 kb) was identified in the first MRSA isolated in the UK and has been 
designated as an archaic clone (122). SCCmec type I usually does not encode resistance to the 
antimicrobial agents other than the β-lactam antibiotics (122, 128).  
SCCmec type II (53 kb) was identified in a strain obtained from Japan in 1982 (122, 130) and 
contains a plasmid (pUB110) which encodes for a broader spectrum of antimicrobial 
resistance to the aminoglycosides including kanamycin, tobramycin and bleomycin. The 
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element also contains a transposon (Tn554) which contains the ermA gene which encodes 
resistance against the macrolides, lincosamides and streptogramins (128).  
 
Figure 2 : Basic structure of SCCmec types I-VIII 
Pink represents the mec complex, blue represents the ccr complex, and grey represents the J regions. Tn, transposon; 
IS, insertion sequence; p, plasmid; SCCHg, staphylococcal cassette chromosome mercury. SCCmec type 
nomenclature represented as roman numbers and revised designation in parenthesis (ccr complex and mec complex). 
This figure was adapted from Ito et al., 2009.  
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Staphylococcal cassette chromosome mec type III (66.9 kb) was firstly identified in a strain 
isolated in New Zealand in 1985 and is characterised by the presence of an additional SCC 
element (SCCmercury (SCCHg)) which confers resistance to mercury (130). Strains 
harbouring SCCmec type 3 are multiresistant to a wide range of antimicrobial agents 
including the β-lactam antibiotics as well as heavy metals due to the presence of the plasmid 
pI258 (on SCCHg) which encodes resistance to mercury, pUB110 which encodes resistance 
to many aminoglycosides and pT181 responsible for tetracycline resistance. As with SCCmec 
type II, Tn554, containing the ermA gene is also present, encoding resistance to the 
macrolides, lincosamides and streptogramins. The pseudo-transposon ΨTn554 also present in 
SCCmec type III confers resistance to cadmium (122, 135). 
In 1990 MRSA strains harbouring SCCmec type IV (20.9-24.3 kb, according to the variant 
type) spread in the community of many countries around the world (80, 126). Its small size 
(the smallest of the SCCmec elements) may facilitate its mobility between staphylococcal 
species and explain the worldwide spread of SCCmec type IV (121, 136). Currently 10 
variants have been identified (IVa -IVj) (132, 135, 137-140), however most only confer 
resistance to the β-lactams (141). 
The first MRSA strains harbouring SCCmec type V (28 kb) were reported in 2004 from 
isolates of Australian origin, but have since been identified elsewhere (80, 126). This element 
mainly confers resistance to the β-lactams and is predominantly associated with CA-MRSA 
(80, 126).  
Staphylococcal cassette chromosome mec type VI (20.9 kb) has been identified in strains 
isolated in Portugal and France (80, 142-144) and confers resistance to mainly the β-lactams.  
Staphylococcal cassette chromosome mec type VII (35.9 kb) was identified in 2008 in MRSA 
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strains isolated in Sweden and differs from all other SCCmec types in that the ccr complex is 
situated between the J2 and J3 regions (130, 145, 146). This element mainly confers 
resistance to the β-lactams and is predominantly associated with CA-MRSA (145).  
Staphylococcal cassette chromosome mec type VIII (32 kb) was identified in epidemic 
MRSA strains in Canada in 2009. The transposon TN554 is present, conferring additional 
resistance to the macrolides, lincosamides and streptogramins (130, 147).   
In 2011 SCCmec type IX and X were identified in isolates belonging to MLST CC 398 and 
obtained from individuals attending a veterinary conference (148). SCCmec type XI was also 
identified in the same year in isolates belonging to MLST CC 130 (149). These new SCCmec 
types were identified in isolates obtained from individuals who had direct contact with 
animals and this element contains genes conferring resistance to the heavy metals copper and 
arsenic, which are usually present in animal isolates. This suggests that these SCCmec types 
may have originated in other mammalian species. (148, 150) (www.SCCmec.org). 
 
1.5  Molecular epidemiology of MRSA 
Since the first MRSA strains were identified in the UK in 1961, MRSA has spread to or 
emerged in many other countries and become a major public health threat (151). In the 1980s, 
MRSA emerged as an important nosocomial pathogen (HA-MRSA) (152), however, by the 
early 90s; MRSA was isolated from indigenous Australian persons who had no history of 
hospitalisation. This was the first report to show that MRSA could also be acquired in the 
community (CA-MRSA) (153). 
HA-MRSA strains are most commonly associated with SCCmec types I, II and III which 
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confer multiple antibiotic resistances to these strains. This wide spectrum of antibiotic 
resistance provides HA-MRSA the ability to survive in hospital environments with higher 
antibiotic pressures (154). As mentioned above, CA-MRSA is more commonly associated 
with the smaller SCCmec types IV, V or VII elements as well as with the presence of the 
Panton-Valentine leukocidin (PVL)  gene (80, 155).  
However, the epidemiology of MRSA is constantly evolving and the distinction between HA- 
and CA- MRSA has become distorted. CA-MRSA strains have been identified in hospitals 
(156-158) and HA-MRSA clones have successfully propagated in the community (159). In 
Australia, the epidemic (E) MRSA-15 health-care associated clone successfully transferred 
from hospital settings into the community (160, 161). Clones that have been shown to survive 
in both community and hospital environments commonly harbour SCCmec type IV elements 
(162-165).  
It has been shown that MRSA clones evolved when epidemic MSSA strains acquired the 
SCCmec element (121).  MLST analysis shows us that most S. aureus isolates (MRSA and 
MSSA) group into one of the five major clusters, which include clonal complexes (CC) 5, 
CC8, CC22, CC30 and CC45 (117, 121, 166). Various well-described MRSA clones have 
been identified worldwide, including the Archaic, Berlin, Brazilian/Hungarian, Iberian, Irish, 
New York/Japan, Paediatric, Southern German, UK MRSA-2, UK MRSA-3, UK MRSA-15 
and UK MRSA-16 (80, 167) clones. Five of these well-known lineages are considered 
pandemic clones: Iberian, Brazilian/Hungarian, EMRSA-15, New York/Japan and the 
Paediatric clones (168). 
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1.6 Major HA-MRSA clones 
1.6.1 Clonal complex 5 
The New York/Japan clone (ST5-MRSA-II) also known as USA100 belongs to MLST-CC5 
and has been associated with different spa types, including predominantly t001 and t002, 
although other spa-types have also been associated with this clone (reviewed in more detail in 
reference 78) This ST5-MRSA-II clone was first identified in the USA in 1998 (167). Later 
on more strains of this clone were identified in Austria, Croatia, Hong-Kong, Hungary, Japan, 
Portugal, Taiwan and the UK (80, 169). Although this clone is identified as healthcare 
associated, it has spread to the community in South Korea and Sri Lanka; and is therefore 
considered a CA-MRSA clone in these countries (170). In Africa this pandemic clone has as 
of yet only been identified in Senegal (171).  
The Paediatric clone (ST5-MRSA-IV) also known as USA800 also belongs to MLST-CC5. 
This clone is also commonly associated with spa types: t001and t002 , but can also consist of 
spa types t003, t010, t045, t053, t062, t105, t178, t179, t187, t214, t311, t319, t389 and t443 
(80). Strains of this lineage were first reported in Portugal in 1992 (167). As a pandemic 
clone it has spread in different geographical regions including the USA, South America and 
Europe (80, 84). In Africa it has been reported in Morocco as a minor clone, but is more 
predominant in Senegal (171).  
The Southern Germany clone (ST228-MRSA-I), also known as the Italian clone, belongs to 
MLST-CC5 as a double locus variant (DLV) of ST5 and has been identified with different 
spa types including t001 (predominant), t023, t041, t188 and t201 (80). It mainly occurs in 
European countries (84) with a high prevalence in Italy of 57% (2000 – 2007). (172). In 
Germany this clone occurs only in healthcare-associated settings and seems to be less 
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prevalent in recent years (173).  
The UK EMRSA-3 (ST5-MRSA-I) clone (also known as the Geraldine clone) belongs to 
MLST-CC5 and has been associated with different spa types: predominantly t001, t002 and 
other spa types t003 and t010, t045, t053, t062, t105, t178, t179, t187, t214, t311, t319, t389, 
t1443 (80). It has been found mainly in Europe and South America (84). In France, it was 
reported as a minor clone and isolated from both community and hospital-acquired infections 
(143). A study including S. aureus isolates from nine provinces in South Africa showed ST5-
MRSA-I as the third most common clone in healthcare associated settings (174). 
Furthermore, this clone was the second most common S. aureus lineage identified in a group 
of Cape Town hospitals (Groot Schuur, Hospital Mowbray Maternity Hospital, Red Cross 
War Memorial Children′s Hospital, Victoria Hospital and the University of Cape Town 
Private Hospital) in 2011 (175).  
 
1.6.2 Clonal complex 8 
The Archaic clone (ST250-MRSA-I) was first reported in the UK in 1960 and is considered 
the founder of all MRSA strains (122, 167). This clone groups into MLST-CC8 as a single 
locus variant (SLV) of ST8 and is associated with variable spa types including: t008, t009 
and t194. It has been reported in many countries (Australia, Canada, Denmark, Germany, 
Switzerland, Uganda, UK and the USA), but prevalence has declined drastically (169, 176).  
The Brazilian/Hungarian clone (ST239-MRSA-III) belongs to MLST-CC8 as a SLV of ST8 
and is associated with different spa types: t037 (predominant), t030, t234, t387 and t388 (80). 
It has evolved from the integration of a 557-kb DNA fragment (representing 20% of the 
genome) from ST30 into CC8 lineage strains (136). ST239-MRSA-III is presumed to be the 
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first reported pandemic MRSA clone spread worldwide (169) and was first identified in 
Brazil and Hungary in 1992 and 1993 respectively (167). It has subsequently been identified 
in many other countries (80, 169). The predominance of ST239-MRSA-III in Hungary has 
been replaced by both ST228-MRSA-I (Southern Germany clone) and ST5-MRSA-II (New 
York/Japan clone) within a 10 year period of time (from 1994 – 2004) (177). It was also the 
predominant clone in a Portuguese hospital until it was replaced by ST22-MRSA-IV between 
1996 and 2005 (163). In 1980 it became the most dominant clone in Ireland (132), as it was 
imported from Iraq with injured soldiers (178). This clone is usually isolated from Turkey, 
Iran, Saudi Arabia, Hong Kong, China, Taiwan and Singapore (80, 169). In Malaysia, it was 
found that 92.5% of 389 MRSA isolates were ST239-MRSA-III; and it is therefore 
considered the predominant clone in that country (179). In Africa, a study including isolates 
from five countries (Morocco, Senegal, Niger, Cameroon and Madagascar) found ST239-
MRSA-III to be the dominant clone in Morocco (representing 95% of all isolates from this 
country) and Niger (171). Furthermore, Harris et al., studied the micro-evolutionary events of 
a global collection of ST239-MRSA-III clones and showed that this clone was easily 
transmitted across continents, between hospitals and hospital wards. (87). In South Africa, 
two studies identified the Brazilian/Hungarian as the most dominant clone in healthcare 
associated isolates obtained from different infection sites and bacteremia (174, 175). In 
KwaZulu-Natal province it was the second most prevalent clone obtained from health care 
facilities between 2001 and 2003 (180). This clone was also shown to be able to spread from 
hospitals into the community in South Korea, Hong Kong, Taiwan and Vietnam (170). 
The Iberian clone (ST247-MRSA-I) belongs to MLST-CC8 as a DLV of ST8 with different 
spa types; predominantly t008 and t051 and less commonly t052, t054, and t200 (80). The 
prevalence of this clone is decreasing in Portugal and in Spain and has been replaced by 
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ST36-MRSA-II (162). 
The Irish clone (ST8-MRSA-II) belongs to MLST-CC8 and has been reported with different 
spa types t008 (predominant), t024, t064, t190, t206, t211 (80). The first clone was identified 
in Ireland in 1990 (181). It has subsequently been reported in Australia, Canada, Ireland, the 
UK and the USA (80).  
The UK EMRSA-2 (ST8-MRSA-IV) clone also known as USA500 or the Lyon clone 
belongs to MLST-CC8. It is associated with various spa types including t008 (predominant), 
t024, t064, t190, t206 and t211 (80). This clone is commonly isolated in France (143), but has 
been reported in Canada, Europe, Australia, and the USA (84).  
ST612-MRSA-IV has clustered in MLST-CC8 and evolved as a DLV of ST8 
(http://www.mlst.net). This clone has been reported in limited geographic regions (173) and 
is predominantly found in South Africa and Australia where it is associated with different spa 
types including: t64 (predominant), t008, t951, t1257, t1443, t1555, t1774, t1779, t1930, 
t1952, t1971 and 2196 (174, 175, 182). 
 
1.6.3 Clonal complex 22 
The UK EMRSA-15 (ST22-MRSA-IV) clone belongs to MLST-CC22. It has been associated 
with the following spa types: t032 (predominant), t005, t022, t223, t309, t310, t417 and t420 
(80). This clone is more prevalent in Europe, Australia, Canada and Indonesia (84). It was the 
predominant clone in the UK and represented 85% of all blood isolates included in a recent 
study, replacing the predominant UK MRSA-16 clone which showed a decrease in 
prevalence over the same time period (21.4% in 2001 to 9% in 2007) (183). ST22-MRSA-IV 
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strains harbouring the pvl gene have been reported in numerous geographical regions (173), 
including South Africa, where the prevalence was 1.9% (174).  
 
1.6.4 Clonal complex 30 
UK MRSA-16 (ST36-MRSA-II), also known as USA200, clusters in MLST-CC30 as a SLV 
of ST30 and has been associated with different spa types including t018 (predominant), t253, 
t418 and t419 (80). It was first reported in the UK in 1993 and subsequently followed by 
other reports from the USA, Australia, Canada and South Africa (84, 167). Recently, this 
clone has been reported less frequently (173). However, a study conducted in Spain which 
included S. aureus isolates obtained between 1998 and 2002 showed that ST36-MRSA-II was 
still more common than the Iberian (ST247-MRSA-I) clone (184). In Africa this clone was 
not found in Morocco, Senegal, Niger, Cameroon or Madagascar (171). However, in South 
Africa it was reported as the most predominant clone in six of the country’s provinces (174). 
This was substantiated by another study including S. aureus isolates collected from Cape 
Town hospitals, but excluding Tygerberg Hospital (175). 
 
1.6.5 Clonal complex 45 
The Berlin clone (ST45-MRSA-IV) also known as the USA600 clone is grouped in MLST-
CC45 with variable spa types (t004, t015, t026 and t031). This clone was first reported in 
Spain in 1989 and is one of the more commonly isolated strains in Germany and the 
predominant strain in Belgium (167). It has been found in isolates collected from the UK, the 
Netherlands (185), Switzerland (186), Croatia (187) and Australia (80).  
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1.6.6 Major CA-MRSA Clones 
The USA400 clone (ST1-MRSA-IV) is grouped as MLST-CC1. It has been associated with 
different spa types including t127 (predominant), t128, t174, t176, t386 and t558 (80). Strains 
of this clone are mostly found in European countries, Canada and the USA (80, 167). In 
Australia ST1-MRSA-IV (nearly always PVL negative) was found to be the most dominant 
CA-MRSA clone throughout the country in 2008 (188).  
The USA300 clone (ST8-MRSA-IV) is grouped into MLST-CC8 and has been associated 
with different spa types, such as t008 (predominant), t024, t064, t190, t206 and t211 (80). 
ST8-MSSA (the presumptive ancestor of the USA300 clone) evolved to USA300 after 
acquisition of a SCCmec type IV element, PVL and arginine catabolic mobile element 
(ACME) virulence factor genes (189). The presence of the pvl gene and ACME in the ST8-
MRSA-IV lineage is considered a genetic trait of the USA300 clone (190, 191). In 1999, the 
first outbreak of USA300 was reported in football players from Pennsylvania and prisoners 
with SSTI from Mississippi (189). Recent studies showed ST8-MRSA-IV is the most 
prevalent CA-MRSA clone in the USA, Canada, Samoa, Columbia, Ecuador and Venezuela 
and that it is continually spreading, becoming a major global concern (192, 193). In the USA, 
this clone has exhibited an ability to adapt and to spread rapidly into the community and 
hospitals, leading to a higher rate of healthcare associated bloodstream infections (194).   
The Southwest Pacific clone (SWP) (ST30-MRSA-IV also known as USA100) is grouped 
into MLST-CC30 and has been associated with different spa types including t012 
(predominant), t018, t019, t021, t038, t268, t275, t318, t338 and t391 (80). The globally 
disseminated ST30-MSSA clone is the predictive ancestor of this SWP clone (167). 
Currently, it is one of the most commonly isolated clones in Australia, Asia, South America, 
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Europe and Middle East (80, 195). This clone is more susceptible to antibiotics compared to 
the other CA-MRSA lineages (196, 197). 
The USA 1000 clone (ST59-MRSA-IV/V) belongs to MLST-CC59 and has been associated 
with different spa types: t216 (predominant), t199, t347 and t444 (80). USA 1000 is one of 
the most commonly identified clones in Asian countries including China and Taiwan where 
this clone spread from the community into hospitals (170, 195). In Taiwan, ST59 carries a 
specific SCCmec element containing two different ccrC genes (ccrC2-C8) and is classified as 
SCCmec V (also known as the Taiwan clone) (146, 198). This clone has also been identified 
in Australia (182).  
The European (ST80-MRSA-IV) clone belongs to MLST-CC80 and has been identified with 
several spa types including t044 (predominant), t131, t376, t416, t436, tt455 and t1109 (80). 
It was mostly identified in European countries, North Africa, the Middle East and Australia 
(80, 167, 186, 195), however the prevalence is on the decrease in European countries (173, 
196). This clone is still highly prevalent as a hospital associated and CA-MRSA in North 
Africa and the Middle East and it seems to spread from these regions into European countries 
via migration (199).  
 
1.7 MSSA Lineages 
It has been hypothesised that MRSA originated from the repeated horizontal transmission of 
the SCCmec element into common MSSA lineages: CC5, CC8, CC22, CC30 and CC45 
(121). Genetic relatedness between the MSSA and MRSA clones harbouring SCCmec type 
IV support the hypothesis of recent acquisition of the element into the reliable genetic 
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background of MSSA lineages (200). The genetic background of 67% of MSSA isolates 
obtained from Portuguese hospitals and the community were related to one of the five major 
MRSA clones in that region (168). In Belgian hospitals, 45% of MSSA isolates shared 
genetic background with the most common MRSA clones (200). Another study including S. 
aureus blood culture isolates obtained from patients at a Dutch hospital found that 50% of 
MSSA isolates had a genetic background common to the major MRSA clones in that setting 
(201). It has been shown that MSSA lineages are more divergent than MRSA clones. 
Currently, many MSSA lineages have been reported in different geographic regions and 
distributed across 15 ST in 8 MLST CC (202-207).   
MSSA strains similar to common MRSA lineages were found to be more receptive to mecA 
acquisition, integration and expression than MSSA stains belonging to other lineages. The 
authors hypothesised that the genetic environment of MSSA strains belonging to uncommon 
major clones is not convenient for mecA gene integration and expression (208). 
 
1.8 S. aureus Virulence Factors 
Comparison of the genome of different S. aureus strains reveals that more than 97% of the 
genome is conserved throughout the species. The remaining 3% is the core variable (CV) 
region which gives rise to the different S. aureus lineages, and consists of the various mobile 
genetic elements (MGEs) which encode for virulence factors and antibiotic resistance genes; 
and allow S. aureus to adapt to differing environments (88, 209, 210).  
Staphylococcus aureus is a common human pathogen causing a wide variety of diseases 
which can be categorised into: (i) superficial skin lesions such as impetigo and furunculosis; 
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(ii) deep seated infections such as pneumonia and bacteremia; (iii) toxaemia such as toxic 
shock syndrome (TSS) as well as food poisoning (211-213). S. aureus produces an 
abundance of virulence factors that contribute in different ways to infection processes and 
allow it to adapt to different environments (50). S. aureus possess two main virulence factors 
groups: (i) cell wall attached virulence factors known as Microbial Surface Component 
Recognising Adhesive Matrix Molecules (MSCRAMMs) including fibronectin-binding 
protein A (FnBPA) and B (FnBPB), collagen-binding protein (CNA), clumping factor A 
(ClfA) and B (ClfB); and (ii) the extracellular secreted toxins including alpha hemolysins 
(Hla), enterotoxins, lipase and protease (214). These two virulence factor groups assist S. 
aureus in reaching and colonising various sites of the body, evading the innate immune 
system, and causing infection (215). 
 
1.8.1 Virulence factor mobilisation 
Recent microarray analysis showed that the S. aureus genome is structured from a core 
genome (~ 75%), a core variable genome (CV) (~ 10%) and a mobile genetic element (MGE) 
(~ 15%) (88). Different types of MGEs have been identified including plasmids, 
pathogenicity islands, and genomic islands. Vertical transmission of MGEs from parent to 
daughter cells leads to a strong association of specific MGEs with bacterial lineages (216). 
Horizontal transmission is another route of MGE mobilisation, leading to the spread of these 
elements between different lineages (216, 217). However, there is evidence that certain 
lineages may have a limited ability to acquire specific MGEs such as SCCmec. (208). MGEs 
carry a variety of virulence factor and antibiotic resistance genes, therefore increasing the 
ability of S. aureus to adapt to new environments (210). It has been reported that when S. 
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aureus  acquires virulence factor genes by horizontal transmission, it leads to the emergence 
of more virulent strains (218).  
Some gene clusters such as the innate immune evasion cluster (IEC), are introduced into S. 
aureus by phages. The IEC consists of Staphylococcal complement inhibitor (SCIN), 
chemotaxis inhibitory protein (CHIP), staphylokinase (SAK), and enterotoxin A (SEA) or 
enterotoxin P (SEP) virulence factor genes (210, 219). The genetic structure of the IEC and 
the variety of phages carrying this cluster has resulted in a wide distribution of this IEC 
throughout different S. aureus populations. Based on the combination of innate immune 
evasion genes located on the IEC, this cluster can be classified into 7 types (A-G) (219). The 
enterotoxin gene cluster (egc) is another MGE which is horizontally transferred by phages 
into S. aureus and consists of enterotoxin G (seg), enterotoxin I (sei), enterotoxin M (sem), 
enterotoxin N (sen) and enterotoxin O (seo). (86, 216). The egc may be absent in some clonal 
complexes (CC1, CC7, CC8, and 15) and very prevalent in other clonal complexes (CC5, 22, 
25, 30, and 45). The prevalence of egc in nasal isolates has been shown to be significantly 
higher than in invasive blood isolates suggesting that this cluster may enhance the nasal 
carriage ability of these strains (220). Genes encoding enterotoxin D (SED) and enterotoxin J 
(SEJ) were located in the same plasmid (221).  
 
1.8.2 Cell-Wall Attached Virulence Proteins 
Colonisation is a very important first step for S. aureus to develop infection. The 
MSCRAMMs mediate the adherence between S. aureus and the extracellular components of 
the host cells. Of these, FnBPA and FnBPB, encoded by two highly related genes, play an 
important role in assisting S. aureus binding to any surface coated with fibronectin (222). 
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FnBPs bind to endothelial fibronectin protein thereby allowing S. aureus to attach to the 
target cells (223). Collagen binding protien is responsible for S. aureus attachment to 
collagen mediating colonisation of bone and cartilage (219), leading to infections such as 
arthritis (224). Clumping factor A  is more likely to be the main adhesion factor up to the 
early exponential growth phase, while ClfB, plays a minor role in adhesion. This could be 
due to the higher tendency of ClfA to bind to fibrinogen and/or due to its abundance in the 
bacterial cell wall. The two clumping factors could potentiate each other to assist S. aureus 
attachment to thrombi , which may lead to endocarditis (225). These factors, can also work 
independently to induce platelet aggregation (226).  
The serine-aspartate proteins (SdrC, SdrD and SdrE) are surface proteins and members of the 
MSCRAMM family encoded by the sdrC, sdrD and sdrE genes respectively, and located in 
the sdr locus. Previous studies have found that all S. aureus isolates have a sdr locus and at 
least two of the 3 sdr genes(227). The adhesion of S. aureus to squamous cells was found to 
be activated by SdrC and SdrD (228). Peacock and colleagues detected sdrC in all tested 
isolates and demonstrated a significant association between the presence of the sdrE  gene 
and virulence (223). A strong association was found between MSSA and sdrC-positive, 
sdrD-negative and sdrE -negative sdr gene profiles as well as a significant association 
between MRSA and the sdrD gene. The presence of both the sdrD and sdrE genes was also 
found to be associated with an increased potential for S. aureus to infect bones (229).  
The extracellular adherence protein (Eap), also known as the major histocompatibility 
complex class II analogous protein (Map), is a member of the surface proteins that contribute 
to S. aureus pathogenesis by allowing attachment to variable host ligands (230). Extracellular 
adherence protein geneis highly conserved in S. aureus and therefore detection of this gene is 
a promising tool for molecular identification of this bacterium (231). It has the ability to bind 
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to the host extracellular matrix and plasma proteins as well as to bind back to S. aureus, 
thereby enhancing the pathogen’s attachment to host tissues (232). As a result of the broad 
range of ligands Eap can attach to, it contributes to and enhances S. aureus’ ability to be 
internalised in eukaryotes (233). The immune modulatory effect of Eap results from its 
interaction with intracellular adhesion molecule 1 (ICAM-1) receptors of antigen presenting 
cells (APC) and T cells, thereby inhibiting neutrophil chemotaxis and modulating  the 
inflammatory response (232, 234). The presence of the intracellular adhesion locus A (ica) 
gene enhances the ability of S. aureus to form biofilms (235). A combination of different 
virulence factors, including the ica gene, have been found to be associated with more virulent 
strains (223). 
 
1.8.3 Superantigenic Toxins (SAgs) 
S. aureus produces many types of exotoxin that can induce disease or toxicosis such as toxic 
shock syndrome (TSS). The most commonly reported superantigens are: TSS toxin 1 (TSST-
1), enterotoxin A (SEA) to enterotoxin E (SEE), enterotoxin G (SEG) to enterotoxin R (SER) 
and enterotoxin U (SEU) (236).  
Superantigenic toxins encoded by genes located on phages include: (i) staphylococcal phage 
Ф3, containing either sea, sep, or sea-sek-seq; (ii) pathogenicity islands, including S. aureus 
pathogenicity island I1 (SaPI1) which carries seb-sek-seq, S. aureus pathogenicity island I2 
(SaPI2) which carries tst-sec3-sel and S. aureus pathogenicity island I3 (SaPI3) which 
carriers sec-sel; (iii) a genomic island (vSAβ) containing the egc gene cluster which includes 
seg-sei-sem-sen-seo and occasionally seu; and finally; (iv) other SAgs genes located on 
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plasmids  (sed-sej-ser) or on the SCCmec transposable element (seh) (216).  
Both TSST-1 and SEB can down-regulate other exoproteins and auto-regulate their 
production, thereby inhibiting the inflammatory response (237). These SAgs are also known 
as  pyrogenic toxin superantigens (PTSAgs), which are able to bind directly to the major 
histocompatibility receptor class II (MHC II) on the antigen-presenting cells (APC), thereby 
introducing these toxins to the T Cells (238). The subsequent activation of host macrophages 
and T cells results in a high production of monokines and lymphokines (239).  
S. aureus can multiply on food and produce enterotoxins, thereby leading to staphylococcal 
food poisoning (SFP), which is symptomatically characterised by vomiting and occasional 
diarrhoea, when consumed. SFP is a self-limiting disease, with resolution within 24 to 48 
hours (239).  Exfoliative toxins A (ETA) and B (ETB) can both cause impetigo and 
staphylococcal scalded skin syndrome (SSSS) that is characterised by skin erythema as a 
result of intra-epidermal desquamation (212, 240).  
 
1.8.4 Immune Avoidance Virulence Factors 
The ability of S. aureus to evade the host immune system, by inhibiting the innate immune 
system and compromising humoral and cell-mediated immunity via several mechanisms, 
leads to an increase in its pathogenicity and its ability to cause repeated infection (234). The 
immune modulatory genes staphylokinase (sak), chemotaxis inhibitory protein (chp), 
staphylococcal complement inhibitor protein (scn) and enterotoxin A (sea) or enterotoxin p 
(sep) are located in the immune evasion cluster (IEC) that is carried by the active βC-Фs 
bacteriophage (219).  
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Chemotaxis inhibitory protein (CHIP) binds to the formal peptide receptor (FPR) and the C5a 
receptor (C5aR). This binding inhibits the migration of neutrophils to the infection sites 
(241). CHIP is introduced with other components of IEC into S. aureus by β-haemolysin-
converting bacteriophages (219). Staphylococcal complement inhibitory (SCIN) virulence 
factors stabilise and deactivate complement as well as inhibit S. aureus phagocytosis and 
killing by neutrophils (242). Production of CHIP and SCIN during the early growth phase 
may be responsible for S. aureus survival during the first stage of colonisation and/or 
invasion (243). 
The alpha-defensins are peptides produced by the innate immune system, including the poly 
morphonuclear cells (PMNs), which produce neutrophil peptides-1 (HNP-1) and 2 (HNP-2) 
to protect the mucosal surface and skin from bacterial infections (244). Staphylokinase (SAK) 
combines with HNP-1 and HNP-2 in specific sites, thereby allowing S. aureus to evade 
destruction by the host’s innate immune system and to subsequently colonise the body and 
mucosal surfaces. The SAKs predispose to super-infections by other Gram-positive and 
Gram-negative bacteria that are sensitive to alpha-defensins, including Escherichia coli and 
S. epidermidis (245). The gene encoding SAK is carried in a bacteriophage, transduced into S. 
aureus and up-regulated by the accessory gene regulator locus (agr) (246). 
The majority of the S. aureus strain microcapsules belong to serotype 5, 8 or 336 (247, 248). 
However, type 5 (more common in MRSA) and 8 are responsible for 75% of human 
infections (240). The capsule increases bacterial resistance to phagocytosis and opsonisation 
(248, 249) by hiding the antibodies′ target sites and disrupting the binding of complement 
(c3b) to receptors on neutrophils (250, 251). The capsule’s hydrophilic structure and low 
antigenicity also protect it from phagocytosis (252). Capsule 5 and 8 expressions have been 
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shown to enhance S. aureus virulence in an animal model (253, 254).  
 
1.8.5 Hemolysins 
S. aureus produces soluble cytotoxic molecules that induce inflammatory reactions and have 
a cytolytic effect. Alpha-hemolysin (Hla), encoded by the hla gene has haemolytic, 
dermonecrotic and neurotoxic effects (239). Hla binds to specific receptors on the target cell 
membrane. This integration leads to pore formation across the host cell membrane, followed 
by membrane destruction and cell lysis (255, 256). Hla plays an important role in brain 
abscess formation (257) and is also an important factor in biofilm formation. S. aureus hlaˉ 
mutants are able to colonise the host surface, but are unable to form multicellular 
macrocolonies (258). It has also been reported that hla expression significantly enhances the 
mortality rate of mice in a murine model of pneumonia (259). Ohlsen et al., found that 
subinhibitory concentrations of β-lactam antibiotics activate hla expression and increase the 
production of alpha-toxin, while clindamycin suppresses hla gene expression completely 
(257). Some MRSA isolates produce 30 times more Hla when grown in methicillin enriched 
media than when cultured in control media (260). Alpha-toxin is inhibited in S. aureus during 
TSS, while in contrast, gamma and delta hemolysins are still produced (261).  
Beta-hemolysin (Hlb) is produced by many S. aureus strains isolated from animals. In a 
murine model of pneumonia, expression of Hlb increased the extent of lung injury through its 
ability to enhance neutrophil inflammation and extravascular protein leakage (262). 
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1.8.6 Panton-valentine leukocidin 
Panton-valentine leukocidin is more commonly associated with CA-MRSA strains (263). It is 
encoded by the lukPV operon which was introduced and integrated into the S. aureus genome 
by phage transduction (209). Vandenesch et al., found an association between CA-MRSA 
SCCmec type IV and PVL production (264). This association was confirmed by Shukla and 
co-workers (265). Another study indicated that less than 5% of SCCmec types I-III harbour 
PVL, while 40-90% of MRSA SCCmec type IV do (266). However, the association between 
SCCmec type IV and PVL production is still under debate. The active form of PVL consists 
of two polypeptide molecules, PVL-F and PVL-S (85). The PVL-S molecules are responsible 
for the initial attachment to the polymorphonuclear neutrophil (PMN) membrane and along 
with PVL-F, create the pore forming unit which leads to cell necrosis (267) and apoptosis 
(due to its effect on the host cell’s mitochondria). PVL is a cytolytic, pro-inflammatory and 
pore forming exotoxin, which, due to these effects, can be used against the host immune 
system (268). It plays an important role in S. aureus SSTI and has a high affinity to collagen 
types I and IV; and laminin [Extracellular Matrix Component (EMC)] which is abundant in 
the lungs, leading to biofilm formation (269) and necrotising pneumonia (270, 271). PVL 
positive S. aureus strains were isolated from 97% of abscesses (272). Production of many 
secreted toxins, including haemolysin and protease, is down-regulated when PVL is 
expressed (271), which is a similar effect to when TSST-1 or SEB are produced (237). 
Staphylococcis aureus strains causing sepsis were found to harbour more than one SAg 
encoding gene. The presence of the sea gene was associated with the severity of infection, 
while egc gene clusters were negatively correlated with pathogenicity (273). A study 
investigating the relationship between agr group type and human disease showed that agr 
does not have an influence on the site of infection caused by S. aureus (274). Investigation of 
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the presence of enterotoxin genes in S. aureus isolates obtained from nasal carriers and 
bacteraemic patients revealed that strains isolated from blood were significantly more likely 
to harbour the sea, seb, sec, and seh enterotoxin genes than those isolated from the nose 
(275).  
The acquisition of antibiotic resistance in S. aureus has been suggested to influence virulence 
factor expression, due to the fitness cost associated with expression of resistance (127, 276). 
Furthermore, HA-MRSA strains containing a SCCmec type II element express fewer 
virulence factors than CA-MRSA containing SCCmec type IV, suggesting that antibiotic 
resistance is negatively associated with gene expression (277). The majority of the studies 
investigating the prevalence of these virulence factor genes were conducted on MRSA 
strains, therefore more studies need to be done on MSSA strains for a proper comparison. In a 
study including MRSA and MSSA isolates obtained from children (≤14 years), the 
prevalence of the pvl gene was significantly higher in MRSA compared to MSSA strains, 
while the presence of the seb gene was significantly higher amongst MSSA than MRSA 
isolates (278). Comparing the virulence gene profiles of three groups of isolates including 
CA-MRSA (USA 400), clinical MSSA and nasal carriage MSSA; the CA-MRSA virulence 
factor profile showed significantly higher percentages of  the sea, sec, seg, seh, sek, sel, pvl 
and clfA genes, compared to the other two groups of isolates (279). In another study, MRSA 
harboured the seg and sei genes more frequently than MSSA strains (280).  
South African MSSA isolates showed a distinct PFGE genotype compared to MSSA isolates 
from the U.S.A. The presence of the sdrD, sea and pvl virulence factor genes was 
significantly higher in the South African MSSA isolates compared to U.S.A. MSSA isolates 
(281). A collection of S. aureus bloodstream isolates from North America and Europe also 
showed a significant difference between the virulence gene profiles obtained from the 2 
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regions, thereby suggesting that S. aureus strains from different geographical regions vary in 
their virulence factor gene profiles (282). 
 
1.9 Quorum Sensing 
Bacteria were thought to be primitive single-cell organisms which could survive and multiply 
independently without any interaction with other members of the same species. However, 
quorum sensing is a form of intra-species (and sometimes inter-species) communication 
which enables the bacteria to detect population density and to alter and synchronise gene 
expression based on population density. The ability of bacteria to overcome the host immune 
response (thus facilitating infection) depends on the bacterial population density, otherwise 
known as the infective dose (283). Bacterial propagation is essential to survival and should be 
carefully controlled (284). For bacteria to colonise a specific body site, they need to attach to 
host cells and then multiply until reaching a critical mass, after which nutrients and space 
become limited. To survive, the bacteria must then invade other body sites, which would 
require suppression of genes that encode for adhesion at the current site and expression of 
genes that contribute to invasiveness (285). During the early exponential phase of growth, S. 
aureus produces surface proteins including the adhesins, protein A, fibronectin-binding 
protein and collagen. These factors are later down-regulated at the end of the exponential 
phase of growth. S. aureus will then up-regulate the extracellular proteins, including the 
toxins and hemolysins. This regulation of virulence factors assists S. aureus in colonising the 
skin of different body sites in the first stage of infection, and to then invade the host tissue via 
extracellular virulence factors as soon as it reaches a critical mass. The agr locus is 
responsible for this virulence factor regulation via a quorum sensing mechanism (286, 287). 
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The expression of the agr locus is controlled by two different promoters, P2 and P3, which 
function together as a typical autoactivation circuit (288) (Figure 3) . The P2 promoter 
consists of the agr B,D,C and A genes, which via RNAII, encode for the signal transducer 
(AgrC), the response regulator (AgrA), a propeptide that is processed to an autoinducing 
peptide (AIP) (AgrD); and the integral membrane protein that is responsible for the 
maturation and/or secretion of AIP (AgrB) (289, 290).  
The Staphylococcal accessory protein A , encoded by the staphylococcal accessory protein 
regulator (sar) and AgrA, binds to a specific region between the P2 and P3 promoters (291). 
This binding up-regulates transcription of the agr locus via the P2 and P3 promoters, leading 
to increased RNAII and RNAIII production (292). When the agr locus is activated by RNAII, 
AgrD will be modified to AIP and secreted out of the cell by the AgrB assistant (290). 
Autoinducing peptide  then binds to its specific receptors on AgrC leading to AgrC 
phosphorylation (293) and the transfer of the phosphate group from AgrC to AgrA, resulting 
in AgrA activation (294). RNAIII up-regulates the production of extracellular toxins and 
down-regulates cell surface proteins (295). 
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Figure 3 :  agr locus structure and autoactivation. (281) 
AIP: autoinducing peptide; Heterologous AIP: produced by different agr type; P2: promoter 2 
which activate agr B, D, C and A genes via RNAII; P3: promoter 3 which provoke exotoxin 
production and supress surface protein expression via RNAIII. 
 
According to the sequence differences in the agr B, D and C regions, the agr locus can be 
classified into four agr groups (I to IV) (290, 296). Autoinducing peptide produced from S. 
aureus strains that have the same agr group type are able to activate each other’s agr 
responses, while AIP from strains belonging to different agr groups may inhibit the agr 
response in strains from other agr group types (290, 297, 298).  
Accessory gene regulator  group I has been shown to be associated with invasive infections 
especially bacteraemia, while agr group III is associated with non-invasive infections (299). 
Another study found a possible association between agr group IV strains and generalised 
exfoliative syndrome; and agr group I and II strains with suppurative infections and 
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endocarditis (300). Most strains that cause TSS have agr group III (290); and VISA strains 
often consist of agr group types I or II (U.S.A. and Japan (type II), Taiwan (type I) and 
Europe (type I and II)) (301).   
Accessory gene regulator function may control virulence factor gene expression as is 
evidenced by attenuation of  agr dysfunctional strains in different animal models, including 
those with skin abscesses (302, 303), osteomyelitis (304), septic arthritis (305), and 
endocarditis (286). Accessory gene regulator  mutant strains have also been found to be less 
virulent than wild-type strains. Sequencing of the agr locus of these agr dysfunctional strains 
revealed some strains had either an insertion or deletion of an adenine in AgrA, B, or C. 
However, a few of the strains were wild-type for the agr sequence, suggesting that different 
factors may affect agr functionality (306). Another study showed that the acquisition of the 
mecA gene by HA-MRSA causes cell wall changes which can reduced the agr quorum 
sensing activity (307). 
In CA-MRSA strains (SCCmec types IV and V), the agr locus is essentially functional. Thus, 
these strains are highly virulent (308) and transmissible between different hosts (309). HA-
MRSA strains (SCCmec types I-III) are essentially agr dysfunctional and mostly spread in 
hospitals (306, 310). A study investigating the association between agr dysfunction and 
reduced vancomycin susceptibility with CA-MRSA (SCCmec IV/IVa) and HA-MRSA 
(SCCmec I-III) reported a significant association between carrying SCCmec type I-III and 
impaired agr functionality as well as with a reduced vancomycin susceptibility (310). Similar 
results were found in South Korea amongst bacteraemia isolates, where agr dysfunction was 
significantly higher in ST239-MRSA-III and ST5-MRSA-II than in ST72-MRSA-IV (311). 
In a hospital environment, the prevalence of agr dysfunctional MRSA isolates ranges from 15 
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to 60%, whereas the prevalence of agr dysfunctional isolates outside the hospital 
environment is rare ( ̴ 4%) and usually associated with individuals with a recent 
hospitalisation event (309, 312-315). Although agr dysfunctional isolates’ virulence is 
attenuated, some studies show that the impaired agr functionality may confer advantages to 
these strains in health care environments under antibiotic selection pressures (309, 316). 
Exposure to sub-lethal concentrations of certain antibiotics may lead to the selection of agr 
negative strains which thereby increase their fitness advantage (317). MRSA agr 
dysfunctional isolates have been found to be more resistant to thrombin-induced platelet 
microbicidal proteins (tPMP) and lead to a more persistent bacteraemia than agr functional 
isolates (312). Clinical studies have reported that agr-dysfunctional isolates are associated 
with reduced susceptibility to vancomycin, heteroresistance to vancomycin (hVISA); and 
increased trends toward VISA (311, 316, 318, 319). The effect of agr dysfunction on 
mortality rates of bacteraemic patients remains unclear with some studies reporting a higher 
mortality rate in severely ill patients (320), with others reporting no association (310). 
Even though the virulence of agr dysfunctional strains is impaired, they are still able to 
colonise the nostrils of previously hospitalised patients and are transmissible between family 
members (313). The similar percentage of agr dysfunctional strains reported among carriers 
who developed bacteremia and uninfected carriers, suggests that agr function is not essential 
for infection (321). 
Colonisation is a risk factor for S. aureus infection and nostrils are the most common body 
site of colonisation. Colonised individuals are more susceptible than noncarriers to 
subsequent infections, including bacteraemia. Hospitalisation, immune compromise (HIV and 
diabetes) and extremes of age have been reported as predisposing factors for MRSA 
colonisation. Although S. aureus nasal colonisation as a source of endogenous bacteremia has 
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been studied in other countries, it has not been investigated in South Africa.  
The aim of this study is to investigate the phenotypic and genotypic characteristics of isolates 
of S. aureus collected from the blood and nasal cavity of patients admitted to Tygerberg 
Hospital, South Africa. Using PFGE, the following chapter will determine the association 
between blood and nasal isolates of our patient cohort. In Chapter 3 we focus on the 
genotypic characteristics of our isolates using different genotyping methods. In chapter 4 we 
describe the prevalence of virulence factor genes amongst selected representative isolates and 
finally (Chapter 5) we determine the agr functionality of isolates in the cohort.  
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CHAPTER 2 USING PFGE: CORRELATING BLOOD AND NASAL       
STAPHYLOCOCCUS AUREUS ISOLATES IN PATIENTS ADMITTED TO    
AN ACADEMIC HOSPITAL IN SOUTH AFRICA 
2.1 Introduction 
As discussed in section 1.3, the nose can be considered as the main colonisation site as S. 
aureus has high adherence ability to nasal epithelial cells in the anterior part of the nostrils 
(322-324). The nasal secretions contain different innate immune components including 
lysozyme and antimicrobial peptides which protect the nose from colonisation by different 
microbes (325).  
Colonising S. aureus strains are biologically well adapted to the persistent carrier’s nasal 
environment. As a result, following nasal decolonisation, the majority of persistent carriers 
are recolonised with their original specific colonising strain(s) (59, 326).   
In the Netherlands, a recent study on healthy volunteers found that S. aureus colonised the 
nose of approximately 71% of the healthy population (326). This consisted of persistent 
carriers (24%) where ≥80% of the nasal swabs (usually obtained at 3-4 weeks intervals) were 
positive for S. aureus during a six month period, and intermittent carriers (47%), when the 
isolation rate was ˂80% during the same period (326). In this study the authors suggested 
reclassifying carriers into “persistent” and “others”, as the intermittent and noncarriers had 
similar antistaphylococcal antibody profiles and responded in a similar way to an artificial 
nasal inoculation with a S. aureus mixture after prior decolonization. Hospitalisations, length 
of hospital stay and antibiotic treatment have been shown to be risk factors for nasal 
colonisation (42, 327).  
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S. aureus infection in carriers has been found to be higher than in noncarriers (16, 39, 328). 
In patients on continuous ambulatory peritoneal dialysis (CAPD), nasal carriers were found 
to be significantly more vulnerable to develop catheter exit-site infections than noncarriers. 
The similar phage type and antibiotic profile of 85% of colonising and infecting isolates 
supports the endogenous route of infection in colonised CAPD patients (329). Similar results 
were obtained and demonstrated that 93% of nasal and infecting strains had the same phage 
type in patients on haemodialysis (330). Von Eiff and co-workers performed a study in 
Germany applying two approaches to investigate the correlation of blood and nasal S. aureus 
isolates. First, nasal swabs were collected immediately after the blood culture of patients 
admitted to the hospital revealed a positive S. aureus growth. In a second study, they 
screened 1278 patients’ nostrils over a five-year period and followed up each case to identify 
those who developed S. aureus bacteraemia (SAB). According to Pulsed-Field Gel 
Electrophoresis (PFGE) data, the correlation between the blood and nasal isolates in the first 
and second study was 82.2% and 85.7% respectively (331). In another study, S. aureus 
carriers had been found to be three times more likely to develop bacteraemia than non-
carriers (16). In addition, there is evidence that decolonisation of nasal carriage reduces the 
incidence of S. aureus infection (332, 333). Taken together, this indicates that the nose is a 
primary colonising site from where S. aureus can spread to other body sites and cause 
infections.  
Nasal methicillin resistant S. aureus (MRSA) colonisation at admission time or acquisition 
during hospital stay is well known as a predisposing factor for subsequent clinical infection 
(334). Colonisation with MRSA compared to methicillin sensitive S. aureus (MSSA) leads to 
a four times higher risk of developing S. aureus infection (73).  
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Although many studies have evaluated the correlation of S. aureus nasal colonisation as a risk 
factor for subsequent infection, the correlation of blood and nasal isolates has not been 
studied thoroughly in developing countries. The patient population, geographical area, 
differences in infection control practices, disease profiles (such as the prevalence of immune 
suppression caused by HIV) and also possible S. aureus strain type variation between 
developed countries and South Africa may lead to different results. The aim of this study was 
to determine the correlation between the nasal colonising and invasive blood isolates of 
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2.2 Methods 
2.2.1 Study design and setting 
This was a prospective descriptive study designed to illuminate the main characteristics of the 
strains isolated from patients with SAB at Tygerberg Academic hospital, and to determine the 
correlation between blood and nasal isolates using molecular strain typing methods. 
Tygerberg Hospital is a 1384 bed tertiary-care academic hospital that provides a 
comprehensive clinical service. Bed numbers for the intensive care units (ICU) are 101, 
consisting of 83 adult ICU (AICU) beds and 18 paediatric ICU (PICU) beds. At the time of 
the study some wards were temporarily allocated to patients from a secondary level district 
hospital (Khayelitsha District Hospital, 230 beds) and are referred to as Khayelitsha wards.  
The laboratory work for this study was conducted in the research laboratory of the Division 
of Medical Microbiology of the Faculty of Medicine and Health Sciences at Tygerberg 
Hospital. 
 
2.2.2 Study population 
All patients from Tygerberg Hospital with SAB as confirmed by blood culture were included 
in the study. Nasal swabs were collected on these patients to determine S. aureus carriage 
status. 
 
2.2.3 Inclusion criteria 
Cases/Patients were recruited over a period of 24 months from January 2010 to January 2012. 
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Every patient with a positive blood culture from which a pure growth of S. aureus was 
isolated, who consented to be part of the study or who qualified for a waiver of consent (see 
‘ethical considerations’), and from whom it was possible to obtain nasal swabs to determine 
colonisation, was included in the study. 
If more than one S. aureus bacteraemic episode occurred in a patient, an isolate from the 
second episode was only included if the patient’s doctor confirmed clinical improvement 
after the first episode or if a negative blood culture had been documented between the first 
and second bacteraemic episodes. When more than one isolate from the same patient in one 
episode had identical PFGE band patterns, only one isolate was included as a case. 
  
2.2.4 Exclusion criteria 
Cases where the blood culture yielded mixed growth of S. aureus with another bacterial 
species or mixed growth with different S. aureus strains were excluded. Cases (including 
their blood culture isolates) where nasal swabs could not be taken because the patient 
demised, was transferred to another hospital or did not give consent, were also excluded from 
the study.  
 
2.2.5 Data collection  
Limited clinical data including the patient’s underlying diseases was collected and recorded 
by the clinical microbiologist on duty at the time when S. aureus was isolated from a positive 
blood culture as part of the routine consultation with the treating clinician. However, there 
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was no standardised, prospective collection of clinical data for the purposes of the study. 
Due to the fact that the patient population of Tygerberg Hospital, as a referral hospital, have 
often had some form of exposure to health care facilities, and due to practical constraints 
related to acquiring in-depth information about the history of each case, we were not able to 
effectively classify cases of bacteraemia as ‘hospital acquired’ or ‘community acquired’. 
However, in order to gain some insight as to where the patient contracted the invading strain, 
we determined the time interval in days between admission to hospital and blood culture 
collection for all cases.   
As the epidemiology of staphylococci may be different in various age groups in our 
population, patients were stratified at the time of blood culture collection according to the 
following criteria: neonates 1-30 days, children >30 days-13 years and adult ≥ 13 years. 
 
2.2.6 Blood culture isolates 
Blood cultures were taken from patients at clinicians’ discretion, and submitted to the NHLS 
microbiology laboratory at Tygerberg Hospital. Blood culture bottles were incubated in the 
BACTEC Fluorescent 9120 system (Becton Dickinson). Isolates were identified as S. aureus 
based on standard microbiological methods, including Gram morphology, catalase, mannitol 
fermentation, presence of DNAse, and if necessary the PastorexTM Staph-Plus (Biorad) test. 
The Vitek®2 System (Biom′erieux) was used to confirm the identification when the mannitol 
fermentation or DNAse was negative or weakly positive. S. aureus isolates from blood 
cultures processed by the diagnostic microbiology laboratory of the National Health 
Laboratory Service (NHLS) at Tygerberg Hospital were collected for further investigations in 
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this study.  
 
2.2.7 Nasal swab collection  
Nasal swab were collected on the same day that the patient’s blood culture revealed the 
presense of S. aureus. After acquiring informed consent from patients that met the inclusion 
criteria, nasal swabs were taken by sterile distilled water moistened cotton-nasal swab (for 
adults: COPAN 155C RAYON Regular Tip, and for children: 160C RAYON Aluminium 
RAYON Mini Tip) (45, 69). The left and right nostrils were swabbed by inserting the 
moistened nasal swab into the vestibulum nasi (1.5 cm in adults and anatomically appropriate 
distance to reach the vestibulum nasi in children and neonates), applying pressure and 
rotating the swab on the internal side of the nostrils for four continuous times (55, 335). The 
specimens were transported in an ice box to the laboratory within 30 minutes.  
 
2.2.8 Bacterial isolation of S. aureus from nasal swabs 
The nasal swab was plated on 5% horse blood agar (BA) and incubated at 37˚C for 2 days, as 
well as on mannitol salt agar (MSA) as described previously (336), incubated at 37˚C for 2 
days, followed by incubation at 25˚C for another 5 days. The tip of the swab was broken off 
and dropped into mannitol salt broth (MSB) and incubated with shaking at 37˚C for 7 days 
(59). The MSB was prepared according to the Difco manual (337) and stored at 4˚C in the 
dark and used within a one month period. If the colour of MSB changed from orange to 
yellow, the broth was subcultured on BA. More than one colony was chosen for identification 
when different colonies showed variable phenotypic characters. S. aureus identification was 
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based on conventional methods, as described for blood culture isolates.  
 
2.2.9 Storage of bacterial isolates 
A single colony from each pure culture obtained from the blood culture and/or the nose and 
identified as S. aureus was subcultured on BA. A cryopreservative tube (Pro-Lab 
Diagnostics) was inoculated with colonies from this pure culture according to the 
manufacturer’s instructions. The inoculated cryovial tubes were stored at -80˚C for further 
testing. 
 
2.2.10 Methicillin susceptibility testing 
Methicillin susceptibility was determined using the disc diffusion method and interpreted 
according to the 2010 CLSI guidelines (338), where 0.5 McFarland of S. aureus suspension 
streaked on Mueller-Hinton agar and cefoxitin 30 µg (Mast Diagnostics) discs were used. 
Both MRSA and MSSA isolates were included for further study.   
 
2.2.11 Molecular typing of isolates 
Pulsed-field gel electrophoresis (PFGE), the most discriminatory S. aureus genotyping 
technique (203), was performed as previously described (97). 
Briefly, a single colony of a pure culture was inoculated into brain heart infusion broth 
(BHIB) and incubated overnight at 37ºC. The cell suspension volume used in plug 
preparation was calculated by adjusting to a spectrophotometer (Amersham Biosiences) 
absorbance of 0.9 at 600 nm. The bacterial cell suspension was centrifuged and the 
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supernatant discarded. Plugs were prepared by re-suspension of the bacterial pellets in 300 μl 
of TE buffer (10 mM Tris HCL, 1 mM EDTA), 300 μl of 1.8x agarose (Lonza, Switzerland) 
and 4 μl of lysostaphin (130 μg/l; Sigma, St. Louis, USA).  Solidified plugs were 
subsequently immersed in EC lysis buffer (6 mM Tris HCL, 1M NaCL, 100mM EDTA, 0.5% 
Brij-58, 0.2% sodium deoxycholate, 0.5% sodium lauroylsarcosine) and allowed to incubate 
overnight at 37ºC followed by four washes in TE buffer. The bacterial genome was restricted 
by SmaI enzyme (Fermentas life science) for 4 hours at 25ºC followed by electrophoresis in a 
1% pulsed-field certified agarose gel (BIO-RAD). The electrophoresis was performed by 
using the CHEF-DR® III system (BIO-RAD) and the following parameters were used: 200 
(6V/cm), temperature 14ºC, initial switch 5 seconds (s), final switch 40s and running time 
was 21 hours. The gel was then stained with ethidium bromide (EtBr) (Promega) solution 
(1µg/ml) for 30 minutes followed by destaining in fresh water for 45 min. Separation bands 
were visualised and the image captured as a TIFF file for analysis with GelCompar®II 
Version 6.0 software to identify PFGE clusters and strain similarities. Tolerance and 
optimisation at 1.5 and 0.5% respectively were used to set bands and an 80% similarity 
coefficient was used to define the pulsed-field type clusters (97). Isolates that exhibited 
indistinguishable PFGE band patterns were considered the same strain. 
 
2.2.12  Definitions 
We identified a ‘case’ as any patient with an episode of S. aureus bacteraemia that met the 
inclusion criteria. Endogenous SAB was defined as cases where the nasal and blood isolates 
had identical PFGE band patterns (as shown in Fig 2.1, N1 and B1; N5 and B5; N6 and B6), 
as this indicated that the patient was likely to be infected by his/her own colonising strain. 
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Exogenous SAB was defined as any case where there was no nasal colonisation or cases 
where blood and nasal isolates had different PFGE band patterns, as this indicated a possible 
external source of infection, and that the nasal isolate was not the cause of bacteraemia (as 
shown in Fig 4, N2 and B2; N3; N4 and B4). When S. aureus was not isolated from the nasal 
swab the patient was identified as a non-colonised patient.  Although these patients were 
included in the exogenous SAB group, they were excluded when the correlation between 
nasal and blood culture isolates was analysed. 
 
2.2.13 Statistical analysis 
The correlation between blood culture and nasal S. aureus isolates was evaluated by the T-
test for a single proportion. The Chi-squared test was used to estimate the significance of the 
correlation between the source of bacteremia and methicillin resistance. The difference in the 
time of admission and blood sample collection as well as the difference in the time of blood 
sample collection and nasal swabbing was statistically evaluated by Mann-Whitney U Test. 
Statistical significance was set at a p value of <0.05. Statistical analysis was performed using 
Statistica, version 10 (2012). 
 
2.2.14 Ethical considerations 
The study was approved by the Committee of Human Research at the Faculty of Medicine 
and Health Sciences, Stellenbosch University (N09/10/266) (Appendix A1). Three different 
consent forms were used to obtain informed consent from variable ages and groups: adults 
(≥18 years old) (Appendix A2), adolescents (≥13 - 17 years old) and the parents or guardians 
Stellenbosch University  https://scholar.sun.ac.za
 54 
of adolescent children and neonates (<13 years old) (Appendices A3 and A4, respectively). A 
waiver of consent was approved to take nasal swab from intubated, unconscious patients and 
children in cases where their parents or guardians were not available. Patient confidentiality 
was assured by allocating a case number to each isolate which also indicated the source of 
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2.3 Results 
2.3.1 Patient demographics 
Of a hundred and sixty four patients with SAB, 162 met the case definition during the period 
of specimen collection and were therefore included in this study. Two patients were excluded 
because they were infected with more than one strain of S. aureus. In one patient one of the 
nasal isolates correlated with one of the blood isolates, however differed to the other blood 
isolate in the other, therefore making classification of endogenous or exogenous infection 
problematic. 
The mean age of the study population was 29 years, ranging from 2 days to 87 years. 
Interquartile range (IQR) was 44.36 years.  
The majority of patients were adults, 108 (66.7%) followed by 31 (19.1%) neonates and 23 
(14.2%) children. The gender breakdown of the different age categories is shown in Table 2. 








Adults 63 (38.9) 45 (27.8) 108 (66.7) 
Children 11(6.8) 12 (7.4) 23 (14.2) 
Neonates 17 (10.5) 14 (8.6) 31(19.1) 
Total 91 (56.2) 71(43.8) 162 (100) 
* Percentages are shown using the total number of SAB cases (162) as denominator 
 
2.3.2 Blood and nasal isolate correlation in colonised patients. 
Nasal colonization was detected in 128 (79%) of the 162 patients included in the study. Blood 
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and nasal isolate correlation in colonised patients was evaluated by using PFGE gel band 
patterns analysis (Figure 4), which showed a highly significant correlation (p < 0.000001) 
between the blood and nasal isolate pairs where 93/128 (72.7%) of the colonised patients 
were infected with the same strain.  
 
2.3.3 Endogenous and exogenous bacteraemia 
PFGE gel band pattern analysis results were used to classify SAB into endogenous and 
exogenous categories for all 162 cases based on the band pattern similarity between the blood 
and nasal isolate of a patient.   
Identical blood and nasal isolates were found in 93 patients, establishing the colonizing strain 
as a likely source of infection in 57.4% of all SAB cases. From the limited clinical data the 
main underlying conditions among endogenous bacteraemia cases were burns (n=12), renal 
failure (RF) (n=9) and HIV infection (n=7).  
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Figure 4 : SmaI PFGE band patterns results for blood and nasal isolates obtained from 
different patients.  
*(N) Represent nasal isolates and (B) represent blood isolates. Similar colonizing and invading strains as shown in lanes N-1 
and B-1 (patient 1), N-5 and B-5 (patient 5) and N-6 and B-6 (patient 6).  Different blood and nasal isolates as shown in N-2 
and B-2 (patient 2) and N-4 and B-4 (patient 4). Lane B-3 represents a strain from a patient that was not colonized and the 
first and last lanes (NCTC 8325-4) were used as markers. 
 
The source of SAB was classified as exogenous in the other 69 (42.6%) patients: 35 (21.6%) 
colonized with one or more S. aureus strains that were not related to the blood isolate and 34 
(21%) not colonised with S. aureus at all (Table 3). The main underlying conditions among 
exogenous bacteraemia cases were burns (n=15), RF (n=6), heart disease (n=5) and cancer 
    NCTC 
    8325-4 
   N-1   B-1   N-2  B-2       B-3  N-4  B-4   N-5   B-5    N-6  B-6   NCTC 
  8325-4 
   Marker   Patient 1 
 
 Patient 2 Patient 3    Patient 4   Patient 5     Patient 6 Marker 
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(n=2). Exogenous SAB was more common in medical emergency and gynaecology wards 
(Fig 5).  
 
Table 3 : Correlation of blood and nasal S. aureus isolates in patients with SAB 
Related / identical blood and nasal 
isolates 
93 (57.4%) 








with invading strain 
plus another S. 
aureus strain(s) 
Patients colonised with one 
or more S. aureus strains that 
did not match with the blood 
isolates 
non S. aureus 
colonised 
patients 
89 (55%) 4 (2.4%) 35 (21.6%) 34 (21.0%) 162 
*Percentages are shown using the total number of SAB cases (162) as denominator. 
The demographics of the patients with endogenous and exogenous bacteraemia are shown in 
Table 54. 
 


















Adult 64 (39.5) 44 (27.2) 108 (66.7) 
Children 11 (6.8) 12 (7.4) 23 (14.2) 
Neonates 18 (11.1) 13 (8) 31 (19.1) 
 
Gender 
Male 48 (29.6) 43 (26.6) 91 (56.2) 
Female 45 (27.8) 26 (16) 71 (43.8) 
 *Percentages are shown using the total number of SAB cases (162) as denominator. 
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When comparing endogenous infection to exogenous infection with respect to the different 
hospital wards, the ratio of endogenous to exogenous infection was highest in internal 
medicine wards compared to other wards (Figure 5). 
 
 
Figure 5 : Ratio of the exogenous versus endogenous SAB in Tygerberg Hospital wards with 
the highest number of cases.  
AICU, adult intensive care unit; PICU, paediatric and neonatal Intensive care unit; paediatric wards includes neonatal 
patients.    
 
2.3.4 MRSA/MSSA bacteraemia  
Of the S. aureus strains isolated from blood, 42.6% (69/162) were MRSA. The adult surgical 
ICU (AICU) and paediatric wards had the highest number of MRSA cases, 39.1% (27/69) 
and 27.5% (19/69) respectively (Table 5). MRSA bacteraemia in neonates constituted 14.2% 
(23/162) of all SAB cases and 33.3% (23/69) of all MRSA bacteraemia cases, reflecting the 
high prevalence of MRSA bacteraemia in neonates (Table 6).  
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Table 5 : Numbers and percentages of endogenous versus exogenous MRSA and MSSA 




















AICU 18 (26.1) 9 (13) 14 (15.1) 21 (22.5) 62 (38.3) 
Paediatric wards 11 (16) 8 (11.6) 7 (7.5) 7 (7.5) 33 (20.4) 
Internal medicine 7 (10.1) 0 13 (13.8) 6 (6.5) 26 (16.2) 
Surgery 3 (4.3) 1 (1.4) 8 (8.6) 5 (5.4) 17 (10.5) 
PICU 5 (7.3) 0 1 (1.1) 2 (2.2) 8 (4.9) 
Khayelitsha 4 (5.8) 3 (4.3) 1 (1.1) 2 (2.2) 10 (6.1) 
Gynecology 0 0 1 (1.1) 2 (2.2) 3 (1.8) 
Medical emergency 0 0 0 3 (3.2) 3 (1.8) 
Total 48 (69.6) 21 (30.4) 45 (48.3) 48 (51.7) 162 
 
2.3.5 Endogenous and exogenous bacteraemia and MRSA/MSSA 
The MRSA prevalence in cases of endogenous bacteraemia (48/69; 69.6%) was higher than 
the MRSA prevalence in cases of exogenous bacteraemia (21/69; 30.4%). MRSA 
significantly correlated with endogenous infection (p = 0.007). In adults, MRSA bacteraemia 
was more likely to be endogenous (29/40; 72.5%) than MSSA bacteraemia (35/68; 51.5%). A 
similar finding was present in neonates, with MRSA bacteraemia being endogenous in 16/23 
cases (69.6%) compared to MSSA bacteraemia (endogenous in 2/8; 25%, of cases).    
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Table 6 : Correlation of MRSA/MSSA and endogenous/exogenous bacteraemia in adults, 

















MRSA 29 (18.0) 11 (6.8) 0.042 40 (24.8) 
MSSA 35 (21.6) 33 (20.4) NS 68 (42.0) 
 
Children 
MRSA 3 (1.8) 3 (1.8) NS 6 (3.6) 
MSSA 8 (4.9) 9 (5.6) NS 17 (10.5) 
 
Neonates 
MRSA 16 (9.9) 7 (4.3) 0.042 23 (14.2) 
MSSA 2 (1.2) 6 (3.7) NS 8 (4.9) 
Total 93 (57.4) 69 (42.6) NS 162 (100) 
*Percentages are shown using the total number of SAB cases (162) as denominator. 
 
2.3.6 The time between hospital admission and blood sample 
collection 
The average time between admission and collection of the blood culture for endogenous 
cases was 5.1 days, while for exogenous cases it was 4.75 days. This difference was not 
significant. The median time between the admission and blood sample collection (Figure 6) 
was significantly (P = 0.002) longer in patients with MRSA bacteraemia (5.8 days) than in 
those with MSSA bacteraemia (4.2 days). 
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2.4 Discussion 
2.4.1 Blood and nasal S. aureus correlation in colonised patients 
Our results showed a 72.7% correlation between the nasal and blood S. aureus isolates in 
colonised patients. Previous studies conducted in developed countries reported that 
approximately 80% of blood and nasal S. aureus isolates in colonised patients were the same 
(16, 331, 339). In this study, the correlation between blood and nasal isolates was slightly 
lower than what has been reported in developed countries, which may reflect the impact of 
exogenous sources of bacteraemia in patients at Tygerberg Hospital.  
Molecular typing techniques with a high discriminatory power like PFGE have in recent 
studies lead to improved discrimination between isolates and better determination of the 
source of bacteraemia (340). A study conducted in 1992 reported all nasal and blood S. 
aureus isolates in HIV patients were identical, by using the antibiotic profile of the colonising 
and invasive strains (341). In 1995 by using phage typing technique, Kluytmans et al., found 
92% of the nasal and postoperative wound infection isolates were identical (342). In these 
studies less discriminatory techniques were used and therefore the correlation was higher 
compared to recent studies. 
 
2.4.2 Endogenous and exogenous bacteraemia  
We were able to establish that nasal colonisation was a possible source of infection in 57.4% 
of patients. In the other 42.6% of cases, the source may have been either colonisation of 
another body site, or, more likely, an external source.  
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2.4.3 MRSA bacteraemia  
Tygerberg Hospital is a tertiary-academic hospital receiving patients referred from other 
hospitals. In this study, 42.6% (69/162) of S. aureus bacteraemia cases were due to MRSA. 
This is much higher than previous data in 1988 and 2009 where the proportion was 25% and 
30.1%, respectively (24, 25). However, our MRSA prevalence is still comparable to average 
MRSA prevalence in South African hospitals which has been reported as between 30-60% 
(343). Lack of effective infection prevention and control procedures and antibiotic 
stewardship may be a possible cause of the high prevalence of MRSA bacteraemia cases at 
Tygerberg Hospital. 
In the Netherlands, which effectively implemented active screening and decolonisation 
measures, along with a history of restricted antibiotic usage, the prevalence of MRSA among 
clinical S. aureus isolates is less than 1% (344, 345). Higher prevalence rates have been 
reported in different countries: Germany 19%, Belgium 19% and France 33% (345).  
Results of this study also showed a significant association of MRSA bacteraemia with MRSA 
nasal colonisation in adult surgical ICU patients and neonates. Several studies reaffirmed the 
vulnerability of colonised patients admitted to ICU to develop subsequent S. aureus 
infections, including SAB. This includes the study of Pujol et al., where they measured the 
risk of patients colonised with S. aureus at the time of admission to the ICU to develop 
endogenous SAB. They found that S. aureus colonisation was a risk factor, but MRSA nasal 
carriage was a greater risk than MSSA (339). In another study, nasal carriers admitted to an 
ICU surgery unit were twice as likely to develop postoperative infections than were 
noncarriers (346). Nasal carriage of MRSA on hospital admission and during hospital stay 
has been reported as a predisposing factor for subsequent clinical infection in different 
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hospital wards including ICU and general medical surgery (334, 346).  
 
2.4.4 MRSA/MSSA endogenous versus exogenous bacteraemia 
This study clearly showed a significant association between MRSA bacteraemia and 
endogenous infection. Patients with MRSA bacteraemia were more likely to have an 
endogenous source than patients with MSSA bacteraemia (odds ratio 2.4, 95% CI 1.3-4.7). 
Milstone and his team found that MRSA colonisation in hospitalised children and adults was 
a predisposing factor for subsequent clinical infection (43). In that study, ICU admitted 
patients often had a serious clinical condition that compromised their immune systems and 
increased the risk of nasal colonisation and subsequent SAB. The high neonatal MRSA nasal 
carriage rate may therefore be due to mothers holding their infants close to their chest, 
facilitating S. aureus transmission, and due to the immune compromised status of the 
neonate. It would be interesting to test this hypothesis by examining the nasal carriage status 
of mothers in the maternity and/or neonatal wards.  
Other studies have shown that subsequent clinical infection is four times more likely in those 
colonised with MRSA as opposed to MSSA colonisation (73). In our study, 69.5% of MRSA 
bacteraemia cases were colonised with the same strain. This confirms the need for good 
infection control practices including the identification and decolonisation of carriers at risk of 
developing infection to decrease the spread of MRSA in the hospital and preventing carriers 
from developing subsequent S. aureus clinical diseases. In our study, approximately 50% of 
patients with MSSA bacteraemia, developed bacteraemia with the same strain that was 
present in the nares. 
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The average time between the admission and blood culture collection was significantly longer 
(P = 0.002) for patients with MRSA bacteraemia than MSSA bacteraemia (5.8 and 4.2 days 
respectively) which may indicate hospital acquisition of MRSA. However, further studies are 
required to investigate when S. aureus nasal colonisation occurs in hospitalised patients and 
in particular when colonisation with MRSA occurs. Although most cases of MRSA (and 
MSSA) bacteraemia were endogenous, it is not clear whether the colonisation with MRSA 
was present on admission, or whether colonisation with MRSA developed in hospital.  
The current study was limited in that it was not designed as an active surveillance study and 
that bacteraemia may have occurred before nasal colonisation. Due to the limited availability 
of clinical data, we could not determine if patients had received prior antibiotic treatment that 
could have eliminated S. aureus nasal carriage and lead to false negative results. However, 
this is not commonly practised in this hospital, and is felt to be an unlikely confounder. We 
did not investigate the colonisation of other body sites which may have caused us to miss 
some carriers. Lastly, Tygerberg Hospital is a tertiary referral hospital, therefore it was 
difficult to categorise isolates as causing either healthcare- associated or community 
associated infections, as some patients would have been referred in from secondary or district 
level health services..  
This was the first study that investigated the correlation between nasal and blood S. aureus 
isolates of patients in a tertiary hospital in South Africa and we conclude that, (i) in patients 
with MRSA bacteraemia, approximately 70% have evidence of nasal colonisation with the 
same strain, while with MSSA bacteraemia, only 50% have evidence of nasal colonisation, 
which highlights the need for more studies to explore the feasibility of nasal decolonisation in 
a prevention control strategy of SAB in patients at an institution such as ours; (ii) our results 
also show that S. aureus nasal colonisation was not the only source of infection in patients 
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with S. aureus bacteraemia, 42.6% acquired the infection from sources other than the nostrils; 
(iii) occurrence of MRSA bacteraemia was significantly associated with MRSA nasal 
colonisation in adult surgical ICU patients and neonates. Studies to determine the population 
at risk in this specific population will also assist targeted infection control and prevention 
policies in a resource constrained environment such as ours, in order to lower the incidence of 
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CHAPTER 3 MOLECULAR CHARACTERISATION OF BLOOD AND 
NASAL S. AUREUS ISOLATES OBTAINED FROM PATIENTS WITH 
BACTERIA ADMITTED AT TYGERBERG HOSPITAL 
3.1 Introduction 
It has been suggested that MRSA clones evolved from MSSA lineages by horizontal 
acquisition of the SCCmec element at only one occasion; this is therefore called the single-
clone theory (347). However, descriptions of both heterogenetic MRSA lineages as well as 
different SCCmec elements in isolates from the same genetic background supports the multi-
clone theory where MRSA clones emerged from repeated independent introduction of 
different SCCmec elements into successfully adapted MSSA clones (117, 121, 136, 348). 
However, MSSA strains isolated from the hospital environment in 1960 revealed similar 
genetic characteristics to recently identified predominant MRSA clones. This suggests that 
these clones were well adapted to the hospital environment through host colonisation and 
invasion even before SCCmec element acquisition (349). Currently, there are a few MRSA 
clones that have disseminated worldwide, namely CC5, CC8, CC22, CC30 and CC45 (117, 
121, 350). 
Healthcare associated MRSA (HA-MRSA) causes nosocomial infection in individuals 
admitted to hospital or who are exposed to the healthcare environment (such as  long-term-
care facilities) (351). As discussed previously, the distinction between healthcare and CA-
MRSA is becoming less clear as recent reports showed dissemination of CA-MRSA into 
hospitals causing serious infections (352, 353).  
Limited information has been published regarding the molecular epidemiology and 
population structure of the MSSA lineages considered the genetic ancestors of emerging 
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MRSA clones. The genetic diversity of MSSA is higher than MRSA, which is not surprising 
given shorter evolutionary time of MRSA (≈ 50 years) compared to MSSA clones which are 
much older and thus more heterogeneous (202-204, 354). MSSA isolates related to the 
common MRSA clones have been identified in many countries (80). However, MSSA 
lineages other than the common MRSA clones have been reported worldwide such as CC7, 
CC9, CC12, CC15, CC25, CC51 and CC101, which supports the fact that MSSA strains are 
genetically more diverse than MRSA strains (200, 355). This might be influenced by the fact 
that some epidemic MSSA lineages showed more ability to acquire and maintain the SCCmec 
element than other clones (121). 
 
3.1.1 Geographic distribution 
The prevalence of S. aureus clones is variable in different geographical areas (84). Of the 5 
common HA-MRSA clonal complexes, CC22 is prevalent worldwide; CC30 (ST36) is 
common in the USA and the UK while CC45 is frequently isolated in the USA and Europe 
(80, 356). In Asia the most commonly reported clones are CC5 (ST5), CC8 (ST239) and 
CC22 (ST22) (170, 179, 357). In Latin America CC5 (ST5), CC8 (ST239) and CC30 are the 
most frequently identified strains (358).  
 
3.1.2 Situation in Africa and South Africa 
In Africa, there are limited studies on S. aureus prevalence and antibiotic resistance, leading 
to an outdated and incomplete understanding of S. aureus epidemiology on the continent. In 
Algeria, a study that included 46 MRSA isolates from one hospital showed that 50% of the 
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isolates harboured SCCmec type VI and 43.75% SCCmec type V. All PVL positive strains 
(29.68%) harboured SCCmec type IV (359). A recent study including MRSA isolates from 
five different African countries, Morocco (Casablanca), Senegal (Dakar), Niger (Niamey), 
Cameroon (Yaounde) and Madagascar (Antananarivo), found that the dominant clones were 
ST239-MRSA-III (40%) followed by ST88-MRSA-IV (28%) and ST5-MRSA-IV (21%) 
(171). Another study including 228 MSSA isolates from the same African countries showed 
that 132 (58%) of the isolates belonged to one of five MLST clonal complexes, namely CC1 
(9%), CC15 (12%), CC30 (9%), CC121 (19%) and CC152 (9%) (205). In Nigeria, MRSA 
isolates were found to belong to one of three MLST CCs: ST241 and ST8 (CC8), ST37 and 
ST39 (CC30) and ST88 (CC88), while 8 MSSA sequence types were identified: ST5, ST8, 
ST15, ST30, ST80, ST121, ST152 (singleton), ST508 (CC45) (207).  
In South Africa, MRSA prevalence ranges from 27% to 46% across the 9 provinces (360, 
361). Of 97 MRSA isolates obtained from different clinical specimens from Steve Biko 
Academic Hospital, in Pretoria, SCCmec type II was predominant (67%) followed by 
SCCmec type III (14%) (362). In this study MLST clonal complexes and ST were not 
investigated. In a study conducted in KwaZulu-Natal province including 241 isolates from 16 
hospitals, 24 MRSA and MSSA isolates were randomly chosen for further MLST analysis. 
MLST analysis identified ST8-MRSA-IV (67%), ST239-MRSAIII (13%), ST8-MRSA-II 
(8%), ST5-MRSA-IV (8%), and ST45-MRSA-IV (1%). The MSSA clones identified were 
ST1, ST5, ST6, ST8, ST9, ST22, ST30, ST31, ST45, ST72, ST88, ST121, ST199, ST239 and 
ST243 (206). Another study included 100 MRSA isolates from 5 hospitals in Cape Town 
(excluding Tygerberg Hospital) and found ST239-MRSA-III, ST36-MRSA-II, ST5-MRSA-I 
and ST612-MRSA-IV were the most frequently identified clones (175). To investigate the 
prevalent MRSA clones in South Africa, 320 isolates were collected from 9 provinces and 
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characterized by PFGE, spa typing, MLST, SCCmec typing and PCR for PVL genes. The 
predominant clonal lineages were ST612-MRSA-IV (25.3%), ST36-MRSA-II (23.8%), 
ST239-MRSA-III (20.9%), and ST5-MRSA-I (6.6%) (174).  
At Tygerberg Hospital (one of the academic hospitals in Cape Town that provides healthcare 
services to a large population in the Western Cape Province), two previous studies have been 
conducted. The first study (included S. aureus blood isolates collected during the period 
March 2008 to May 2009) aimed to describe the spa type, methicillin susceptibility and pvl 
gene prevalence of S. aureus strains causing bacteraemia in Tygerberg Hospital. In this study 
the MRSA prevalence was 30.1% (34/113). In blood culture isolates, spa types t037, t891, 
t1257, t002, t015 and t021 were identified as the predominant types among the 113 strains 
(25). This was followed by another study (included isolates were collected over one year 
from September 2009 to 2010) in which isolates from specific sites of infection were 
investigated by PFGE, spa typing, MLST analysis, SCCmec typing, agr typing and PVL 
detection. In this study, MRSA among S. aureus isolates was 15.3% (56/367). The major 
MRSA clonal lineages were ST612-MRSA-IV (n = 21), ST5-MRSA-I (n = 9), ST36-MRSA-
II (n = 6) and ST239-MRSA-III (n = 5) (363). 
In the current study we characterised blood and nasal isolates collected from patients with S. 
aureus bacteraemia at Tygerberg Hospital using molecular techniques to estimate the 
correlation between the colonising and invasive isolates. In this chapter we describe the 
molecular characteristics of nasal (colonising) and blood (invasive) S. aureus isolates (MRSA 
and MSSA) obtained from patients with bacteraemia at Tygerberg Hospital.  
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3.1.3 Aims of the study: 
Genotypic characterisation of colonising and invasive S. aureus (MRSA and MSSA) strains 
collected from patients with S. aureus bacteraemia at Tygerberg Hospital.  
3.1.4 Objectives 
1- To determine the dominant spa type disseminated in Tygerberg Hospital and the 
dominant spa clonal complexes 
2- To determine the SCCmec type of collected MRSA isolates 
3- To determine the agr group of the isolates 
4- To determine the MLST sequence types and MLST clonal complexes of a representative 














The isolates examined were those collected from 164 patients. Of these, 162 were those 
described in chapter 2, and the two excluded patients were included in this analysis. The two 
patients excluded from analysis in Chapter 2 were included for analysis in this chapter and 
consisted of 6 additional isolates (3 blood and 3 nasal isolates). Of 164 patient, 333 blood and 
nasal isolates were collected and genotyped using PFGE, spa typing, SCCmec typing, agr 
typing and were also examined for the presence of the pvl gene.  Where a patient had both 
blood and nasal isolates, and these had the same PFGE pulsotype, only the isolate from blood 
was included in the data analysis. However, where the nasal and blood isolates had different 
pulsotypes, both isolates were included. Likewise, if patients had more than one isolate (from 
nasal swab or blood) with different pulsotypes, all isolates were included. If patients had only 
blood culture isolates, and no nasal carriage, the blood isolate was included. A total of 208 
blood and nasal isolates were obtained from 164 patients with SAB included in the study. Of 
the 208 isolates, 90 (43.3%) were MRSA and 118 (56.7%) were MSSA. The numbers of 
isolates from each group are specified in Table 7. 
A total of 208 blood and nasal isolates were obtained from 164 patients (Table 7): 93 males 
(average age, 32 years; range, 3 days to 87 years) and 71 females (average age, 23.7 years; 
range, 2 days to 86 years) with SAB. Of the 164 patients, 110 (67%) were adults, 23 (14%) 
children and 31 (19%) neonates.  
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92 Obtained from the blood sample of carriers where the blood and nasal isolates had the same 
pulsotype.  
34 Obtained from the blood sample of noncarriers 
35 Recovered from the blood sample of carriers where the blood and nasal isolates had different 
pulsotype. 
35 Recovered from the nasal swab of carriers where the blood and nasal isolates had different 
pulsotype. 
6 Additional isolates from the nasal swab of carriers where more than one strain was identified 
6 Additional blood isolates obtained from 3 patients where each patient infected with 2 different 
isolates according to PFGE gel patterns analysis.  
 
 
3.2.2 Control strains 
The control strains used in this section were obtained from the ATCC.  ATCC 49775 was 
used as a positive control for detection of pvl, and the strains used as controls for SCCmec 
and agr typing are listed in Table 8. 
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Table 8 : S. aureus control strains used in this study 
Strain SCCmec type agr type 
BAA1680 IV I 
BAA1681 II II 
BAA1683 - III 
BAA-1688 V VI 
BAA-38 I - 
BAA-39 III - 
BAA-42 VI - 
 
3.2.3 DNA extraction 
The DNA was extracted by a modified version of a previously described method (364). One 
bead from the frozen strains was streaked on blood agar plate for 18-24 hours at 37˚C then a 
single colony inoculated in Brain heart infusion broth (BHI) for 18-24 hours at 37˚C. One ml 
of cultured BHI broth was centrifuged (sigma, model 1-15) at 13 000 rpm for 1 minute, the 
pellet was re-suspended in 50 µl of lysostaphin (130µg/ml; Sigma) and incubated at 37˚C for 
2 hours. A volume of 50 µl of proteinase K (PK) (130 µl/ml; Sigma) was added with 150 µl 
of Proteinase K buffer (0.1 M Tris [PH 7.5]) and incubated at 37˚C. After one hour the 
suspension was incubated at 100˚C for 10 minutes in a heating block. Finally the suspension 
was centrifuged at 13 000rpm for 3 minutes. The extracted DNA was used as a template in 
the various PCR assays. DNA integrity and concentration were determined using a Nanodrop 
ND 1000 Spectrophotometer V3.1.0 instrument (Nanodrop Technologies, Inc., Wilmington, 
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DE, USA).  
 
3.2.4 spa typing 
3.2.4.1 PCR performance 




Table 9) were used:  Each PCR reaction contains 1.5 mM of spa primers, 1 µL of DNA 
template, and 12.5 µl of Go Taq® Colourless Master Mix (Promega). The final PCR reaction 
volume was 25 µl. The amplification conditions were 94˚C for 4 minute, 35 cycles (94˚C for 
45 seconds, 63˚C for 45 seconds and 72˚C for 90 seconds) with a final extension at 72˚C for 
10 minutes (106) . A 5ul aliquot of the final PCR reaction was visualised by electrophoresis 
in a 1% agarose gel containing 50µg EtBr (Sigma) per 100ml agarose. Amplification of the 
spa gene in non-typeable strains was repeated at different annealing temperatures (62, 61 and 






















1095 F AGACGATCCTTCGGTGAGC 
polymorphic 
1.5 (106) 










4 agr1-F GTCACAAGTACTATAAGCTGCGAT 439 
5 agr2-F TATTACTAATTGAAAAGTGCCATAGC 572 
6 agr3-F GTAATGTAATAGCTTGTATAATAATACCCAG 321 
7 agr4-F CGATAATGCCGTAATACCCG 657 
PVL 8 
luk-PV-1 ATCATTAGGTAAAATGTCTGGACATGATCCA 




























284 2 (14) 




RIF5 F10 TTCTTAAGTACACGCTGAATCG 
414 
4 (368) 




CIF2 F2 TTCGAGTTGCTGATGAAGAAGG 
495 
CIF2 R2 ATTTACCACAAGGACTACCAGC 
V, J1 19 SCCmec V J1 F TTCTCCATTCTTGTTCATCC 377 4 (369) 
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SCCmec III J1 F CATTTGTGAAACACAGTACG 
243 




ccrC F2 GTACTCGTTACAATGTTTGG 
449 
8 (369) 
ccrC R2 ATAATGGCTTCATGCTTACC 




ccrB2 F2 AGTTTCTCAGAATTCGAACG 
311 
ccrB2 R2 CCGATATAGAAWGGGTTAGC 
I, II, IV, 
and VI, J3 
region 
23 
dcs F2 CATCCTATGATAGCTTGGTC 
342 8 (368) 
dcs R1 CTAAATCATAGCCATGACCG 
Table 9 cont.      Primers for different gene targets used in this study. 




mecI P2 ATCAAGACTTGCATTCAGGC 
209 
 (42) 





mecA P4 TCCAGATTACAACTTCACCAGG 
162 
mecA P7 CCACTTCATATCTTGTAACG 
ccrA 26 
ccrA R1 YCCWAA YTA YTG TGGYCGTGT 
296 
0.5 (370) 
ccrA F1 TKY TKG TGC RTTKAT NCC T 
ccrB 27 
ccrB F1 CGW YTR GCW MGW AAY ACHTC 
496 









257 1 (146) 
ccrC2-R2 TTCAATCCTATTTTTCTTTGTG 
 
3.2.4.2 Determination of spa type  
S. aureus spa types were identified as described previously (111). Resultant PCR reaction 
products were sent for sequencing and analysed using the Ridom StaphType
TM
, version 1.4 
(Ridom Gmb, Würzburg, Germany) software package to determine the different spa types. 
Based upon repeat patterns (BURP) analysis in the software was used to identify spa clones 
or clonal complexes using the following parameters: spa types shorter than 5 were excluded 
from BURP analysis and spa types belonging to the same group were only cloned if the cost 
was less than or equal to 5.          
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3.2.5 agr typing 
 A multiplex PCR assay to amplify the agr alleles of all blood and nasal isolates was 




Table 9): 3 (pan reverse primer), 4, 5, 6, 7, and 8 (366).  The PCR mixture contained 12.5 µl 
of Go Taq® Colorless Master Mix (Promega), 5 mM of each primer, 1 µl of the crude DNA, 
and 2.75 mM MgCl2. Denaturation at 95˚C for 6 minutes was followed by 30 cycles of 95˚C 
for 0.45 S, 58˚C for 0.45 S and 72˚C for one minute and a final extension at 72˚C for 10 
minutes. Twenty µl of amplification products were visualised in 3.5% agarose gels with EtBr 
and electrophoresed at 120V for 2 hours. Isolates with non typeable agr were repeated as a 
uniplex PCR with each primer pair combination.  
 
3.2.6 SCCmec typing 
SCCmec types were initially determined using a multiplex PCR as described by Milheirico 
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Table 9) were used to amplify different genetic component in the SCCmec element. The PCR 
reaction contained 12.5 µl of Go Taq® Colorless Master Mix (Promega), 1 µl of the crude 
DNA, and 3 mM MgCl2. Cycling conditions were 95˚C for 5 min followed by 35 cycles of 
95˚C for 45 s, 49˚C for 45 s and 72˚C for 60 s and a final extension time of 72˚C for 10 min. 
The PCR reaction products were visualised by electrophoresis at 120V for 2 hours in 3.5% 
agarose gels withEtBr. The SCCmec type was assigned by comparing the sizes (Table 9) of 
the bands generated with those generated by the 6 control strains (Table 8) using a 100 bp 
ladder. 
 
3.2.7 Untypeable SCCmec band patterns  
Further characterisation of the SCCmec element was carried out where necessary by uniplex 
PCR of specific genes and subsequent DNA sequence analysis. The assay to amplify the class 




Table 9, primer set 28) contained: 2.5 mM MgCl2, 500 μM of each dNTP, 0.2 μl of 
QIAGEN
®
LongRange Taq enzyme, 1 μl of DNA (100ng) and 0.5 mM of primers, in a final 
volume of 25µl. PCR was performed under the following conditions; 35 cycles of 93˚C for 
15 S, 45˚C for 15 S and 68˚C for 4 min following an initial denaturation at 95 C˚ for 3 min, 
and ended by final elongation at 68˚C for 7 min. Twenty microliters of the amplification 
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Table 9) by the Inqaba Biotec Company.  
Separate uniplex PCR assays for ccrA, ccrB and ccrC were performed using the following 
primer pairs: 




 Table 9 (ccrA R1 and ccrA F1 at concentration of 0.5mM). 




 Table 9 (ccrB R1 and ccrB F1 at concentration of 0.5mM). 




 Table 9 (ccrC R2 and ccrC F2 at concentration of 1mM).  
Each assay was performed in a total volume of 25µl, with 12.5µl of Go Taq® Colorless 
Master Mix (Promega), 2.5 mM of MgCl2 and commenced with denaturation at 95ºC for 5 
Stellenbosch University  https://scholar.sun.ac.za
 82 
minutes. The remainder of the assay conditions are shown on Table 10.  











# of cycles Reference 
ccrA 95/ 60 s 50/ 60 s 72/ 120 s 72/10 min 30 (370) 
ccrB 94/30 s 44/60 s 72/120 s 72/4 min 35 (370) 
ccrC 95/60 s 50/45 s 72/60 s 72/ 10 min 30 (369) 
Five μl of the amplification products of the above PCR assays (class A mec gene complex, 
ccrA, ccrB and ccrC genes) were visualised by electrophoresis on 1% or 1.5% agarose gels 
(diluted in 1X TAE) with EtBr (Sigma) at 120V for 45 minutes.  Selected amplification 
products were sent to Inqaba Biotec Company for sequencing. 
 
3.2.8 MLST 
Isolates were selected from each of the major (five isolates) and intermediary (five isolates) 
PFGE clusters, as well as some of the minor clusters (10 isolates) in order to have a 
representative collection of isolates for Multi locus sequence type (MLST) analysis. The 
seven housekeeping genes, carbamate kinase (arc), shikimate dehydrogenase (aroE), glycerol 
kinase (glpF), guanylate kinase (gmk), phosphate acetyletransferase (pta), rtiosephosphate 
isomerase (tpi) and acetyle coenzyme A acetyltransferase (yqiL) were amplified by using 
primer sets 9-15 ( 
 




Table 9) in a uniplex PCR (115). The thermal cycles were slightly modified and consisted of: 
primary denaturation at 95 ̊C for 5 min followed by 30 cycles of 95 ̊C for 45s, 56 ̊C for 45s 
and 72 ̊C for 1 min followed by final extension at 72 ̊C for 10 min. The reaction contained; 
12.5 µl of Go Taq® Colorless Master Mix (Promega), 1 mM of each primer, 2.5 mM MgCl2, 
1 µl crude DNA with the final volume adjusted to 25 µl. Five µl of PCR product was 
visualised by electrophoresis at 120V for 1 hour in a 1.5% EtBr containing agarose gel 
(diluted in 1X TAE).  
The remainder of the amplification product (20 µl) was sent for sequencing (Inqaba Biotec). 
Each gene sequence was aligned and compared to the standard sequence as described by the 
MLST web site (http://www.mlst.net). The allelic profile number for each single isolate was 
determined by submitting the seven gene sequences to the MLST web site where the 
sequence type (ST) was identified. Isolates with the same ST were considered to belong to 
one MLST clonal complex and therefore one isolate was selected for further analysis. The 
eBURST program was used to identify the MLST clonal complex of different STs, and to 
determine the evolutionary model of the collection of study isolate. Novel STs were 
confirmed by re-sequencing both the forward and reverse primers and resending the 
sequences to the MLST group for confirmation. 
 
3.2.9 DNA sequencing 
DNA sequencing was performed by Inqaba Biotec using ABI V3.1 Big dye kit on the ABI 
3500XL genetic analyser, using the same forward primers (10mM) as used in the PCR assays 






Table 9).  
 
3.2.10 Definitions  
Pulsed-field gel electrophoresis clusters were classified into three categories as follows: 
major clusters contained more than 10 different pulsotypes, intermediate from 6 to 10 
different pulsotypes and minor clusters when less than 6 different pulsotypes were identified 
in one cluster.  
Isolates obtained from the nostrils and blood or only from the blood were classified as 
invasive isolates. Colonising isolates were defined as any isolates obtained only from the 
nasal cavity. Bacteraemia episodes were categorised as endogenous and exogenous as 




Pulsed-field gel electrophoresis of the 208 isolates showed 179 unique pulsotypes, grouped 
into 31 clusters and 24 singletons using a similarity cut-off of 80%. The clusters were named 
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alphabetically (A, B, C to AF). One major and 2 minor PFGE clusters contained isolates 
belonging to different spa clonal complexes and agr groups. Pulsed-field gel electrophoresis 
was repeated on the isolates from these 3 clusters using ApaI restriction enzyme. This 
resulted in 4 clusters each of which contained strains belonging to the same spa-CC and agr 
groups. One strain was resistant to ApaI enzyme and considered as a singleton.   
Restriction with SmaI and ApaI resulted in four major clusters (2 consisting of only MRSA 
isolates and 2 only MSSA isolates), 4 intermediary clusters, all exclusively MSSA except for 
1 cluster that contained a mixture of MSSA and MRSA isolates, and 23 minor clusters (5 
MRSA, 16 MSSA and 2 mixed MSSA and MRSA). The details are shown in Table 11. The 
major clusters (D, S, U and AA) represented 39.4% of all isolates analysed. The dominant 
MRSA clone (U) represented 19.2% (40/208) of all included isolates, and 44.4% of all 
MRSA isolates. The intermediary clones represented 13.9% (29/208) of all study isolates 
(Table 11). 
Of the ninety MRSA isolates, 52 (57.8%) clustered in the two major clones: S (n = 12) and U 
(n = 40), 2 were in the intermediary clone G and the other MRSA strains were scattered 
between the minor clones and 8 singletons.  
The MSSA strains (n = 118) were distributed among 2 major clones: D (n = 18) and AA (n = 
12), 4 intermediate clones: G (n = 5), P (n = 7), Q (n = 8) and AE (n = 7), with the rest 
distributed between 23 minor PFGE clones and 16 singletons.  


















D major 0 18 (15.3) 9 (9.5) 5 (6.9) 4 (9.9) 18 (8.6) 
S major 12 (13.3) 0 6 (6.3) 3 (4.2) 3 (7.3) 12 (5.7) 
U major 40 (44.4) 0 22 (23.3) 10 (13.9) 8(19.6) 40 (19.2) 
AA major 0  12 (10.2) 3 (3.2) 6 (8.3) 3 (7.3) 12 (5.8) 
G Intermediary 2 (2.2) 5 (4.2) 3 (3.2) 4 (5.6) 0 7 (3.3) 
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P Intermediary 0 7 (5.9) 5 (5.4) 0 2 (4.9) 7 (3.3) 
Q Intermediary 0 8 (6.8) 3 (3.2) 4 (5.6) 1(2.4) 8 (3.8) 
AE Intermediary 0 7 (5.9) 1 (1) 4 (5.6) 2 (4.9) 7 (3.3) 
A Minor 0 4 (3.4) 0 3 (4.2) 1(2.4) 4 (1.9) 
B Minor 4 (4.5) 0 3 (3.2) 1 (1.4) 0 4 (1.9) 
C Minor 0 2 (1.7) 2 (2.1) 0 0 2 (1) 
E Minor 0 2 (1.7) 0 2 (2.7) 0 2 (1) 
F Minor 1 (1.1) 4 (3.4) 3 (3.2) 2 (2.7) 0 5 (2.4) 
H Minor 0 2 (1.7) 0 1 (1.4) 1 (2.4) 2 (1) 
I Minor 0 2 (1.7) 1 (1) 1 (1.4) 0 2 (1) 
J Minor 0 2 (1.7) 1 (1) 1 (1.4) 0 2 (1) 
L Minor 0 2 (1.7) 1 (1) 1 (1.4) 0 2 (1) 
M Minor 10 (11.1) 0 7 (7.4) 2 (2.7) 1 (2.4) 10 (4.8) 
N Minor 5 (5.6) 0 3 (3.2) 1 (1.4) 1 (2.4) 5 (2.4) 
O Minor 1 (1.1) 1 (0.8) 2 (2.1) 0 0 2 (1) 
R Minor 4 (4.5) 0 1 (1) 0 3 (7.3) 4 (1.9) 
T Minor 3 (3.3) 0 1 (1) 0 2 (4.9) 3 (1.4) 
V Minor 0 2 (1.7) 0 1 (1.4) 1 (2.4) 2 (1) 
W Minor 0 8 (6.7) 3 (3.2) 3 (4.2) 2 (4.9) 8 (3.8) 
X Minor 0 2 (1.7) 0 2 (2.7) 0 2 (1) 
Y Minor 0 2 (1.7) 1 (1) 0 1 (2.4) 2 (1) 
Z Minor 0 2 (1.7) 1 (1) 1 (1.4) 0 2 (1)  
AB Minor 0 2 (1.7) 2 (2.1) 0 0 2 (1) 
AC Minor 0 2 (1.7) 1 (1) 1 (1.4) 0 2 (1) 
AD Minor 0 2 (1.7) 1 (1) 1 (1.4) 0 2 (1) 
AF Minor 0 2 (1.7) 1 (1) 1 (1.4) 0 2 (1) 
24 Singleton 8 (8.9) 16 (13.5) 8 (8.4) 11 (15.3) 5 (12.2) 24 (11.5) 
Total  90  118 95 72  41  208 
 
 
3.3.1.1 Source of the major PFGE clusters 
The ICU was the most common source of isolates belonging to the 4 major clusters as shown 
in Table 12. Interestingly, 72.5% (29/40) of the isolates in cluster U were from patients in the 
adult ICU (n = 29).  
 
 
Table 12 : Ward of origin for isolates belonging to the major PFGE clusters  






N = 40 
AA (%) 
N = 12 
AICU  7 (38.9) 2 (16.8) 29(72.5) 5 (41.6) 
PICU 0 0 3 (7.5) 0 
Internal medicine 5 (27.8) 4 (33.3) 1 (2.5) 2 (16.7) 
Surgery 2 (11.1) 1 (8.3) 1 (2.5) 1 (8.3) 
Paediatrics 2 (11.1) 1 (8.3) 5 (12.5) 2 (16.7) 
Khayelitsha 2 (11.1) 4 (33.3) 1 (2.5) 0 
Gynaecology 0 0 0 2 (16.7) 







3.3.2 spa typing  
The spa gene was detected in 206 of the isolates and only 2 MSSA isolates were nontypeable.   
Using Ridom software, 68 different spa types were identified that segregated into 10 clones 
and 17 singletons. Two strains were excluded from this analysis as the number of repeats was 
less than 5 (Table 13). After Ridom spa server synchronisation, 4 MSSA strains were 
identified as novel spa types (t7330, t7335, t7343, t9499).  
 
3.3.2.1 Distribution of different spa types  
The most prevalent spa type in this study was t037, with 44 isolates (21.4%) belonging to this 
spa type. All spa type t037 strains were MRSA and all except for 4 isolates were assigned to 
the major PFGE cluster, U. The 4 other isolates included 3 strains in PFGE cluster T, and one 
singleton.  The second most common spa type was t045 representing 15 (7.3%) of the 
isolates. These were also all MRSA and belonged to two minor PFGE clusters. The third 
most prevalent was spa t1257, represented by 12 isolates (5.8%) all of which were MRSA. 
Ten were assigned to the major PFGE cluster S and two assigned to the minor PFGE cluster, 
Medical emergency 0 0 0 0 
Total 18 (100) 12 (100) 40 (100) 12 (100) 
Stellenbosch University  https://scholar.sun.ac.za
 88 
R. All spa type t084 isolates were MSSA (n=9; 4.4%), 7 assigned to one PFGE cluster and 
two singletons. The frequency of the remaining spa-types is presented in Table 13.  
 








t37 44 (21.4) MRSA 
t045 15 (7.3) MRSA 
t1257 12 (5.8) MRSA 
t084 9 (4.4) MSSA 
t1476 8 (3.9) MSSA 
t891 8 (3.9) MSSA 
t012 6 (2.9) MRSA (4)/MSSA (2) 
t015 5 (2.4) MSSA 
t2360 5 (2.4) MSSA 
t701 5 (2.4) MSSA 
t002 4 (1.9) MSSA 
t 064 4 (1.9) MRSA 
t1443 4 (1.9) MRSA 
t032, t050, t071, t073, t148, t318, t359, 
t888, 
Reported 3 times MRSA and MSSA 
t021, t127, t160, t174, t267, t355, Reported twice MRSA and MSSA 
t008, t022, t026, t088, t094, t1062, 
t1154, t116, t133, t160, t164, t1866, 
t2194, t223, t2293, t2554, t2643, t2763, 
t279, t304, t346, t363, t3662, t3772, 
t4463, t4490, t465, t537, t5471, t570, 
t690, t7020, t7330, t7335, t7343, t7515, 






MRSA and MSSA 
 
3.3.2.2 Most dominant Spa clonal complexes  
Using the BURP algorithm of the RIDOM StaphType software, the spa types were grouped 
into 10 spa clonal complexes and 13 singletons while 2 spa types with less than 5 repeats 
were excluded (Table 14).  
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Table 14 : spa typing BURP clone analysis of S. aureus strains at Tygerberg Hospital. 








t008, t064, t304, t701, 
t1257, t1443, t1476, 
t2293, t2360. 
9 (13) 41 (20) 
2 002 
t002, t045, t071, t088, 
t570, t1062, t1154, 
t7515. 
8 (12) 27 (13) 
3 073/015 
t015, t050, t073, t116, 
t133, t465, t2194, 
t7343. 
8 (12) 16 (8) 
4 021 
t012, t021, t037, t318, 
t363, t1866, t2643 
7 (10) 58 (28) 
5 084 
t084, t094, t279, t346, 
t1517 
5 (7) 13 (6) 
6 174 
t127, t174, t5471, 
t8637 
4 (6) 6 (3) 
7 022 t022, t032, t891 3 (4) 12 (6) 
8 160 t160, t888, t 4490 3 (4) 6 (3) 
9 267 t267, t359, t7335 3 (4) 6 (3) 
10 No founder t3662, t3772 2 (3) 2 (1) 
Singletons  
t164, t355, t690, t939, 
t2763, t4463, 7020, 
9499, t148, t223, t537, 
t8079, 8636, 
13 (19) 16 (8) 
Excluded  t026, t2554 2 (3) 2(1) 
 
Clone 1: represents spa-CC 064 which includes 9 (13%) of all 68 spa types and 41 strains 
(20%). The founder of this spa-CC was spa type t064 which evolved to 8 spa types t2293, 
t1443, t1257, t1476, t304, t008, t701 and t2360 ( 
Figure 7). The isolates belonging to spa-CC 064 were distributed across 7 PFGE clusters: 1 
major, 2 intermediary and 4 minor.  
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Figure 7 : The founder and the evolved spa types grouped in spa-CC 064  
Clone 2: spa-CC 002 consists of 8 (12%) spa types and 27 (13%) strains. Seven spa types 
evolved from the founder (t002): spa type t045, t071, t088, t570, t1062, t1154 and t7515 
(Figure 8). This spa-CC was found in 1 intermediary and 6 minor PFGE clusters. 
 
Figure 8 : The relatedness of spa types identified as spa-CC 002.  
 
Clone 3: represents spa-CC 073/015, which includes 8 (12%) spa types and 16 (8%) of all 
strains. Both spa type t073 and t015 have an identical founder score and are closely related to 
the spa types t050, t116, t133, t465, t2194 and t7343 (Figure 9). This spa-CC was related to 
only one MSSA PFGE cluster. 
 
Figure 9 : The evolution of spa types grouped in spa-CC 073/015. 
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Clone 4: represents spa-CC 021, and includes 7 (10%) spa types and 58 (28%) of all strains. 
Six spa types, t012, t021, t037, t318, t363, t1866 and t2643 evolved from the founder spa 
type t 021 (Figure 10). PFGE further differentiates these strains into 4 (2MRSA, 2MSSA) 
minor and 1 (MRSA) major PFGE cluster. 
 
Figure 10 : The evolutionary model of spa types grouped in spa-CC 021. 
 
Clone 5: spa-CC 084 represented 5 (7%) and 13 (6%) of all spa types and strains 
respectively. spa types t094, t279, t346 and t1517 evolved from spa type t084 (Figure 11). 
Based on PFGE, spa-CC 084 was represented in 1 major cluster and 2 singletons.  
 
Figure 11 : The evolutionary model of spa types grouped in spa-CC 084. 
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In clone 6: spa types t127, t5471 and t8637 evolved from spa type t174. spa-CC 174 
represented 4 (6%) and 6 (3%) of the spa types and strains respectively (Figure 12). This spa-
CC disseminated into two minor MSSA PFGE clusters. 
 
Figure 12 : The evolutionary model of spa types grouped in spa-CC 174. 
 
3.3.3 MLST 
For MLST analysis, 21 strains were selected from different PFGE clusters as follows: one 
strain from each of 4 major, 4 intermediary and 11 minor PFGE clusters. Furthermore, an 
additional strain with a different SCCmec type was chosen from the dominant PFGE cluster 
U, and an additional strain from the intermediary PFGE cluster, G. The additional strain from 
clone G was chosen so that the two strains from clone G consisted of one MSSA, PVL 
positive strain, and one MRSA, PVL negative strain. Strains selected for MLST analysis were 
thus selected from 19 PFGE clusters which represents 75.5% (157) of the 208 strains. 
Analysing the sequence of the seven housekeeping genes of all selected strains yielded 14 
different sequence types (ST): 239 (dominant, n = 40), 2122, 2126, 1, 12, 612, 6, 97, 461, 5, 
8, 45, 1865 and 36.  Two novel STs were identified: ST 2122 with allelic profile 
1.4.1.4.232.1.1 and ST2126 with allelic profile 13.13.1.1.12.112.13. ST 2122 is a double 
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locus variant (DLV) of ST5 (pta and yqil alleles were different), and ST 2126 is a single 
locus variant of ST15, where one new tpi allele was identified. ST 2126 was identified in 16 
(10.2%) of the isolates. MLST eBURST analysis for the all identified STs revealed 9 MLST 
clonal complexes (MLST-CC) as shown in Table 15.  
As a result of the identification of the two new S. aureus STs, the MLST data base eBURST 
indicated that STs belonging to MLST-CC 8 should be grouped into MLST-CC 5. However, 
in this study we will consider MLST-CC 5 and 8 as separate clonal complexes as they have a 
genetic diversity and in order to keep our data compatible with previous studies (195). 
 





















1 1 174 
t5471, t127 Z (Minor) MSSA 2 
4 (2.5) 




















AE (Intermediary) MSSA 7 
461 002 t045 N (Minor) MRSA 5 
5 
002 t045 M (Minor) MRSA 10 
002 t002, t570 Y (Minor) MSSA 2 
8 
















064 t1476 Q (intermediary) MSSA 8 
064 t2293, t008 O (Minor) MRSA/MSSA 2 































D (Major) MSSA 18 18 (8.7) 
30 
36 021 t012 B (Minor) MRSA 4 8 
(3.8) 1865 021 t318, t012 A (Minor) MSSA 4 
97 97 267 
t7330, t7335 
t359, t267 
P (Intermediary) MSSA 7 
7 (3.
4) 
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3.3.4 SCCmec typing 
SCCmec typing was performed on all 90 MRSA isolates; all were mecA positive, confirming 
methicillin resistance. Comparison with the multiplex PCR banding patterns of the control 
strains allowed for designation of the SCCmec type for 38 of the isolates as follows: type II 
5.6% (n = 5), type III 11.1% (n = 10), type IV 23.3% (n = 21), type V 2.2% (n = 2). 
Examples of these are shown in Figure 13. In addition, 6 isolates (6.7%) were non-typeable. 
The banding pattern of the remaining 46 isolates did not correspond to any of the controls 
used, with two unrecognised patterns being identified, as discussed below, and illustrated in 
the flowchart (Figure 18).  
 
 
Figure 13 : Determination of SCCmec types of included clinical isolates.     
lane 1, 100 bp ladder; Lane 2, SCCmec type I (BAA 38); lane 3, SCCmec type II (ATCC 1681); lane 4, SCCmec III (BAA 
39); lane 5, SCCmec IV (ATCC 1680); lane 6, SCCmec  V (ATCC 1688); lane 7, SCCmec VI (BAA 42); lane 8, Untypeable 
SCCmec type (ccrA1B1, ccrC/Class B mec); lane 9, SCCmec type II; lane 10, SCCmec type III; lane 11, SCCmec type IV; 
lane 12, SCCmec type V; lane 13, Untypeable SCCmec type (ccrC/ Class A mec); lane 14, negative control; lane 15, 100 bp 
ladder.   
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3.3.4.1 Untypeable SCCmec type (ccrA1B1, ccrC/Class B mec) 
Fifteen of the 90 MRSA isolates had a similar PCR band patterns to the SCCmec type I 
control strain. This is illustrated in Figure 13, lane 8. In this lane, the bands present for these 
two isolates most likely correspond to mecA (162 bp), J3 region (342 bp), J1 region (495 bp) 
and one additional band with the same size as ccrC (449 bp). Uniplex PCR assays for ccrA1, 
ccrB1 and ccrC were performed on two clinical isolates with this SCCmec pattern (TKN-8 
and TKB-16) to confirm the presence and combination of ccrA1B1 and ccrC. 
The ccrA1, ccrB1 and ccrC were amplified (Figures 14-16), sequenced and analysed using 
the BLAST website (http://blast.ncbi.nlm.nih.gov). The results showed a sequence similarity 
of 99% for ccrA1, 99% for ccrB1 and 97% for ccrC (accession numbers: 
gi|408436493|emb|HE579073.1|, gi|32435727|gb|AY254742.1| and gi|254803085|gb|FJ93104 
6.1| respectively). These results thus suggest the presence of both ccrA1B1 and ccrC in one 
SCCmec element, and support the tentative SCCmec designation as ccrA1B1, ccrC/Class B 
mec. This designation will be used for these isolates for the remainder of the thesis. 
 
 
Figure 14 : Uniplex PCR gel of ccrA amplification of untypeable SCCmec type (ccrA1B1, 
ccrC/ Class B mec) strains (TKN-8, TKB-16). 
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Figure 15 : Uniplex PCR assays for ccrA and ccrB.      
Lanes 2-4, ccrB of SCCmec I variant (TKN-8, TKB-16); lanes 5-7, ccrA of untypeable SCCmec (TKB-14, TKN-17); lanes 
8-10, ccrB of untypeable SCCmec (TKB-14, TKN-17); lane 11, negative control; lane 12, ccrA (BAA 38); lane 13, ccrB 




Figure 16 : Amplification of ccrC.  
Lane 1, 100 bp ladder; lane 2, negative control; lane 3, SCCmec type I positive control strain (BAA 38); lane 4, TKN-8; lane 
5, TKB-16.    
 
3.3.4.2 Untypeable SCCmec type (ccrC/Class A mec) 
Thirty one isolates appeared to have banding pattern suggestive of a combination of ccrC and 
class A mec. As seen in Figure 13 (lane 13) the multiplex PCR generated fragment sizes of 
162 bp (mecA), 209 bp (mecI), 414 bp (J3 region) and 449 bp (ccrC). This combination of 
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class A mec gene and type 5 (C) ccr gene complexes has not been reported.   
To confirm this combination, two clinical isolates (TKB-14, TKN-17) with this band pattern 
were analysed further, using uniplex PCR assays for ccrA1, ccrA2, and ccrC, as well as class 
A mec. Neither the ccrA nor ccrB genes were amplified (Figure 15). However, the ccrC gene 
was amplified and sequenced (Figure 16). The nucleotide sequence was found to be 99% 
homologous to the ccrC gene (accession number gi|269939526|emb|FN433596.1|).  
The class A mec gene complex was also amplified (shown in Figure 17), sequenced and 
compared to the database available in the NCBI gene database and was identified as class A 
mec gene complex with 99% similarity (accession number, FJ670542). 
Based on these results, this second SCCmec type, identified in 31 of the isolates, appears to 
consist of a combination of ccrC (ccr 5) and the class A mec gene complex. For the rest of 
the thesis, this SCCmec type will be designated ccrC / class A mec. 
 
 
Figure 17 : mec gene complex amplification. 
 Lane 1, 1 kb ladder; lane 2, negative control; lane 3, TKB-14; lane 4, TKN-17. 
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Figure 18 : Flow-diagram describing the molecular structure of SCCmec element of isolates 
showing different PCR gel band patterns compared to control strains.  
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The association of SCCmec type, spa-CC and MLST CC is shown in Table 16. Isolates with 
SCCmec type ccrA1B1, ccrC/Class B mec were grouped in the M and N minor PFGE clusters 
(similarity between these two clusters is 78.1%). All 31 of the isolates with the SCCmec type 
ccrC/class A mec were assigned to cluster U, and furthermore, 20 of the 31 isolates 
containing this SCCmec type were obtained from the burns unit, with the remainder arising 
from surgical wards (n = 4), the high care unit (n = 3), neonatal internal medicine (n = 3) and 
Khayelitsha wards (n = 1). 
 


























































M (minor) 002 t045 5 5 10 
N (minor) 002 t045 5 461 5 
II 
S 021 t021 - - 1 
B (minor) 021 t021 30 36 4 
III 
T (minor) 021 t037 8 239 3 





022 t8636 22 22 1 
022 t891 22 22 1 
R (minor) 064 
t1443, t1257, 
t064 
8 612 4 
S (major) 064 t1257, t1443 8 612 10 
F (minor) 022 t032 - - 1 
S 022 t022 22 22 1 
S 022 t032 - - 1 
S 064 t064 - - 1 
S 064 t064 - - 1 
V 
O (minor) 064 t008 8 8 1 
S 064 t1443 - - 1 
ccrC/Class 
A mec 




S (major) 064 t1257 8 612 2 
U (major) 021 t037 8 239 2 
S 064 t064 - - 1 
S 021 t021 - - 1 
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During the study period in 2010, five strains harboured SCCmec type III (3 assigned to the 
PFGE clone T and 2 obtained from PFGE clone U) and 6 strains from PFGE clone U were 
identified as untypeable SCCmec type ccrC/Class A mec. However, in 2011 SCCmec type III 
was reported in 5 strains and untypeable SCCmec type ccrC/Class A mec identified in 25 
strains (Table 17).   
 



















II 1 2 1 1 5 
III 1 4 4 1 10 
IV 3 5 7 6 21 
V 1 0 0 1 2 
ccrA1B1, ccrC / class B mec 6 5 4 0 15 
ccrC/ class A mec 5 2 7 17 31 
Total 17 18 23 26 84 
 
 
3.3.5 agr group 
The agr gene was detected in 204 of 208 included isolates, and could not be amplified in 4 
strains which were reported as nontypeable. The prevalence of agr groups was as follows: agr 
type I, 67.3% (n = 145); agr type II, 21.6% (n = 45); agr type III, 9.1% (n = 19). Agr type IV 
was not identified during the study period. The agr typing results, along with agr 
functionality is discussed in more detail in Chapter 5. 
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3.3.6 PVL prevalence 
In our collection 8.7% (n = 18) of the isolates were positive for the pvl gene. All PVL 
positive strains were MSSA (14.4%, 17/118) except for one, identified as MRSA SCCmec 
type IV, spa type t1257, spa-CC 064, ST 612 and MLST-CC 5. The majority of PVL positive 
strains 44.4% (n = 8) were spa type t891, followed by spa type t318 (3, 16.7%), spa-CC 021, 
ST 1865 (local emerging spa-type), MLST-CC 30 (Table 18).  
 
Table 18 : Prevalence and genotypic characteristics of PVL positive strains 
PFGE-CC Spa type Spa-CC ST MLST-CC MRSA/MSSA 
Number of 
isolates 
A t318 021 1865 30 MSSA 3 
F t891 022 - - MSSA 3 
G t891 022 22 22 MSSA 5 
J t355 S - - MSSA 2 
S t1257 064 612 8 MRSA SCCmec IV 1 
Z t5471 174 - - MSSA 1 
AF t174, t8637 174 1 1 MSSA 2 
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3.3.7 Characteristics and prevalence of MRSA clones  
In this study, 8 MRSA clones were identified, four of which, ST239 (ST239-MRSA-III and 
ST239-MRSA-ccrC/Class A mec), ST612-MRSA-IV, ST5-MRSA- ccrA1B1, ccrC/Class B 
mec and ST36-MRSA-II (UK MRSA-16), represented the most dominant strains. The other 
clones, ST22-MRSA-IV (UK MRSA-15), ST461-MRSA-ccrA1B1, ccrC/Class B mec and 
ST8-MRSA-V, accounted for the minority of strains. Of note is the fact that this is, as far as 
the author is aware, only the second time ST461 has been identified as methicillin resistant. 
Clones were designated based on the strain ST and the SCCmec type as shown in Table 19. 
The prevalence of the MRSA lineages is shown in Figure 19.  
 
Figure 19 : Prevalence of MRSA clones. 
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3.3.8 Association between genetic background association and 
endogenous/exogenous infection 
The isolates selected for MLST analysis represented 156 isolates, and the association 
between genetic background and endogenous or exogenous infection was analysed using the 
data from these 156 isolates.  
To investigate the association between CCs and invasion; isolates belonging to any CC 
obtained from the blood and nasal cavity or only from the blood were classified as invasive 
and CCs obtained only from the nasal cavity were classified as colonising. The association of 
MLST CCs with invasive (both exogenous and endogenous) and colonising strains is shown 
in Table 20. 
 









1 2 (4.7) 2 (2.5) 0 4 (2.6) 
5 8 (18.6) 18 (22.2) 6 (19) 32 (20.5) 
8 16 (37.2) 34 (42) 16 (50) 66 (42.3) 
12 0 2 (2.5) 0 2 (1.3) 
15 5 (11.6) 4 (5) 3 (9.3) 12 (7.7) 
22 4 (9.3) 3 (3.7) 0 7 (4.5) 
30 4 (9.3) 3 (3.7) 1 (3) 8 (5.1) 
45 4 (9.3) 10 (12.3) 4 (12.5) 18 (11.5) 
97 0 5 (6.1) 2 (6.2) 7 (4.5) 
Total 43 (100) 81 32 (100) 156 
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Isolates belonging to three CCs (CC1, CC12, and CC22) were invasive, as they were 
obtained from the blood or blood and nostrils only. Two CCs, CC12 and CC97, only caused 
endogenous bacteraemia. Interestingly, CC97 is rarely identified as a human pathogen and it 
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3.4 Discussion 
3.4.1 MRSA transmission  
MRSA strains segregated into two major and one intermediate PFGE clusters, with the other 
strains disseminated between minor clusters and sporadic isolates. Each of the PFGE clusters 
included strains obtained from different hospital wards suggesting the possibility of MRSA 
strain transmission between different hospital wards. Isolates belonging to PFGE cluster U 
were commonly isolated from patients in the burns unit, and interestingly there were more 
isolates from this cluster in the second half of 2011(17/31, 54.8%) than in 2010 (7/31, 22.6) 
or the first half of 2011 (7/31, 22.6). This may represent local transmission within the ward, 
and will help inform infection control practices. However, the fact that a number of isolates 
from this cluster were also identified in patients in other wards could either be due to patient 
movement from the burns unit to other wards, or staff carrying the organism to other wards. 
While we did not examine isolates from other hospitals, it is certainly possible, and even 
likely, that patient transfer between hospitals is another route of transmission of MRSA.  
Isolates from other PFGE clusters were obtained from a variety of different wards in the 
hospital, and there was no clear link found between any of the other PFGE clusters and a 
specific ward or region of the hospital. 
 
3.4.2 MRSA and MSSA clones and genetic diversity:  
Internationally, it has been reported that hospital acquired MRSA infection is mainly caused 
by a few MRSA clones: Iberian (ST247-MRSA-I), Brazilian/Hungarian (ST239-MRSA-III), 
Berlin (ST45-MRSA-IV), New York/Japan (ST5-MRSA-II), Paediatric (ST5-MRSA-IV), 
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EMRSA-15 (ST22-MRSA-IV), and EMRSA-16 (ST36-MRSA-II) (348). In the isolates 
included in this study, the common clones that were identified included: ST36-MRSA-II, 
ST22-MRSA-IV, ST239-MRSA-III and ST239-MRSA-ccrC/Class A mec. The MRSA 
clones that occurred more infrequently were ST5-MRSA-ccrA1B1, ccrC/Class B mec, 
ST461-MRSA- ccrA1B1, ccrC/Class B mec (according to our knowledge, this was the second 
time this was identified as a MRSA clone), ST8-MRSA-V, and ST612-MRSA-IV.  
 In this study ST239 (CC8) was the most prevalent ST. It was identified with two different 
SCCmec types; ST239-MRSA-III and ST239-MRSA-ccrC/Class A mec, both of which were 
spa type t37. This clone was reported as the most dominant in Asian countries except Japan 
and South Korea (371). Recently, 92.5% of the prevalent MRSA clones in Malaysia were 
shown to be ST239-MRSA-III (179). Similar results were reported in Morocco and Niger 
where this clone was predominant in both countries (171). In Tygerberg Hospital, a previous 
study conducted in 2009 used spa typing and found that spa type t37 was the most dominant 
spa type. Considering all spa type t37 in the current collection were ST239 one can suggest 
that ST239 was the most dominant in the 2009 study as well (25). In South Africa, the first 
study reporting the prevalence of ST239-MRSA-III was conducted in KwaZulu-Natal 
province and included 61 MRSA isolates collected between March 2001 and August 2003 
(372). This study reported 16.4% (10/61) of the included MRSA isolates as ST239-MRSA-
III. It was reported as a minor clone in a study conducted in Cape Town where 100 MRSA 
isolates (blood = 7) from city hospitals (except Tygerberg) were analysed (175). It was also 
the second most dominant clone in a study where 38.4% of the isolates were obtained from 
patients with bacteraemia (174). In KwaZulu-Natal province it was the second predominant 
clone obtained from health care facilities between 2001 and 2003 (206). The  dominance of 
this clone (ST239-MRSA-III) in different provinces in South Africa is similar to that reported 
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in Asia (152, 371) and may relate to the migration of Asians due to forced labour in the 
country’s past. 
 This clone (ST239-MRSA-III and ST239-MRSA-ccrC/Class A mec) is the most prevalent in 
Tygerberg Hospital and this may cause concern for two reasons. Firstly, due to the previously 
described ability of this clone to spread between hospitals and wards in one hospital (87), and 
secondly, due to a recent study showing that this clone has spread from hospitals into the 
community (170).  
In agreement with other studies conducted in South Africa, this study reported ST612-
MRSA-IV (a member of CC8 and a double locus variant of ST8) as a spreading clone in 
Tygerberg Hospital (174, 175). To our knowledge this clone has been reported only in South 
Africa and Australia (169). Spread of this lineage in limited geographic regions (South Africa 
and Australia) is supported by other studies that reported certain endemic clones may emerge 
locally in some geographic areas (373, 374). It has been suggested that the small size of the 
SCCmec element type IV compared to other elements enhances its mobility between 
staphylococci and explains the worldwide spread of this element (121, 136). We have 
identified the first strain of this clone that harbours the pvl gene in South Africa. The finding 
that ST612-MRSA-IV isolates were distributed across two PFGE clones, with different spa 
types, as well as one strain acquiring pvl, raises the possibility of the emergence of this local 
S. aureus lineage over a sufficient period of time to the point where it has become more 
genetically diverse. It is known that the pvl gene is introduced into S. aureus by a prophage, 
and we presume that this clone acquired this gene locally through horizontal transfer.  
ST5-MRSA-I (UK EMRSA-3) is a pandemic clone spread worldwide (80, 169). This study 
reported this ST with a potentially novel variant of SCCmec type I, ST5-MRSA-ccrA1B1, 
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ccrC/Class B mec-t045, as the third most prevalent clone in Tygerberg Hospital. Previously, 
ST5 was identified in one study from Cape Town as the second dominant clone (175). Other 
studies also reported the prevalence of this clone in isolates collected from the nine South 
African Hospital provinces (174, 175). Other ST5-MRSA (III and IV) clones have been 
identified in KwaZulu-Natal province in South Africa (206, 372). Nϋbel et al., suggested that 
the spread of ST5 between different areas is limited and that this clone may evolve via local 
horizontal SCCmec element transmission in different geographical areas (373). Therefore, it 
is possible to suggest the local emergence of this clone through horizontal introduction of 
SCCmec type ccrA1B1, ccrC/Class B mec element into hospital MSSA strains, followed by 
spread within the hospital from patient to patient. However, it is also possible it was imported 
from other hospitals.   
We identified another common international clone ST36-MRSA-IV (UK EMRSA-16) in our 
collection. The first report of this clone came from the UK in 1993 (84). Subsequent reports 
showed the spread of this clone in USA, Australia, Canada and recently South Africa (84, 
167). This clone has been identified as a hospital clone in many South African hospitals, in 
multiple provinces (169, 174, 175, 361, 375). A study of isolates from Spanish hospitals 
between 1998 and 2002 showed the prevalence of EMRSA-16 which was recently replaced 
by ST247-MRSA-1 (184). The spread of EMRSA-16 from the UK into South Africa may 
have been facilitated, at least in part, by the historic and social links between the two 
countries.  
ST461-MRSA-ccrA1B1, ccrC/Class B mec (SLV of ST5 and a member of CC5) clone was 
identified in this study. According to our knowledge this is only the second time that this ST 
has been identified as MRSA [http://www.mlst.net]. Considering the limited prevalence of 
this clone in South Africa, which has only been reported in Tygerberg Hospital, and that 
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independent horizontal introduction of SCCmec elements into S. aureus occurs locally (373), 
we suggest the possible local emergence of this clone. The limited genetic variation revealed 
by PFGE (all isolates were representative of one PFGE cluster) and spa-typing (all strains 
were spa type t045), suggest the recent local emergence of ST461-MRSA- ccrA1B1, 
ccrC/Class B mec spa t045.  
ST22-MRSA-IV (UK EMRSA-15) spa type t8636 was reported in this study as one of the 
minor STs. It is commonly identified in Europe, Australia, Canada and Indonesia (84), and 
was recently introduced into Malaysian hospitals (179).  It was first identified in the UK in 
1993 (167). In contrast to our results indicating a low prevalence of this clone in Tygerberg 
Hospital, recent studies showed increasing prevalence of this clone in Europe and 
replacement of ST36-MRSA-II in the UK (169, 183). On the other hand, our results are in 
agreement with previous studies which reported a low prevalence of this clone in South 
Africa (174, 175). This clone has also not been reported in other African countries including 
Nigeria (207), Morocco, Senegal, Niger, Cameroon and Madagascar (171). The low 
prevalence of ST22-MRSA-IV in South Africa as well as the absence in other African 
countries may reflect only recent spread in Africa or, possibly, a lack of adaptation to the 
environment.  
Finally ST8-MRSA-V spa type t008 was reported in our study as a representative of a minor 
PFGE clone. It is an infrequently identified clone and has been identified in Australia (169) 
and Nigeria. In Nigeria it was identified with two different spa types (t064 and t451) (376). 
This is the first study reporting this clone in South Africa. 
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3.4.3 Commonly identified MSSA STs 
The prevalent MSSA STs were: ST1865-MSSA, ST45-MSSA, ST8-MSSA, ST22-MSSA, 
ST97-MSSA, ST1-MSSA, ST5-MSSA, ST2122-MSSA, ST2126-MSSA, ST12-MSSA and 
ST6-MSSA. Our results showed more MSSA STs than MRSA STs and supported the 
suggestion that the MSSA genetic background is more diverse (203, 204). The presence of 
certain MSSA STs that correspond to MRSA clones in the same study population and time 
period raises the possibility of the local emergence of MRSA clones after horizontal 
acquisition of SCCmec elements locally, as has been previously hypothesized (121, 200).  
ST45-MSSA spa-CC 073/015 was identified in this study as the most predominant MSSA 
clone. It has been identified as a worldwide spreading clone (80, 169). In this study all ST45 
strains were only identified as methicillin susceptible, in contrast to a previous study in 
KwaZulu-Natal where ST45 isolates were identified as both methicillin susceptible and 
resistant (206). The identified MSSA STs of CC5 are: ST2122-MSSA spa-CC 002 (novel), 
ST6-MSSA spa-CC 064, and ST5-MSSA- spa-CC 002. Similar results were reported in a 
previous study conducted in KwaZulu-Natal showing a prevalence of both MSSA ST5 and 
ST6 (206). ST5 has been identified only in Cameroon, Madagascar, Niger and Senegal (205), 
and Nigeria (376). ST8-MSSA spa-CC 064 is assigned to CC8, and has also been identified 
in KwaZulu-Natal province (206), and Nigeria (376). Two MSSA STs of CC8 have been 
identified in some African countries; ST8 in Senegal, Niger and Morocco; and ST1404 
identified in Madagascar (205). ST22-MSSA spa-CC 022 (spa type t891) PVL positive, was 
identified in this study as a member of CC22. This clone has been identified worldwide as 
both MRSA and MSSA (80), and has been reported in KwaZulu-Natal province (206). This 
clone grouped together with ST22-MRSA-IV in one PFGE clone, again raising the possibility 
of local SCCmec element transfer.   
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3.4.4 Infrequently identified MSSA STs 
In this study, MSSA ST2126 spa-CC084 and ST97 spa-CC267 were identified as members 
of CC15 and CC97 respectively, and all members of these two CCs were MSSA; this is in 
agreement with previous reports that showed members of these CCs are mainly MSSA strains 
(168, 169). MSSA strains belonging to CC15 have been identified in Belgium, England, 
Germany and Portugal (80). In Africa two MSSA STs of CC15 have been identified; ST15 in 
Senegal, Niger, Cameroon, Madagascar and Morocco; while ST1403 has only been described 
in Senegal and Cameroon (205). ST97 (a member of CC97) is commonly isolated from 
animals and rarely identified in humans (169). This study is the first report of ST97 in South 
Africa.. ST1 spa-CC174 PVL positive was prevalent in KwaZulu-Natal province (206). The 
genetic background of this ST has been described as providing a convenient environment for 
community associated SCCmec element integration (80).  
Two strains were identified as ST12-MSSA spa-CC022 and belonged to CC12. This is a 
worldwide clone which has been identified in Germany, Belgium, Brazil, England, Portugal 
and the Netherlands (80), however, it has not been identified in South Africa. Finally, 
ST1865-MSSA spa-CC021 PVL positive was identified in this study. According to our 
knowledge this clone has not been identified in other countries as well as other hospitals in 
South Africa. 
 
3.4.5 SCCmec element 
Our preliminary data showing the presence of ccrA1B1, ccrC and Class B mec in the same 
SCCmec element suggests that a new SCCmec I variant is prevalent in isolates from our 
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patient population. According to the International Working Group on the Classification of 
Staphylococcal Cassette Chromosome Element (IWG-SCC) when two ccr genes are 
integrated in one SCCmec element it should be considered as a variant of the previously 
identified element and designated as (1B&5). Two STs (ST5 and ST461) were found carrying 
this SCCmec element, both belong to CC5.  
A possibly novel SCCmec element, ccrC/Class A mec (5A), was carried by strains of ST239 
spa type t37. This combination indicates the potential prevalence of a novel SCCmec type in 
Tygerberg Hospital. In Nigeria, the same combination was identified in one MRSA strain 
belonging to ST8 (CC8) (207).  During the study period the prevalence of the untypeable 
SCCmec ccrC/Class A mec was higher in 2011 than 2010. In addition, the prevalence of 
SCCmec ccrC/Class A mec in 2011 was higher than SCCmec type III suggesting the possible 
replacement of SCCmec type III with the potentially novel SCCmec ccrC/Class A mec. These 
findings may indicate the emergence of a new MRSA clone in Africa that has evolved from 
the integration of a new SCCmec type into CC8 strains.  
To avoid misclassification, the IWG-SCC recommends sequencing of the whole SCCmec 
element to identify any putative new SCCmec types, as available multiplex PCRs only 
represent limited parts of the element and are not necessarily indicative of the entire 
nucleotide sequence of the element (130). Therefore, further studies, involving sequencing of 
the entire SCCmec element, are required to confirm these preliminary results. The presence 
of novel SCCmec elements and the emergence of a new MRSA lineage (ST461-MRSA-
ccrA1B1, ccrC/Class B mec) in Tygerberg Hospital supports the local evolution of MRSA via 
several independent horizontal transmission events of the SCCmec element into local MSSA 
isolates. This has been suggested as the multi-clone theory in previous studies (121, 348, 
373).  
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In this study 3 PFGE clusters (F, G and O) contained both MRSA and MSSA. It has been 
presumed that the presence of MRSA and MSSA isolates in the same PFGE cluster may be 
due to local transfer of the SCCmec element into MSSA or deletion of mecA from prevalent 
MRSA isolates (377). Another finding reported in this study was that of different SCCmec 
types grouping in one PFGE cluster (SCCmec type III and untypeable SCCmec ccrC/Class A 
mec in PFGE cluster U). In agreement with this result, a study investigating MRSA genotypic 
characteristics in KwaZulu-Natal reported 4 different SCCmec types grouped in one PFGE 
cluster (372). The presence of multiple SCCmec types in the same PFGE cluster raises the 
possibility of particular mechanisms of adaptation in certain MRSA lineages via excision of 
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3.5 Conclusion  
This is the first study to investigate the molecular characteristics of nasal and blood S. aureus 
(MRSA and MSSA) isolates at Tygerberg Hospital. The results showed the majority of 
MRSA strains were ST239 followed by ST612-MRSA-IV and ST5. Untypeable SCCmec 
types were identified in both ST239 and ST5 and the preliminary results suggest a new 
SCCmec type (ccrC/Class A mec) and new variant of SCCmec type I (ccrA1B1, ccrC/Class B 
mec). However, the nucleotide sequence of the entire SCCmec element should be determined 
to confirm these findings. This is the first study to report ST612-MRSA-IV as being PVL-
positive in South Africa and worldwide. It is also the first study reporting the prevalence of 
ST461-MRSA-IV in South Africa and the second report worldwide. Novel MSSA STs were 
identified (ST2122 (CC5) and ST2126 (CC15)), and MSSA STs were more diverse than 
MRSA clones. 
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CHAPTER 4 PREVALENCE AND ASSOCIATION OF VIRULENCE 
FACTOR GENES IN REPRESENTATIVE STRAINS OF 
STAPHYLOCOCCUS AUREUS ISOLATES AT TYGERBERG HOSPITAL 
4.1 Introduction: Prevalence and association of virulence factor genes 
with S. aureus genetic structure  
The association between S. aureus genetic background and certain virulence factors remains 
unclear (378). Microarray analysis showed that the variation in the genetic component of 
different lineages of invasive and colonising isolates does not influence variation in 
pathogenesis (88). Another study which included different genotypes of S. aureus isolates 
obtained from the nasal cavity, blood and other body sites suggested that the pathogenesis of 
isolates was not associated with genotypes and that in the same lineage some strains were 
more virulent than others (379). Although there is no clear association between virulence and 
any specific genetic lineage, invasive disease has been associated with S. aureus strains 
harbouring different combinations of seven virulence factor genes including: exfoliative toxin 
A (eta), fibronectin binding protein A (fnbA), collagen binding protein (cna), serine-aspartate 
repeat protein E (sdrE ), staphylococcal enterotoxin J (sej), gamma hemolysin (hlg), and 
intracellular adhesins A (icaA) (380). This study did control for the different frequencies of 
virulence genes in different lineages. 
A number of associations between specific virulence factors and genetic background have 
been reported (21). For example, one study reported an association between ST8-MRSA-IV 
and Panton-Valentine leukocidin (pvl), enterotoxin Q (seq) and enterotoxin K (sek) virulence 
factor genes, while ST30 was associated with the presence of the pvl gene, and ST36 was 
associated with the presence of enterotoxin A (sea) and toxic shock syndrome toxin (tst) 
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genes (218). The presence of seb and sec virulence factor genes has been associated more 
frequently with spa-CC002 compared to other spa-CCs (008, 037, 0084 and 1039 and spa 
types t037 and t1151 (275).  
The association of specific virulence factors with MRSA or MSSA is variable between 
studies conducted in different areas. A study conducted in Spain reported that MRSA was 
associated with the presence of sep, while tst was associated with MSSA (381). In the Czech 
Republic, a study comparing the prevalence of enterotoxin, exfoliatins, pvl and tst between 
MRSA and MSSA showed that seg and sei were significantly associated with MRSA strains 
(280). In Columbia, MSSA was associated with seb and sed while pvl was more common in 
MRSA (278). This chapter aimed to describe the prevalence of virulence factor genes among 
the representative nasal and blood isolates selected for MLST analysis as described 
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4.2 Methods 
4.2.1 Bacterial isolates 
For detection of pvl, all 208 isolates were chosen, however, the presence of the other 
virulence factor genes was investigated in 21 representative isolates (Table 21) that were 
previously analysed by PFGE, spa typing, MLST, SCCmec typing and agr typing 
(CHAPTER 2 and CHAPTER 3). These 21 were chosen to represent the range of lineages 
present in the study, as well as to include both MRSA and MSSA. The decision to use only a 
representative sample of isolates for these genes was made primarily due to practical 
considerations; in addition, it was felt that since PVL has arguably been more widely studied 
than many of the other virulence factors, analysis of PVL in all isolates may be more valuable 
for this specific virulence factor. The control strains used for virulence factor detection were 
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Table 21 Characteristics of selected representative isolates.  
# Genetic lineage PFGE clone MLST-CC 
spa type 
agr PVL 
1 ST1865-MSSA A (minor) 30 t318 III +ve 
2 ST36-MRSA-II B (minor) 30 t012 III -ve 
3 ST45-MSSA D (major) 45 t015 I -ve 
4 ST22-MRSA-IV G (intermediary) 22 t8636 I -ve 
5 ST22-MSSA G (intermediary) 22 t891 I +ve 
6 ST5-MRSA-I M (minor) 5 t045 II -ve 
7 ST461-MRSA-I N (minor) 5 t045 II -ve 
8 ST8-MRSA-V O (minor) 8 t008 I -ve 
9 ST97-MSSA P (intermediary) 97 t267 I -ve 
10 ST8-MSSA Q (intermediary) 8 t1476 I -ve 
11 ST612-MRSA-IV R (minor) 8 t1257 I -ve 
12 ST612-MRSA-IV S (major) 8 t1443 I +ve* 
13 ST239-MRSA-III U (major) 8 t037 I -ve 
14 ST239-MRSA-ccrC/class A U (major) 8 t037 I -ve 
15 ST2122-MSSA W (minor) 5 t071 II -ve 
16 ST5-MS Y (minor) 5 t570 I -ve 
17 ST1-MSSA Z (minor) 1 t5471 I -ve/+ve** 
18 ST2126-MSSA AA (major) 15 t084 II -ve 
19 ST12-MSSA AB (minor) 12 t160 II -ve 
20 ST6-MSSA AE (intermediary) 5 t701 I -ve 
21 ST1-MSSA AF (minor) 1 t174 III -ve 
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Table 22 : S. aureus control strains used for the detection of virulence factor genes  
Strain Target gene(s) Reference 
BAA-1681 Eta (363) 
BAA-38 seb, chp (363) 
NCTC 8325-4 
cap5, sak, hld, hla, hlb (363) 





fnbA, fnbB (363) 
hlgA This study 
Newman 





seh, seg, sel (383) 
sen, seo, sem (363) 
ATCC 23235 
coa, nuc, sej, scn (363) 
Sed (384) 
ATCC 700699 sea, sec, sei, see, tst (363) 
ATCC 25923 Can (363) 
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4.2.2 Virulence factors 
Thirty-eight virulence factor genes were investigated including the adhesins  (clfA, clfB,  
fnbA,  fnbB, sdrC, sdrD, sdrE, cna, icaA and eap (map)), the superantigenic toxins (sea, seb, 
sec, sed, see, seg, seh, sei, sej, sel, sem, sen, seo, eta and tst), the immune avoidance genes 
(chp, sak, scn, cap5, and cap8), the hemolysins (hld, hlg, hlgv, hla and hlb) and toxins (pvl, 
coa and nuc) (Table 23).  
  
4.2.3 Detection of Virulence factor genes by PCR 
4.2.3.1 Panton-Valentine leukocidin (PVL) 
All 208 unique non-repeated isolates included in chapter 3 were screened for the presence of 
pvl. Uniplex PCR was set up as following: primary denaturation was at 95 ̊C for 4 min 
followed by 30 cycles of 95 ̊C for 30 s, 60 ̊C for 30 s and 72 ̊C for 1 min. The final extension 
was at 72 ̊C for 10 min. The final PCR reaction volume was 25 µl and included 12.5 µl of Go 
Taq® Colorless Master Mix (Promega), 1 mM of primers (Table 24) and 1 µl of template 
(367).  
 
4.2.3.2 Other virulence factors  
The virulence factor genes were amplified by uniplex PCRs except four sets of genes which 
were amplified by multiplex PCRs: (coa, nuc and sed), (seg and sej), (sea and sec) and (hld 
and hlg).  
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Table 23 : Virulence factor genes investigated in this study 






Clumping factor A ClfA clfA 
Clumping factor B ClfB clfB 
Fibronectin binding protein A FnBPA fnbA 
Fibronectin binding protein B FnBPB fnbB 
Collagen binding protein CNA cna 
Extra cellular adherence protein/MHC 
class II analogous protein 
Eap/Map eap/map 
Serine-aspartate protein C sdrC sdrC 
Serine-aspartate protein D sdrD sdrD 
Serine-aspartate protein E sdrE sdrE 






Enterotoxins  A, B, C, D, E, G, H, I, J, 
L, M, N and O 
Sea, Seb, Sec,  Sed, See Seg, 
Seh, Sei, Sej, Sel, Sem, Sen, Seo 
(in order) 
Sea, seb, sed, seg, seh, 
sei, sej, sel, sem, sen, seo. 
(in order) 
Toxic shock syndrome toxin-1 TSST-1 tst 
Exfoliative toxin ETA eta 
Immune 
avoidance 
Chemotaxis inhibitory protein CHIP chp 
Staphylokinase SAK sak 
Staphylococcal complement inhibitor SCIN scn 
Capsule type 5 Cap5 cap5 
Capsule type 8 Cap8 cap8 
Hemolysins 
Alpha-hemolysin, Beta-hemolysin, 
Delta-hemolysin, Gama-hemolysin and 
Gama-hemolysin variant 
Hla, Hlb, Hld, Hlg, HlgA hla, hlb, hld, hlg, hlgA 
Other virulence 
factors 
Paton-Valentine leukocidin PVL pvl 
Coagulase Coa coa 
Nuclease Nuc nuc 
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The primers used for each reaction, along with the primer concentration and annealing 
temperature for each reaction are shown in Table 24. All uniplex and multiplex PCRs started 
with an initial denaturation at 95°C for 5min followed by 30 cycles of 95°C for 0.45s, 
annealing temperatures (as shown in Table 24) for 0.45 s and extension at 72°C for 1 min; 
with a final extension at 72°Cfor 10 min. PCR reactions consisted of 12.5 µl of Go Taq® 
Colourless Master Mix (Promega, USA), primers (Inqaba Biotech or Whitehead Scientific, 
South Africa), 1 µl of crude DNA and brought to a final volume of 25µl with ddH2O. 
Amplified genes were separated by gel electrophoresis and visualised on a 1.5% and 3.5% 
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luk-PV-1 ATCATTAGGTAAAATGTCTGGACATGATCCA 433 1 60°C (367) 
luk-PV-2 GCATCAASTGTATTGGATAGCAAAAGC 
sea 
SEA-F1170 TAA GGA GGT GGT GCC TAT GG 180 1 
 
56°C (383) 
SEA-R1349 CAT CGA AAC CAG CCA AAG TT 
seb 











SEC-R578 TCC CAT TAT CAA AGT GGT TTC C 
sed 





SED-R916 TTT TTC CGC GCT GTA TTT TT 
see 
 
Forward TGCCCTAACGTTGACAACAAGTCCA 532 1 60°C (281) 
Reverse TCCGTGTAAATAATGCCTTGCCTGAA 
seg 





SEG-R753 TGC AGA ACC ATC AAA CTC GT 
seh 





SEH-R722 TCG GAC AAT ATT TTT CTG ATC TTT 
Sei 
SEI-F71 CTC AAG GTG ATA TTG GTG TAG G 300 1 
 
66°C (383) 
SEI-R637 CAG GCA GTC CAT CTC CTG TA 
sej 
 
SEJ-F349 GGT TTT CAA TGT TCT GGT GGT 306 1 
 
56°C (383) 
SEJ-R654 AAC CAA CGG TTC TTT TGA GG 
Sel 





SEL-R397 CTG TTT GAT GCT TGC CAT TG 
sem 
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Table 25 Cont.  Primers used in the study 
seo 
 



























HLD-1 AAGAATTTTTATCTTAATTAAGGAAGGAGTG 111 1 56°C (274) 
HLD-2 TTAGTGAATTTGTTCACTGTGTCGA 
hlg 






mpHLG2-1 GACATAGAGTCCATAATGCATTYGT 390 1 59°C (274) 
mpHLG2-2 ATAGTCATTAGGATTAGGTTTCACAAAG 
eta 
ETA- F CGCTGCGGACATTCCTACATGG 676 1 68°C (281) 
ETA-R TACATGCCCGCCACTTGCTTGT 
clfA 
Forward 368 GTAGGTACGTTAATCGGTT 1,584 1 
 
56°C (380) 
Reverse 1951 CTCATCAGGTTGTTCAGG 
clfB 



























Forward GCAGCAGCGCATGACGGTAAAG 894 1.5 65°C (281) 
Reverse GTCGCCACCGCCAGTGTCATTA 
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COA-F2591 CCG CTT CAA CTT CAG CCT AC 204 0.5 
 
56°C (383) 
COA-R2794 TTA GGT GCT ACA GGG GCA AT 
nun 
NUC-F166 AGT TCA GCA AAT GCA TCA CA 400 2 56°C (383) 
NUC-R565 TAG CCA AGC CTT GAC GAA CT 
cna 
 
CNA-F TTCACAAGCTTGGTATCAAGAGCATGG 452 1 62°C (281) 
CNA-R GAGTGCCTTCCCAAACCTTTTGAGC 
chp 


















eap-CON1 TACTAACGAAGCATCTGCC 230 1 
 
53°C (231) 
 eap-CON2 TTAAATCGATATCACTAATACCTC 
cap5 
Cap5 K1 GTCAAAGATTATGTGATGCTACTGAG 361 0.5 59°C (388) 
Cap5 K2 ACTTCGAATATAAACTTGAATCAATGTTATACAG 
cap8 
 
Cap 8K1 GCCTTATGTTAGGTGATAAACC 173 0.5 
 
58°C (388) 
Cap 8K2 GGAAAAACACTATCATAGCAGG 
ica 















4.2.4 Statistical methods 
In this study 21 representative isolates were used to investigate the prevalence of virulence 
factor genes among different S. aureus genetic lineages. Owing to the small number of 
isolates included, statistical analysis was done by comparing isolates belonging to one genetic 
structure to other isolates belonging to all other genetic lineages. The Fisher exact and two-
tailed tests were used to analyse all results, however, the distribution of virulence factor genes 
among the 3 identified agr groups was analysed by the Chi-squared test. Statistical analysis 
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4.3 Results 
4.3.1 Virulence factor gene prevalence  
All the included isolates harboured the clfA, fnbA and fnbB genes, and all but one isolate 
(ST97-MSSA) contained the clfB gene. Among the superantigenic virulence factor genes the 
most prevalent was sea (76%), followed by sei and sel (47%), sem, sen, seo and seg (42%), 
seb (14%), sec, (19%), sed (4.8%), see (38%), seh, sej and eta (9.5%) and tst (14%). The 
prevalence of immune avoidance genes among the clones was chp (42%), sak (81%), scn 
(85%), cap5 (52%) and cap8 (48%). The presence of hemolysin toxin virulence factor genes 
was hld (100%), hlg (90%), hlgA (76%) hla (90%) and hlb (4.8%). Amongst the other toxin 









Table 27). The pvl gene was detected in 18 (8.7%) of the 208 isolates (1 MRSA and 17 
MSSA). 










Table 27 : Prevalence of virulence factor genes among included isolates 
Group Virulence factor genes 
Prevalence (%) 
N = 21 
Adhesins 
clfA 21 (100) 
clfB 20 (95) 
fnbA 21 (100) 
fnbB 21 (100) 
cna 11 (52) 
Eap 20 (95) 
sdrC 11 (52) 
sdrD 12 (57) 
sdrE 15 (71) 
icaA 19 (90) 
Super antigenic 
toxins 
Sea 16 (76) 
Seb 3 (14) 
Sec 4 (19) 
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Sed 1 (4.8) 
See 8 (38) 
Seg 9 (42) 
seh 2 (9.5) 
Sei 10 (47) 
Sej 2 (9.5) 
Sel 10 (47) 
Sem 9 (42) 
Sen 9 (42) 
Seo 9 (42) 
Eta 2 (9.5) 
Tst 3 (14) 
Table 28 cont. Prevalence of virulence factor genes among included isolates 
 
Immune avoidance 
Chp 9 (42) 
Sak 17 (81) 
Scn 18 (85) 
cap5 11 (52) 
cap8 10 (47) 
Haemolysins 
Hld 21 (100) 
Hlg 19 (90) 
Hlgv 16 (76) 
Hla 19 (90) 
Hlb 1 (4.8) 
Other virulence 
factors 
Nuc 21 (100) 
Coa 21 (100) 
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4.3.2 Innate immune evasion cluster: 
Of the 21 included isolates, 18 harboured four different types of innate immune evasion 
clusters (IEC): sea, sak, scn, chp (type A); sea, sak, scn (type D); chp, scn (type C) and sak, 





Table 29 : Distribution of IEC among identified MLST clonal complexes.  
IEC type (N)  Gene combination Clones (N) 
A (8) sea, sak, scn, chp (8) CC5 (1), CC8 (2), CC22 (2), CC30 (2), CC45 (1) 
D (8) sea, sak, scn (8) CC1 (2), CC5 (1), CC8 (4), CC12 (1) 
C (1) chp, scn (1) CC15 
E (1) sak, scn (1) CC97 
 No IEC gene (3) CC5 (3) 
4.3.3 Enterotoxin gene cluster (egc): 
The distribution of the egc genes among the included isolates showed genetically diverse 
gene combinations. However, four (80%) of the CC5 isolates harboured the sei, seg, sem, sen 
and seo genes. All CC8 isolates contained only the sei gene, while CC22, CC30 and CC45 
isolates contained the seg, sem, sen, seo genes. Six isolates lacked any egc genes (Table 30).  
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Table 30 : Distribution of egc genes among identified MLST clonal complexes 
egc gene combination (N) Clones (N) 
sei, seg, sem, sen, seo (4) CC5 (4) 
seg, sem, sen, seo (5) CC22 (2), CC30 (2), CC45 (1) 
sei (6) CC8 (6) 
No egc gene (6) CC1 (2), CC5 (1), CC12 (1), CC15 (1), CC97 (1) 
 
From this data, we can see that the distribution of virulence factor genes amongst the 
included S. aureus clonal complexes was variable; however significant differences were 
identified in the distribution of certain virulence factor genes in some lineages compared to 
other CCs (Table 31). All isolates belonging to CC5 were positive for egc genes except one 
isolate (ST6). The sed and sej genes were amplified in one isolate belonging to CC5, whereas 
only the sei gene was present in all isolates belonging to CC8.  
Comparing the virulence factor gene profiles of MRSA (90 isolates) versus MSSA (118 
isolates) revealed significant differences in the presence of the pvl gene [MSSA 14.4% and 
MRSA 1.1% (p = 0.0007)]. In contrast, among 21 selected isolates, sei gene presence was 

















MLST CCs (total number) 
No of positive (%) 
P value 
sdrC CC5 (5) 
5 (100) 
Other CCs (16) 
6 (37.5) 
0.0350 
sdrC CC8 (6) 
6 (100) 
Other CCs  (15) 
5 (33.3) 
0.0123 
icaA CC30 (2) 
0 
Other CCs (19) 
19 (100%) 
0.00476 
Sec CC1 (2) 
2 (100) 
Other CCs (19) 
2 (10.53) 
0.0285 
Seg CC8 (6) 
0 (0) 
Other CCs (15) 
9 (60) 
0.0185 
She CC1 (2) 
2 (100) 
Other CCs (19) 
0 
0.00476 
Sei CC8 (6) 
6 (100) 
Other CCs (15) 
4 (20.67) 
0.00387 
Sem CC8 (6) 
0 
Other CCs (15) 
9 (60) 
0.0185 
Sen CC8 (6) 
0 
Other CCs (15) 
9 (60) 
0.0185 
Seo CC8 (6) 
0 
Other CCs (15) 
9 (60) 
0.0185 
Sak CC5 (5) 
2 (40) 
Other CCs (16) 
15 (93.75) 
0.0275 
Scn CC5 (5) 
2 (40) 
Other CCS (16) 
16 (100) 
0.00752 
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Hla CC5 (5) 
3 (60) 
Other CCs (16) 
16 (100) 
0.0476 
hlgA CC22 (2) 
0 
Other CCs (19) 
16 (84.21) 
0.0476 
Pvl CC1 (2) 
2 (100) 




The distribution of virulence factor genes among spa-CCs was variable and significant 
differences were found in some spa-CC compared to others ( 
Table 32).  
 
Table 32 : Selected virulence factors which have significance difference between one of spa-




Spa- CCs (total number) 
No of positive (%) 
P value 
Can spa-CC002 (4) 
0 (0.00) 
Other spa-CCs (17) 
11 (64.7) 
0.035 
Sak spa-CC002 (4) 
1 (25) 
Other spa-CCs (17) 
16 (94.12) 
0.011 
Scn spa-CC 002 (4) 
1 (25) 
Other spa-CCs (17) 
17 (100) 
0.003 
Hla spa-CC 002 (4) 
2 (50) 
Other spa-CCs (17) 
17 (100) 
0.028 
cap5 spa-CC 021 (4) 
0 (0.00) 
Other spa-CCs (17) 
11 (64.7) 
0.035 
cap8 spa-CC 021 (4) 
4 (100) 
Other spa-CCs (17) 
6 (35.29) 
0.035 
sdrC spa-CC064 (5) 
5 (100) 
Other spa-CCs (16) 
6 (37.5) 
0.035 
sdrD spa-CC 021 (4) 
0 (0.00) 
Other spa-CCs (17) 
12 (70.59) 
0.021 
sdrD spa-CC 064 (5) 
5 (100) 
Other spa-CCs (16) 
7 (43.75) 
0.045 
sdrE  spa-CC 021 (4) 
4 (100) 
Other spa-CCs (17) 
11 (64.7) 
0.002 
Sea spa-CC002 (4) 
1 (25) 
Other spa-CCs (17) 
15 (88.24) 
0.0275 
Seg spa-CC 002 (4) 
4 (100) 
Other spa-CCs (17) 
5 (29.14) 
0.021 
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Seg spa-CC 064 (5) 
0 (0.00) 
Other spa-CC (16) 
9 (56.25) 
0.045 
Sei spa-CC 002 (4) 
4 (100) 
Other spa-CCs (17) 
6 (35.29) 
0.035 
Sel spa-CC 002 (4) 
4 (100) 
Other spa-CCs (17) 
6 (35.94) 
0.035 
Sem spa-CC 002 (4) 
4 (100) 
Other spa-CC (17) 
5 (29.41) 
0.021 
Sem spa-CC 064 (5) 
0 (0.00) 
Other spa-CC (16) 
9 (56.25) 
0.045 
Sen spa-CC 002 (4) 
4 (100) 
Other spa-CC (17) 
5 (29.41) 
0.021 
Sen spa-CC064 (5) 
0 (0.00) 
Other spa-CCs (16) 
9 (56.25) 
0.045 
Seo spa-CC 002 (4) 
4 (100) 
Other spa-CCs (17) 
5 (29.41) 
0.021 
Seo spa-CC064 (5) 
0 (0.00) 
Other spa-CCs (16) 
9 (56.25) 
0.045 
icaA spa-CC 021 (4) 
2 (50) 




4.4.1 Prevalence of virulence factor genes in different lineages: 
The adhesion virulence factor genes were most prevalent amongst the 21 representative 
isolates. Three CCs; 12, 30 and 45 were negative for the sdr locus, which is in contrast to a 
previous study that found that all isolates were positive for at least one gene of this locus 
(227). However, this study did not specify whether these were MSSA or MRSA, or what the 
genetic lineage was. All CCs except CC30 were positive for the icaA gene. The high 
prevalence of the icaA gene has previously been reported in community acquired MSSA and 
MRSA isolates (279). A study comparing the presence of the icaA gene in MSSA isolates 
from the USA and South Africa found that all isolates from both countries were positive 
(281). Another study which included invasive and nasal isolates found that 51% of CC30 
isolates harboured the icaA, fnbB, hlg and cna genes (380). This is in contrast to our results, 
where all the CC30 isolates were positive for fnbB, hlg and collagen binding protein (cna) 
genes.  
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The enterotoxin genes sed, sej and ser are located on the same plasmid (221). This study 
showed the presence of the sed and sej genes in CC5 (new ST2122) and the sej gene in ST8. 
These genes are usually identified in isolates belonging to CC8 (389). While previous studies 
have reported a high association of the tst gene with isolates belonging to CC30 (88, 380, 
389), this study only detected the tst gene in 3 isolates; CC30 (n = 1) and CC5 (n = 2). In 
accordance with a previous study the seh gene was only identified in CC1 isolates, 
confirming the restriction of this gene to CC1 (218). 
Superantigenic toxin genes were absent in both CC15 and CC97. The absence of these genes 
in CC15 is in agreement with a previous study where the authors hypothesised that the 
restriction modification system may interfere with the acquisition of all SAg genes carried by 
MGEs by horizontal transfer (389). Isolates belonging to CC97 are rarely isolated from 
humans and mostly occurs in animals, thus the literature regarding virulence factors 
associated with CC97 is limited (169, 390). In this study, isolates from CC97 showed an 
absence of SAg genes, similar to findings from isolates belonging to CC15.  
 
4.4.2 Association with the Immune Evasion Cluster 
The majority of isolates (except 3 of the CC5 isolates) were positive for one or more of the 
IEC genes. IEC types varied despite similar genetic backgrounds. Of the six isolates from 
CC8, four contained IEC type D, and two contained type A. Similarly, IEC type A was 
present in 1 CC isolate, and IEC type D in another CC isolate. IEC type A was found in 
isolates belonging to 5 different CCs, and IEC type D in isolates from 4 CCs. Taken together, 
these findings suggest that this MGE transferred into the S. aureus population regardless of 
the genetic background structure. A similar hypothesis was presented in a previous study 
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where the same IEC type was identified in isolates obtained from different PFGE clones and 
agr groups and different IEC types were identified in related isolates (219, 391). 
 
4.4.3 Association with the Enterotoxin gene cluster 
The seg, sei, sem, sen and seo genes which make up the egc are introduced into S. aureus by 
phages (392-394). We showed an association between genes of the egc and CC5, CC22, 
CC30 and CC45. The egc genes were absent in other CCs (CC1, CC12, CC15, CC97, and 
ST6 of CC5) and CC8 was only positive for sei.  These results reaffirm results from previous 
studies which have shown that the egc genes are associated with specific genetic lineages, 
with a low prevalence in CC1, CC12, CC15, CC8 and CC395; and a high prevalence in CC5, 
CC22, CC30 and CC45 (220, 389). Other studies have found a high prevalence of the seg and 
sei genes among colonising (57.1%) and invasive (53%) isolates (395) and that the 
combination of sei, seg, sem, sen and seo was restricted to isolates belonging to CC5 and 
CC30 (218). Our study showed the same findings for most isolates belonging to CC5, apart 
from the one ST6 isolate which did not have these genes present. Our CC30 isolates 
contained another egc gene combination, namely: seg, sem, sen and seo. The high prevalence 
of egc genes amongst the representative isolates in this study is in line with previous reports 
that isolates containing these genes are more successful in invasion and colonisation (395).  
spa typing is more discriminative than MLST and isolates belonging to one spa CC are 
genetically more related to each other than isolates belonging to one MLST CC. The 
association between certain virulence factors and specific spa CCs or MLST CCs showed 
that isolates with these virulence factors may have evolved from one ancestor.  
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4.4.4 Association with spa type 
Based on spa genetic background, the sea gene showed a low prevalence in spa-CC002 as 
has been previously reported (275). The egc gene combination seg, sei, sem, sen, seo was 
present in all isolates belonging to spa-CC002 and was absent in all spa-CC064 isolates. This 
finding may due to the genetic structure of spa-CC002 being more receptive to egc MGE 
acquisition than spa-CC064. In agreement with a previous study, no SAg genes were detected 
in spa-CC084 (389).  
4.4.5 MRSA/MSSA 
The virulence factor profiles of MRSA and MSSA vary across different studies conducted in 
diverse geographical regions. Our results showed the prevalence of the sei gene among 
MRSA was significantly higher than in MSSA isolates. Another study found both the seg and 
sei genes to be more prevalent in MRSA than MSSA (280). Additionally, in Colombia, a 
study compared the prevalence of SAgs and pvl between MRSA and MSSA isolates and 
found that the presence of the seb and sed genes were  significantly higher in MSSA isolates, 
while the presence of the pvl gene was significantly more prevalent in MRSA isolates (278). 
In a study which included S. aureus isolates from the United States and South Africa, among 
the USA isolates the sdrC, eap, fnbB, tst, sea, sed, seg, sej, sdrD, sdrE, eta, etb and see genes 
were associated with MRSA, while MSSA isolates from South Africa were more likely than 
MSSA isolates from the United States to carry sdrD, sea, and pvl genes (281). Similar results 
have been reported in Beijing, China, where all pvl positive isolates were MSSA (396). These 
results are different from those reported in Shanghai, China, where the emergence and spread 
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of pvl positive MRSA has been documented (396, 397).  
According to some studies and the MLST website (www.mlst.net), ST6 is categorised as a 
member of CC5 (169). In this study, the ST6 isolate differed from other isolates belonging to 
CC5 in that it showed the presence of the cap8 gene and had no IEC genes. Therefore, due to 
the genetic diversity of the virulence factor profile of ST6 in our population, we suggest that 
it be considered as a separate CC. However, further studies on a much larger selection of ST6 
isolates would be needed. 
 
4.4.6 PVL prevalence and association with studied clones  
In this study, the prevalence of the pvl gene among MRSA isolates was very low, with only 
one MRSA isolate being pvl gene positive. This is in accordance with previous studies 
conducted in different provinces in South Africa all of which showed a low prevalence of the 
pvl gene among MRSA isolates (174, 175, 362, 372). These studies reported that all MRSA 
pvl gene positive isolates were SCCmec type IV. However, in this study, for the first time 
MRSA clone ST612-MRSA-IV was identified as a pvl gene positive lineage. The prevalence 
of the pvl gene (8.7%) was lower than a previous study conducted at Tygerberg Hospital that 
found 15.9% of included blood isolates were pvl gene positive; all were MSSA isolates. Our 
study showed similar results where MSSA pvl positive spa type t891 was the most prevalent 
among the included isolates (25). In Nigeria, of 51 S. aureus isolates 17 were pvl gene 
positive, 1 of which was MRSA (207). Another study reported a high prevalence of pvl gene 
(40%) among MSSA isolates in Nigeria (376). The pvl gene was present in 57% of MSSA 
isolates collected from Cameroon, Madagascar, Morocco, Niger and Senegal (205). The 
prevalence of the pvl gene in MRSA isolates in Algeria was 29.7% and all pvl gene-positive 
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isolates were SCCmec IV (359). From the limited data available, the high prevalence of the 
pvl gene among MSSA isolates in west and sub-Sahara Africa countries is a common finding 
while reports from North Africa show a higher presence of this gene in both MSSA and 
MRSA isolates. This is a major concern as PVL-positive MSSA can cause severe infection 
and is a potential reservoir which may lead to the emergence of MRSA PVL-positive clones 
in Africa.  
 
 
4.5 Study Limitations 
Due to the large number of virulence factors analysed, only 21 representative isolates were 
chosen. This small sample size was one of the study limitations as it was difficult to 
determine statistically significant associations. Furthermore, the isolates for this study were 
restricted to blood and/or nasal isolates and this may not representative of all S. aureus 
















Despite these limitations, we have shown that the virulence factor genetic profile is variable 
among different genetic backgrounds of S. aureus. The acquisition of MGEs carrying SAg 
genes is uncommon in isolates from CC15 and CC97. Interestingly, the association of the 
icaA gene with CC30 was reported in another study; however this study showed the two 
CC30 isolates were negative for the presence of this gene. The presence of IEC genes in 
different genetic lineages indicates that the acquisition of this gene cluster is not restricted to 
specific lineages while conversely egc genes were restricted to specific S. aureus CCs. The 
pvl gene was highly prevalent in MSSA isolates which may evolve to PVL positive MRSA 
following SCCmec element acquisition. This is the first study to report ST612-MRSA-IV as 
being PVL-positive in South Africa and worldwide. A larger selection of isolates needs to be 
tested to confirm some of these findings, and a prospective study capturing clinical 
information may be helpful to elucidate the potential clinical relevance of these findings. 
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CHAPTER 5 PREVALENCE AND GENOTYPIC 
CHARACTERISTICS OF AGR DYSFUNCTIONAL 
STAPHYLOCOCCUS AUREUS BLOOD AND NASAL 
ISOLATES OBTAINED FROM PATIENTS WITH 
BACTERAEMIA AT TYGERBERG HOSPITAL 
5.1 Introduction 
As described in section 1.9, the accessory gene regulator (agr) locus is a global regulatory 
gene which controls the expression of the most important cell wall associated and secreted 
virulence factors in S. aureus (398). It is also considered to be the main quorum sensing 
system coordinating intra-species communication in S. aureus (399).   
The agr locus consists of four genes (agrB, agrD, agrC and agrA) in operon RNAII under the 
control of promoter P2 and one delta-haemolysin gene (hld) in operon RNAIII (213, 400, 
401) under the control of promoter P3. Activation of the agr locus occurs when the RNAII 
operon expresses the auto-inducing peptide (AIP) which then accumulates outside bacterial 
cells until it reaches a critical level which activates AgrC and AgrA transcription. This results 
in the activation of the RNAIII operon, with a resultant up-regulation of extracellular 
virulence factor and delta-haemolysin production (chapter 1, figure 3) (402). Thus, the agr 
functionality may be evaluated by analysing delta-haemolysin production, but not beta-
haemolysin which is only weakly regulated by agr (403); or alpha-haemolysin which is 
controlled by the staphylococcal accessory regulator gene (sar) via the agr global regulatory 
system and directly by AgrA (402, 404). In several studies, the synergistic relation between 
delta and beta-haemolysin and the inhibitory interaction of alpha and beta-haemolysins to 
lyse sheep red blood cells have been used as a phenotypic assay to detect agr functionality 
(310-312, 318, 320, 403, 405, 406).  
Stellenbosch University  https://scholar.sun.ac.za
 144 
The prevalence of agr dysfunction among isolates obtained from hospital environments 
ranges from 15 to 60%,(309, 312-315), and these less virulent agr dysfunctional strains may 
be commonly isolated from chronic infections sites such as the lungs of cystic fibrosis 
patients (407). The association of agr dysfunction with increased mortality in patients with 
bacteraemia is still unclear; Schweizer et al., found the mortality rate among bacteraemic 
patients infected with agr dysfunctional isolates to be significantly higher (18%) than patients 
infected with agr functional isolates (12%) (320). In contrast, another study found similar 
mortality rates in bacteraemic patients infected with agr functional and dysfunctional isolates 
(310).  
It has been reported that mecA gene acquisition and expression causes cell wall changes 
which attenuate agr function (307). S. aureus strains carrying SCCmec type IV and V (CA-
MRSA) are generally agr functional and highly virulent (308), while strains carrying 
SCCmec types I-III are usually agr dysfunctional and commonly isolated from the healthcare 
environment (306, 310). In South Korean hospitals, agr dysfunction was significantly higher 
among ST239-MRSA-III and ST5-MRSA-II than in ST72-MRSA-IV (311).  
A study comparing the agr function of isolates obtained from both blood and nasal cultures 
showed that in the majority of cases, there was no difference in the agr function between the 
colonising and invasive isolates (321). In the same study they showed that development of 
bacteraemia was not related to whether isolates were agr functional or dysfunctional.       
Although S. aureus strains with defective agr are attenuated, they are still transmissible, able 
to colonise the nose (313), lead to bacteraemia (321), and even result in poorer clinical 
outcomes than agr functional strains in bacteraemic patients (320). This chapter aimed to 
determine the prevalence of agr dysfunction among invasive and non-invasive S. aureus 
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isolates in Tygerberg Hospital and to describe the correlation between the agr dysfunction 
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5.2 Methods   
The study design, patient population, included clinical isolates, DNA extraction and isolate 
genotyping methods are described in chapter 3. 
 
5.2.1 Detection of delta-haemolysin 
The agr functionality was determined by evaluating the level of delta-haemolysin production 
as it is encoded by RNAIII which is considered to be the agr locus activator (306). One bead 
of each stored isolate was inoculated into 10 ml brain heart infusion broth (BHI) and 
incubated at 37°C overnight. This was then subcultured onto horse blood agar (BA) plates 
(National Health Laboratory Service Media Laboratory, South Africa) and incubated 
overnight at 37°C; and a single colony of this subculture was then used for agr function 
assessment. Haemolysin activity was analysed by cross-streaking each isolate against 
RN4220 (kindly provided by the Network of antimicrobial resistance in Staphylococcus 
aureus (NARSA)) which is positive for only beta-haemolysin on tryptose blood agar base 
(Oxoid LTD) with 5% sheep blood (SBA). These agar plates were incubated at 37°C 
overnight and the level of delta-haemolysin production was measured by the enhanced 
haemolysis in the overlapping area of this haemolysin with the beta-haemolysin zone 
produced by RN4220 (Figure 20) (318).  
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Figure 20 : Typical results for the assessment of agr functionality by measuring delta-
haemolysin production on sheep blood agar.  
RN4220 producing only beta-haemolysin is streaked vertically. The tested clinical isolates (A, B, C, D and E) are streaked 
horizontally. 
 
5.2.2 agr typing 
Multiplex PCR with specific agr primers (Table 33) were used to amplify the agr alleles of 
all blood and nasal isolates as previously described (366). Briefly, the PCR mixture consisted 
of 12.5 µl of Go Taq® Colorless Master Mix (Promega), 5 mM of the primers, 1 µl of the 
crude DNA, and 2.75 mM of additional MgCl2. Cycling parameters included an initial 
denaturation step at 95˚C for 6 minutes, followed by 30 cycles of 95˚C for 0.45 s, 58˚C for 
0.45 s and 72˚C for one minute. Following a final extension at 72˚C for 10 minutes, the PCR 
products were resolved on a 3.5% agarose gel. Nontypeable isolates were repeated as uniplex 
PCRs.  
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Agr-1F GTCACAAGTACTATAAGCTGCGAT 439 
Agr-2F TATTACTAATTGAAAAGTGCCATAGC 572 
Agr-3F GTAATGTAATAGCTTGTATAATAATACCCAG 321 
Agr-4F CGATAATGCCGTAATACCCG 657 
 
 
5.2.3 Shifting of agr function 
To determine agr function shifting between similar isolates obtained from the same patient, 




Isolates were classified as agr dysfunctional when they showed complete absence of delta-
haemolysin production as indicated by the absence of enhanced haemolysis in proximity to 
the beta-haemolysin of RN4220 (Figure 20; sample A, D). Functional agr isolates showed 
enhanced haemolysis close to the beta-haemolysin zone due to delta-haemolysin production 
(Figure 20, samples B, C, E).  
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5.2.5 Statistical analysis 
The association of agr dysfunction with methicillin resistance was assessed by the Chi-square 
test using Statistica version 9 (StatSoft, Tulsa, USA). A p value of less than or equal to 0.05 
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5.3 Results  
5.3.1 agr group 
The agr gene was detected in 204 of 208 included isolates. agr could not be amplified in 4 
strains and these were reported as nontypeable. The prevalence of agr groups was as follows: 
agr type I, 67.3% (n = 140); agr type II, 21.6% (n = 45); agr type III, 9.1% (n = 19). agr type 
IV was not identified during the study period. 
 
5.3.2 Association between agr types and genetic background of 
included blood and nasal isolates 
To investigate the association of identified agr types (I-III) with specific clones and genetic 
backgrounds, isolates represented by selected isolates for MLST analysis were included (n = 
156). As shown in Table 34 all isolates belonged to CC8, CC22, CC45 and CC97 contain agr 
type I. Isolates belonging to CC12, CC15 and CC5 (except ST6) carried agr type II. Isolates 
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agr I (107) 
1 1 2 ST1-MSSA 
6 5 7 ST6-MSSA 
8 8 10 ST8-MSSA (7) and ST8-MRSA-V (1) 
22 22 7 ST22-MSSA (5) and ST22-MRSA-IV (2) 
45 45 18 ST45-MSSA 
97 97 7 ST97-MSSA 
239 8 40 
ST239-MRSA-III (9) and ST239-MRSA-ccrC/class 
A mec (31) 
612 8 16 ST612-MRSA-IV (14) and ST612-MRSA-NT (2) 
agr II (38) 
5 5 12 
ST5-MRSA-ccrC, ccrA1B1/class B mec (10) and 
ST5-MSSA (2) 
12 12 2 ST12-MSSA 
461 5 5 ST461-MRSA- ccrC, ccrA1B1/class B mec 
2122 5 8 ST2122-MSSA 
2126 15 11 ST2126-MSSA 
agr III (10) 
1 1 2 ST1-MSSA 
36 30 4 ST36-MRSA-II 
1865 30 4 ST1865-MSSA 
agr NT (1) 2126 15 1 ST2126-MSSA 
 
 
Of the 208 isolates, 61 (29.3%) were agr dysfunctional. The prevalence of agr dysfunction 
was significantly higher in MRSA isolates (n = 50/90; 55.5%) compared to MSSA isolates (n 
= 11/118; 9.3%) (P = < 0.0001) as shown in Table 35. 
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Table 35 : Prevalence of agr dysfunctional isolates among MRSA and MSSA isolates 
agr function MRSA (%) MSSA (%) P value Total (%) 
Dysfunctional 50 (55.6) 11 (9.3) < 0.0001 61 (29.3) 
Functional 40 (44.4) 107 (90.7) < 0.0001 147 (70.7) 
Total 90 (100) 118 (100) - 208 (100) 
 
 
5.3.3 MRSA genotype and agr function 
Of the 90 MRSA isolates, 68 belonged to agr group I, 15 to agr group II, 5 to agr group III, 
and 2 were untypeable. All agr group II isolates were agr functional. All the untypeable 
SCCmec types (ccrA1B1, ccrC/Class B mec (n = 15)) and SCCmec type IV (n = 21) were 
identified as agr functional isolates, while all isolates with SCCmec type III (n = 10) and the 
untypeable ccrC/Class A mec (n= 31) were identified as agr dysfunctional. Of the 5 isolates 
with SCCmec II, 4 were agr dysfunctional. MRSA STs 5, 8, 22, 461, and 612 were identified 
only as agr functional. In contrast, all STs 36 and 239 were found to be agr dysfunctional. 
All MRSA isolates belonging to spa-CC002 (n = 15) and 022 (n = 5) were agr functional. 
The majority (81%) of spa-CC64 was agr functional and spa-CC021 (93.87%) was agr 
dysfunctional ( 
Table 36). It is interesting to note that, among CC8 MRSA isolates, all isolates belonging to 
ST 239 were agr dysfunctional, while all the isolates belonging to ST8 and ST612 were agr 
functional. 
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5.3.4 MSSA genotype and agr function 
The majority of MSSA isolates were identified as belonging to agr group I (n = 72) followed 
by agr group II (n = 30), with only 14 of the MSSAs belonging to agr group III. Eleven of 
the MSSA isolates showed agr dysfunction, with the distribution of agr groups, sequence 
types and spa-types shown in  
Table 36.  
The association of agr dysfunction with specific lineages was reported in ST36-MRSA-II, 
ST239-MRSA-III, and ST239-MRSA-ccrC/Class A mec. While other lineages: ST5-MRSA-
ccrAB1/Class B mec, ST8-MRSA-V, ST22-MRSA-IV, ST461-MRSA-ccrAB1/Class B mec 
and ST612-MRSA-IV showed positive results for delta-haemolysin production. 
To determine the shifting of agr functionality within the same strains from nose and blood 
isolates of a patient, all patients infected and colonised with the same strain were included in 
this analysis. Of the 164 included patients, 96 were infected and colonised with the same 
strains. Of these, 67 showed agr functionality in their blood and nasal isolates, while in 28, 
both isolates were agr dysfunctional. In one patient, the same strain was agr dysfunctional in 









Table 36 : Genotypic characteristics of agr functional/dysfunctional S. aureus isolates 
Category Genotype No of isolates 
agr dysfunctional agr functional 
Methicillin susceptibility MRSA (n = 90) 50 40 
agr genotype 
I 45 23 
II 0 15 
III 4 1 
NT 1 1 
SCCmec type 
ccrA1B1, ccrC/ Class B mec 0 15 
II 4 1 
III 10 0 
IV 0 21 
V 1 1 
ccrC/Class A mec 31 0 





ST5 0 10 
ST461 0 5 
CC8 
ST8 0 1 
ST239 41 0 
ST612 0 16 
CC22 ST22 0 2 
CC36 ST36 4 0 
Non applicable (NA) NA 5 6 
spa-CCs 
CC002 0 15 
CC021 46 3 
CC022 0 5 
CC064 4 17 
Methicillin susceptibility MSSA (n = 118) 11 107 
agr genotype 
I 4 68 
II 2 28 
III 4 10 
NT 1 1 
MLST 
CC1 ST1 0 4 
CC5 
ST5 0 2 
ST6 0 7 
ST2122 0 8 
CC8 ST8 0 9 
CC12 ST12 0 2 
CC15 ST2126 2 10 
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CC22 ST22 0 5 
CC30 ST1860 1 3 
C45 ST45 1 17 
CC97 ST97 1 6 
NA NA 6 34 




CC002 0 12 
CC073/015 1 15 
CC021 2 6 
spa-CCs 
CC022 0 8 
CC084 3 10 
CC064 0 20 
CC160 0 6 
CC174 1 5 
CC267 1 5 
No Founder 0 4 
Singletons 2 12 
NT 1 2 
Excluded 0 2 
 
 
5.3.5 Association between agr group and virulence factors 
Distribution of five virulence factor genes was found to be significantly different between the 











Table 38 : Selected virulence factors that have significant differences between one of the agr 













(n = 12) 
agr II 
(n = 6) 
agr III 
(n = 3) 
P value 
cna 7 (58.33%) 1 (16.67%) 3 (100%) 0.05 (agr II compared to agr III) 
sak 12 (100%) 2 (33.33%) 3 (100%) 0.002 (agr II compared to agr I and III) 
scn 12 (100%) 3 (50%) 3 (100%) 0.0125 (agr II compared to agr I and III) 
sea 11 (91.67%) 2 (33.33%) 3 (100%) 0.0135 (agr II compared to agr III) 
icaA 12 (100%) 6 (100%) 1 (33.33%) 
















5.4.1 Association with agr dysfunction, SCCmec type and genetic lineage 
This study showed a significant association of agr dysfunction with MRSA compared to 
MSSA. A similar finding was reported in a South Korean hospital where 302 of 407 blood 
MRSA isolates were agr dysfunctional compared to 29 of 232 MSSA blood isolates (311). In 
the present study the dominant SCCmec type was SCCmec type II (90.7%). However, 
SCCmec element acquisition did not attenuate agr function in S. aureus clinical isolates 
obtained from hospitals in New York city (306), although this study did not categorise the 
SCCmec types of the MRSA isolates.  
A previous study has reported an association between SCCmec types II and III, but not with 
SCCmec types I and IV, and agr dysfunction (311). Although our study also suggests an 
association between agr dysfunction and SCCmec types II, III as well as the untypeable 
element (ccrC/Class A mec), it is not clear whether this is related to the SCCmec element 
itself, or the genetic background of these isolates. SCCmec type II was found exclusively in 
isolates belonging to ST36, and both SCCmec type III and the untypeable SCCmec were 
found in ST239 (CC8). It is interesting to note that, among CC8 MRSA isolates, all isolates 
belonging to ST239 were agr dysfunctional, while all isolates belonging to ST8 and ST612 
were agr functional. 
All MRSA isolates carrying SCCmec type IV and the possible novel variant SCCmec type I 
(ccrA1B1, ccrC/Class B mec) were agr functional. Again, the majority of SCCmec IV 
elements (16/18, 88.8%) were found in isolates belonging to ST612, and the possible 
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SCCmec type I novel variant was found in isolates belonging to ST5 and ST461. Both of 
these are part of CC5.  
Another study also reported a higher rate of agr dysfunction among MRSA harbouring 
SCCmec types I-III (43%) than SCCmec type IV and V isolates (3%) obtained from patients 
with S. aureus bacteraemia. However, only one isolate with SCCmec type I was included in 
this study, therefore the small number of samples included may not be representative of agr 
functionality in MRSA harbouring SCCmec type I (310). The difference in association of agr 
dysfunction with MRSA may be attributed to variable SCCmec element types amongst the 
included isolates, or due to the different lineages associated with methicillin resistance.  
A previous study reported that isolates with impaired agr function are commonly identified in 
hospitals or previously hospitalised individuals (313). Paulander et al., suggested that the 
reduced agr functionality in S. aureus may allow isolates to adapt and survive in intensive 
antibiotic environments (317).  
In accordance with a previous study that reported very infrequent shifting of agr functionality 
within-host (321), our study showed a similar finding. Of the 96 patients with identical nasal 
and blood culture isolates (28 agr dysfunctional and 68 agr functional), only one of these 
patients was found to carry an agr dysfunctional isolate in the nose and shifted into agr 
functional isolate in the bloodstream.  
S. aureus virulence is regulated by the agr locus, but it has been suggested that agr function 
is not essential for colonising isolates to cause subsequent bacteraemia (321). This is 
supported by this study finding where, 27 of the 28 agr dysfunctional colonised isolates  were 
identified from blood culture of the same patients. 




5.4.2 Association of virulence factors with agr type 
The presence of sea in agr type II isolates was significantly less than its prevalence in agr 
type I and III. This is similar to findings by Collery et al., that agr type II and type IV isolates 
were negative for sea genes (218, 408). There was no association between specific IEC types 
with any of the agr types (219). Our results showed that the IEC genes scn and sak were less 
prevalent in agr II isolates. In accordance with this study finding, Diep et al., found that agr 
type II isolates lacked the cna gene(218).  
 
5.4.3 Association between agr type and genetic background 
In accordance to previous study there was an association between CC8, CC22, CC45 and agr 












In conclusion, the prevalence of agr dysfunctional S. aureus isolates was significantly higher 
in MRSA than MSSA. In MRSA isolates, agr dysfunction was more commonly associated 
with isolates carrying SCCmec types II, III and ccrC/Class A mec. In this study, the 
association of agr dysfunction with ST36-MRSA-II, ST239-MRSA-III ST239-MRSA- 
ccrC/Class A mec was also reported. Furthermore, our study showed that agr function 
shifting in the same host was not common. Further studies are required to assess the 
vancomycin susceptibility of MRSA agr dysfunctional isolates, and to evaluate the clinical 
outcome of patients infected with these strains as previous studies reported an association 
between increased mortality and agr dysfunction. 
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CHAPTER 6 GENERAL DISCUSSION AND CONCLUSION 
 
A hundred and sixty four patients with SAB were included in this study; and a nasal swab for 
S. aureus culture was obtained from all patients. Using PFGE, the second chapter aimed to 
describe the correlation between the blood and nasal isolates of 162 patients (two patients 
were excluded from this analysis). 79% (128/162) of the patients had nasal colonisation with 
S. aureus, and there was a significant correlation between the blood and nasal isolates in 
colonised patients. Interestingly, MRSA nasal colonisation was significantly associated with 
endogenous bacteraemia when compared to MSSA. Endogenous bacteraemia was more 
common than exogenous in adults and neonates.  
In the third chapter our study focused on genotyping the invasive and colonising isolates. 
From 164 patients, 208 unique non-repeated isolates were obtained and characterised using 
PFGE, spa typing, MLST, agr typing and SCCmec typing. Based on the PFGE results, the 
isolates were categorised into 31 clones (4 major, 4 intermediate and 23 minor). Three agr 
groups were identified (I, II and III) while agr type IV was not detected. A range of SCCmec 
types (II, II, IV and V) were found in the MRSA isolates including two 2 untypeable SCCmec 
types. Further analysis of these untypeable SCCmec elements suggested two novel structures; 
ccrA1B1, ccrC/Class B mec (type I variant) and ccrC/Class A mec (novel SCCmec type in S. 
aureus). Interestingly, the potential novel SCCmec type was the predominant type (34.4%; 
n=31). Representative isolates from all major, intermediate and 11 minor PFGE clones were 
analysed further by MLST.  The predominant clone was ST239-MRSA-ccrC/Class A mec. 
ST612-MRSA-IV, previously described in South Africa and Australia, was the second 
predominant clone and the first time one of these isolates was shown to be PVL positive. 
ST461-MRSA-ccrA1B1, ccrC/Class B mec was identified as MRSA for the first time. 
Stellenbosch University  https://scholar.sun.ac.za
 162 
Several findings support the local emergence and evolution of new MRSA clones: different 
SCCmec elements within one PFGE clone, MSSA and MRSA strains grouped in one PFGE 
clone, the same ST identified as MSSA and MRSA; and the finding of untypeable SCCmec 
elements which may represent a new SCCmec type (ccrC/ Class A mec) and a new type I 
variant (ccrA1B1, ccrC/ Class B mec). All but one of the 18 PVL positive isolates were 
MSSA. 
Chapter four investigated the virulence factor gene distribution among different genetic 
lineages. Various groups of virulence factors were selected for screening: adhesins, 
superantigenic toxins, immune avoidance genes and hemolysins. In South Africa, there is 
limited data related to the prevalence of virulence factors among local S. aureus clones. 
Selected representative isolates (those selected for MLST analysis) were chosen for virulence 
factor profile screening. Our results showed the presence of the nuc, coa, fnbA, fnbB, clfA and 
hld genes in all the selected isolates. The IEC gene cluster was not associated with specific 
genetic lineages. However, there was an association between specific egc genes types and 
CC5, CC22, CC30 and CC45. As has been reported in previous studies, this study confirmed 
that the SAg genes were absent in CC15 and CC97. The icaA gene was amplified in all CCs 
except isolates belonging to CC30, while the sei gene was associated with CC8. Further 
analysis revealed that MSSA was associated with the presence of PVL and MRSA was 
associated to the sei genes. 
The accessory gene regulator (agr) is the main quorum sensing system that controls virulence 
factor expression in S. aureus. Activation of agr function up regulates the expression of cell 
wall associated virulence factors and down regulates extracellular toxin production. Isolates 
with impaired agr function have been found to be less susceptible to vancomycin, associated 
with persistent SAB and in some studies have been associated with higher mortality rates. 
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The fifth chapter studied the prevalence of agr dysfunctional isolates among blood and nasal 
isolates as well as the association of agr dysfunction with genetic background. The 
prevalence of agr dysfunctional isolates was significantly higher among MRSA (50/90) 
isolates than compared to MSSA (11/118) (P=<0.0001). A similar result was reported in 
South Korean Hospitals where 302 of 407 MRSA blood isolates were agr dysfunctional. In 
MRSA, our study showed an association between agr dysfunction and SCCmec types II, III, 
and the ccrC/class A mec. On the other hand, all strains harbouring SCCmec type IV or 
ccrA1B1, ccrC/Class B mec were agr functional. Analysing the association between agr 
dysfunction and genetic background showed all ST239-MRSA-ccrC/Class A mec isolates to 
be agr dysfunctional. This was the predominant clone harbouring the new SCCmec type, and 
it is possible that acquisition of this new SCCmec type (ccrC/Class A mec) resulted in agr 
dysfunction. Since the isolates were obtained from the blood and via nasal carriage we aimed 
to determine the agr function shift and the importance or role of agr function in invasion. We 
found that agr function shift in the same host was a rare event and that agr function was not 
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6.1 General conclusion 
In South Africa, this is the first study describing the correlation between colonising nasal and 
invasive blood S. aureus isolates. The prevalence of virulence factor genes within S. aureus 
and their association with specific clones is also not well described in South Africa.  
The significant association between blood and nasal isolates indicates that nasal carriage was 
a possible source of subsequent SAB. However, in all patients (colonised and non-colonised) 
nasal carriage was not the main source of SAB which highlights the impact of sources other 
than the colonised nostrils in developing SAB. MRSA bacteraemia was more commonly 
associated with MRSA nasal colonisation in patients admitted to adult surgical ICU and 
neonate units. From these study findings it is possible to conclude: (1) in colonised patients, 
nasal carriage is possible source of subsequent SAB; (2) S. aureus bacteraemia was acquired 
from sources other than colonised nostrils; and (3) endogenous bacteraemia was more 
commonly associated with MRSA nasal colonisation especially in adult ICU and neonates 
units.  
Molecular characterisation of 208 unique non repeated isolates showed a predominance of 
ST239, ST612 and ST5. ST239 was identified with SCCmec type III and the untypeable 
ccrC/Class A mec elements. According to our knowledge ST612-MRSA-IV has been 
identified only in South Africa and Australia and this study reported one isolate as being PVL 
positive which may increase its virulence. It is known that ST5 has acquired different 
SCCmec elements many times in variable geographic regions. Our results showed ST5 
carried an untypeable SCCmec ccrA1B1, ccrC/Class B mec. The emergence of ST461-
MRSA-IV in South Africa was reported in this study as well as novel MSSA STs (ST2122 
and ST 2126). PVL was more prevalent among MSSA isolates than MRSA isolates.  
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In summary, the genotypic characterisation showed: (1) predominance of ST239-MRSA-
ccrC/Class A mec, (2) local emergence of new MRSA clones, (3) local acquisition of new 
SCCmec elements and; (4) the ability of the local clone ST612-MRSA-IV to acquire the PVL 
toxin. 
Twenty one selected representative S. aureus (MRSA and MSSA) isolates were screened for 
the presence of 38 virulence factor genes. Limited studies in South Africa have investigated 
the presence of virulence factor genes other than PVL. The key findings in this section of the 
work included: (1) the nuc, coa, clfA, clfB and hld virulence factor genes were present in all 
included isolates, (2)  the presence of the IEC was not restricted to any specific clones, while 
egc was associated with CC5, CC22, CC30 and CC45, (3) both CC15 and CC97 were 
negative for SAg genes, (4) the biofilm associated gene, icaA was highly prevalent (90.4%) 
among the included isolates and; (5) there genes of the pvl gene was associated with MSSA 
isolates, which may be important with respect to the evolution of  PVL positive MRSA 
clones.  
Impaired agr functionality in S. aureus has been associated with reduced susceptibility to 
vancomycin, persistent bacteraemia and sometimes with a higher mortality rate in the 
literature. Investigating the prevalence of agr dysfunctional isolates among both blood and 
nasal isolates led to the following conclusions : (1) agr dysfunction was significantly 
associated with MRSA, (2) the presence of SCCmec elements type II, III or ccrC/Class A 
mec was associated with agr dysfunction,  while the presence of SCCmec type ccrA1B1, 
ccrC/Class B mec or SCCmec type IV was associated with agr function, (3) Although agr 
dysfunction theoretically reduces S. aureus virulence, a functional agr gene was not essential 
for colonising isolates to cause SAB and; (5) finally, shifting of agr function in the same host 
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6.2 Limitations of the study 
Von Eiff and colleagues in 2001 estimated the correlation between the nasal and blood S. 
aureus isolates by two approaches: (1) they swabbed the nostrils of any patient immediately 
after positive S. aureus blood culture was identified and; (2) in the another approach, nasal 
swabs were obtained from patients prospectively and followed up for 5 years (1994-1995). 
The correlation between nasal and blood isolates was 82.2% and 85.7% in the first and 
second approaches respectively. In our study the correlation of blood and nasal isolates was 
not determined by active surveillance which may raise the possibility of colonisation 
occurring after the development of SAB. From the limited clinical data available it was not 
possible to properly classify the isolates as CA-MRSA or HA-MRSA. The S. aureus isolates 
in this study only represented blood and nasal isolates as other clinical infection and 
colonisation sites were not included. The virulence factor profile screening was performed for 
selected isolates, and since limited clinical data was available it was not possible to link the 
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6.3 Future work 
Further studies and research questions have been raised by this study, including:: (1) will a 
“search and destroy” policy prove to be a feasible prevention control measure in colonised 
patients? (2) The two common untypeable SCCmec elements need further analysis using 
additional PCR typing methods as well as DNA sequence analysis; (3) the association 
between the virulence factors and the clinical presentation and outcome would need to be 
investigated using larger numbers of isolates in a prospectively enrolled cohort; (4) the 
reported association between agr dysfunctional isolates and reduced susceptibility to 
vancomycin as well as clinical outcome would likewise need to be investigated prospectively; 
and (5) further analysis of selected isolates using whole genome sequencing and proteomic 
analysis may shed further light on the consequences of agr dysfunction.   
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Appendix A2: Consent form used when the included patient was ≥ 18 years 
Participant information leaflet and consent form 
TITLE OF THE RESEARCH PROJECT: 
A phenotypic and genotypic characterization of strain types, virulence factors and agr 
groups of colonizing S. aureus strains associated with bloodstream infections 
PRINCIPAL INVESTIGATOR: Karayem. J. Karayem 
ADDRESS: Division of Medical Microbiology, Department of Pathology, PO Box 19063, 
Tygerberg Hospital, 7505 
CONTACT NUMBER: 021 9384032 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the 
study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand what 
this research entails and how you could be involved.  Also, your participation is entirely 
voluntary and you are free to decline to participate.  If you say no, this will not affect you 
negatively in any way whatsoever.  You are also free to withdraw from the study at any point, 
even if you do agree to take part. 
This study has been approved by the Committee for Human Research at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice 
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and the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
 The study will be conducted in Tygerberg Hospital, on patients that suffer from 
serious infections caused by a bacterium called Staphylococcus aureus. 
 All of us carry this organism on our skin and about 50% of healthy people in their 
nose, and usually it does not cause us any harm. Sometimes it may lead to skin 
infections, like boils, which are not very serious. We are interested why some patients 
suffer from more serious infections caused by this organism.  
 No extra examinations or investigations (for example, no extra blood tests or any 
other test like X-rays) will be done on you other than those that your doctor request 
routinely. The only extra procedures of this study is the collection of nasal swabs of 
your nose to find out the association between nasal and bloodstream isolates, more 
information about your condition, and some extra tests will be done in the laboratory 
on the bacteria we isolate from your nose and/or blood that your doctor takes to 
diagnose your disease. 
 We want to include all the patients in this hospital that suffer from this type of 
infection. 
 Your involvement in this study will give the doctors more information about the 
possible reasons for your infection, but it will not change your treatment in any way. 
Why have you been invited to participate? 
 You have been invited to participate in this study because the bacterium 
Staphylococcus aureus had been isolated from blood that your doctor took to 
diagnose your infection. 
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What will your responsibilities be? 
 You have no responsibilities, but the research staff may ask you questions about 
previous infections and perhaps whether you have recently had any antibiotic 
treatment for other infections. We would be glad if you can answer such questions as 
best you can. 
Will you benefit from taking part in this research? 
 By looking at the data we collect about your disease, we may be able to alert your 
doctor to certain risk factors you may have to get better less quickly or get this 
disease again. The information will also be used to help prevent complications in 
patients who get the same disease in future and it will provide clinically useful 
information towards infection control and prevention of invasive S. aureus diseases. 
Are there in risks involved in your taking part in this research? 
 As no extra investigations will be done on you, and as the study will not influence the 
treatment your doctor gives you in any way, this study has no risks for your health. 
If you do not agree to take part, what alternatives do you have? 
 Should you decide that you do not want to be included in this study, your treatment 
and care will continue exactly as before.  
Who will have access to your medical records?  
If you are part of this study, your medical records may be examined for relevant information 
by the staff participating in this study. These people are all registered health care 
professionals and they include a trained nursing sister, medical doctors and medical scientists 
all working for this hospital or the National Health Laboratory Services. The information 
about all the patients included in this study will be analysed in such a way that no personal 
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information about you will be published or made known in any way. 
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study?  
There is no risk of injury as a direct result of this study, as no additional examinations, 
investigations or treatment forms part of this study. 
Will you be paid to take part in this study and are there any costs involved? 
No, you will not be paid to take part in the study and you do not need to come back to the 
hospital for any follow up appointments because of your involvement in this study.  There 
will be no costs involved for you, if you do take p 
Is there anything else that you should know or do? 
 You can contact Prof E Wasserman Tel: 021 9384032 if you have any further queries 
or encounter any problems. 
 You can contact the Committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
Declaration by participant 
By signing below, I …………………………………..…………. agree to take part in a 
genetic research study entitled A phenotypic and genotypic characterization of strain 
types, virulence factors and agr groups of colonizing S. aureus strains associated with 
bloodstream infections. 
I declare that: 
 I have read or had read to me this information and consent form and it is written 
in a language with which I am fluent and comfortable. 
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 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
Signed at (place) ......................….… on (date) …………....……….. 2010. 
Signature of participant Signature of witness 
Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
 I explained the information in this document to …………… 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
 I did/did not use a translator.  (If a translator is used then the translator must sign 
the declaration below. 
Signed at (place) ......................…........……… on (date) …………....……….. 2010. 
......................................................................  ……………………….. 
Stellenbosch University  https://scholar.sun.ac.za
 202 
Signature of investigator Signature of witness 
Declaration by translator 
I (name) ……………………………………………..……… declare that: 
 I assisted the investigator (name) …………………………………… to explain 
the information in this document to (name of participant) ……………..… using 
the language medium of Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
Signed at (place) ................... on (date) ………….. 2010. 
……………                                     …………………………………… 
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Appendix A3:  Consent form used when the included patient was < 18 years 
Participant information leaflet and assent form 
   
TITLE OF THE RESEARCH PROJECT:  
 A phenotypic and genotypic characterization of strain types, virulence factors and agr 
groups of colonizing S. aureus strains associated with bloodstream infection 
RESEARCHERS NAME(S):  Karayem J. Karayem 
ADDRESS: Division of Medical Microbiology, Department of Pathology,  
  PO Box 19063, Tygerberg, 7505 
CONTACT NUMBER:  021 9384032 
What is research?  
Research is something we do to find new knowledge about the way things (and people) 
work.  We use research projects or studies to help us find out more about disease or 
illness. Research also helps us to find better ways of helping, or treating children who 
are sick. 
What is this research project all about? 
The study will be about germs called Staphylococcus aureus. It lives on/in our skin and nose. 
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Sometimes it reaches the blood and causes illness. In this study we want to know how this 
germ can reach the blood, and why it sometimes only stays as normal living germs in others 
and doesn’t cause a serious disease.  
The Staphylococcus aureus germ was found in your blood, and caused you to become ill. We 
would like to know if this germ also lives in your nose. Therefore, we would like to take a 
simple swab of the inside of your nostrils to see if this germ is growing there. It is a simple 
procedure and it will not hurt at all. It will also not be uncomfortable.  
No other examinations and investigations will be done on you other than those that your 
doctor requested routinely.  
Why have I been invited to take part in this research project? 
You have been invited to take part in this study because the germ Staphylococcus aureus had 
been found in your blood that was taken by your doctor.  
Who is doing the research? 
I am a PhD student at the Division of Medical Microbiology, Department of Pathology, 
Stellenbosch University. I am doing this study at Tygerberg Hospital to get PhD degree. 
What will happen to me in this study? 
The Staphylococcus aureus germ was found in your blood sample that had been taken by 
your doctor routinely. We need more information about your condition. We would glad if you 
answer some questions that will be asked to you. We will take swabs of your nose to know if 
you have this germ in your nose and to do more laboratory tests on the germs that we found 
in your blood and nose.   
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Can anything bad happen to me? 
This study doesn’t need any more investigations and does not change your treatment that 
your doctor gives you in any way. This study cannot harm you or cause you pain. 
Can anything good happen to me? 
From the information that we collect about your condition, and the extra laboratory tests that 
we will do on the Staphylococcus aureus germ that we found in your blood and/or nasal 
swabs, we will provide your doctor with advice which will help to cure you and to avoid 
complications or that you may get the same disease again. 
We will also use this information to help other patients who have the same illness and to 
provide the nurses and doctors working in preventing infection with useful information.  
Will anyone know I am in the study? 
If you agree to take apart in this study, all your information will only be examined by the 
staff working in this study. All of them are registered health care professionals. Your name 
will not be connected to our findings and no personal information about you will be 
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Who can I talk to about the study?  
 
 You can contact Prof E Wasserman   at tel 
0219384032……………………… if you have any 
further queries or encounter any problems. 
 You can contact the Committee for Human Research 
at 021-938 9207 if you have any concerns or complaints 
that have not been adequately addressed by your study doctor. 
You will receive a copy of this information and consent form for your own records. 
What if I do not want to do this? 
Only you have the right to decide whether you want to take part in this study or not, even if 
your parents agree to participate. As a participant you can leave the study at any time, while 
the study hasn’t finished. You will not get any trouble and your treatment and care will 
continue exactly as before.  
Do you understand this research study and are you willing to take part in it?   
YES  NO 
 
Has the researcher answered all your questions? 
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Do you understand that you can pull out of the study at any time? 
YES  NO 
 
_________________________  ____________________  
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Appendix A4: Consent form used by parent or guardians when the included 
patient ≤17 years 
  Participant information leaflet and consent form for use by parents/legal guardians 
TITLE OF THE RESEARCH PROJECT: 
A phenotypic and genotypic characterization of strain types, virulence factors and agr 
groups of colonizing S. aureus strains associated with bloodstream infection 
PRINCIPAL INVESTIGATOR:  Karayem J. Karayem 
ADDRESS:  Division of Medical Microbiology, Department of Pathology 
  PO Box 19063, Tygerberg, 7505 
CONTACT NUMBER:  021 9384032 
Your child (or ward, if applicable) is being invited to take part in a research project.  Please 
take some time to read the information presented here, which will explain the details of this 
project.  Please ask the study staff or doctor any questions about any part of this project that 
you do not fully understand.  It is very important that you are fully satisfied that you clearly 
understand what this research entails and how your child could be involved.  Also, your 
child’s participation is entirely voluntary and you are free to decline to participate.  If you 
say no, this will not affect you or your child negatively in any way whatsoever.  You are also 
free to withdraw him/her from the study at any point, even if you do initially agree to let 
him/her take part. 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
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international Declaration of Helsinki, South African Guidelines for Good Clinical Practice 
and the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about?  
The study will be conducted in Tygerberg Hospital, on patients that suffer from serious 
illnesses caused by a germ called Staphylococcus aureus. 
All of us carry this germ on our skin and about 50% of healthy people in their nose, and 
usually it does not cause us any harm. Sometimes it may lead to skin diseases, like boils, 
which are not very serious. We are interested why some patients suffer from more serious 
illnesses caused by this organism.  
No extra examinations or investigations (for example, no extra blood tests or any other test 
like X-rays) will be done on your child other than those that his doctor request routinely. The 
only extra procedures of this study is the collection of nasal swabs of your child nose to find 
out the association between nasal and bloodstream germs, more information about your child 
condition, and some extra tests will be done in the laboratory on the germs we isolate from 
your child nose and/or blood that his doctor takes to diagnose your child disease. 
We want to include all the patients in this hospital that suffer from this type of infection. 
Your child involvement in this study will give the doctors more information about the 
possible reasons for your child disease, but it will not change your child treatment in any 
way. 
Why has your child been invited to participate? 
Your child has been invited to participate in this study because the germ Staphylococcus 
aureus had been found in blood that your child doctor took to diagnose his illness. 
 
Stellenbosch University  https://scholar.sun.ac.za
 210 
What will your responsibilities be?   
You and your child have no responsibilities, but the research staff may ask you questions 
about previous disease and perhaps whether your child has recently had any antibiotic 
treatment for other diseases. We would be glad if you can answer such questions as best you 
can. 
Will your child benefit from taking part in this research? 
By looking at the data we collect about your child disease, we may be able to alert his doctor 
to certain risk factors he may has to get better less quickly or get this disease again. The 
information will also be used to help prevent complications in patients who get the same 
disease in future and it will provide useful information to stop or reduce the disease that is 
caused by this germ. 
Are there any risks involved in your child taking part in this research? 
As no extra investigations will be done on your child, and as the study will not influence the 
treatment of your child doctor gives him in any way, this study has no risks for your child 
health. 
If you do not agree to allow your child to take part, what alternatives does your child 
have?   
Should you decide that you do not want your child to be included in this study, your child 
treatment and care will continue exactly as before.  
Who will have access to your child’s medical records? 
If your child is part of this study, his medical records may be examined for relevant 
information by the staff participating in this study. These people are all registered health care 
professionals and they include a trained nursing sister, medical doctors and medical scientists 
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all working for this hospital or the National Health Laboratory Services. The information 
about all the patients included in this study will be analysed in such a way that no personal 
information about your child will be published or made known in any way. 
What will happen in the unlikely event of your child getting injured in any way, as a 
direct result of taking part in this research study?  
There is no risk of injury as a direct result of this study, as no additional examinations, 
investigations or treatment forms part of this study. 
Will you or your child be paid to take part in this study and are there any costs 
involved? 
You or your child will not be paid to take part in the study, but out-of-pocket expenses will 
be covered for each study visit.  There will be no costs involved for you if your child does 
take part.  
Is there anything else that you should know or do? 
You should inform your family practitioner or usual doctor that your child is taking part in a 
research study.  (Include if applicable) 
You should also inform your medical insurance company that your child is participating in a 
research study (Include if applicable) 
You can contact Prof E. Wasserman at tel   021 9384032. If you have any further queries or 
encounter any problems. 
You can contact the Health Research Ethics Committee at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your child’s study doctor. 
You will receive a copy of this information and consent form for your own records. 
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Declaration by parent/legal guardian 
By signing below, I (name of parent/legal guardian) ……………………agree to allow my 
child (name of child) ………………………………….… who is ………. years old, to take 
part in a research study entitled  
A phenotypic and genotypic characterization of strain types, virulence factors and agr 
groups of colonizing S. aureus strains associated with bloodstream infection 
I declare that: 
 I have read or had read to me this information and consent form and that it is 
written in a language with which I am fluent and comfortable. 
 If my child is older than 7 years, he/she must agree to take part in the study and 
his/her ASSENT must be recorded on this form. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to let my child take part. 
 I may choose to withdraw my child from the study at any time and my child will 
not be penalised or prejudiced in any way. 
 My child may be asked to leave the study before it has finished if the study doctor 
or researcher feels it is in my child’s best interests, or if my child do not follow 
the study plan as agreed to. 
Signed at (place) ......................…........…. on (date) …………....……………   
Signature of parent/legal guardian Signature of witness 
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Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
 I explained the information in this document to …………………… 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understand all aspects of the research, as 
discussed above 
 I did/did not use a interpreter (if a interpreter is used, then the interpreter must 
sign the declaration below). 
Signed at (place) ......................…........………on (date) …………....……….. 2005. 
......................................................................   
Signature of investigator  
Declaration by interpreter (Only complete if applicable) 
I (name) ……………………………………………..……… declare that: 
 I assisted the investigator (name) ………….………………………. to explain the 
information in this document to (name of parent/legal guardian) 
……...………………………... using the language medium of Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the parent/legal guardian fully understands the content of this 
informed consent document and has had all his/her questions satisfactorily 
answered. 
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Signed at (place) ....................…………….. on (date) …………....……………   
Signature of interpreter Signature of witness 
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